<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> RITTER PHARMACEUTICALS INC (Form: 10-K, Received: 03/21/2016 06:31:48) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="97">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="FORM10-K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 18PT">
<B>
	UNITED
	STATES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 18PT">
<B>
	SECURITIES
	AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<B>
	Washington
	, D.C. 20549
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 18PT">
<B>
	FORM
	10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(Mark
	One)
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.35IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	[X]
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	ANNUAL
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	For
	the fiscal year ended December 31, 2015
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	or
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.35IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	[&nbsp;&nbsp;]
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	TRANSITION
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Commission
	File Number 001-37428
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 18PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(Exact
	name of registrant as specified in its charter)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	26-3474527
</B>
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(State
	or other jurisdiction of
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	incorporation
	or organization)
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(I.R.S.
	Employer
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Identification
	No.)
</B>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	1880
	Century Park East, Suite 1000
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Los
	Angeles, California
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	90067
</B>
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(Address
	of principal executive offices)
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(Zip
	Code)
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Registrant&rsquo;s
	telephone number, including area code: (310) 203-1000
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Securities
	registered pursuant to Section 12(b) of the Act:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 49%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
	of Each Class
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 49%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
	of Each Exchange on Which Registered
</B>
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Common
	Stock, par value $0.001 per share
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NASDAQ
	Capital Market
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Securities
	registered pursuant to Section 12(g) of the Act: None
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [&nbsp;&nbsp;]
	No [X]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [&nbsp;&nbsp;]
	No [X]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
	Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
	and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [&nbsp;&nbsp;]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
	preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [&nbsp;&nbsp;]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not
	contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy statements incorporated
	by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
	reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
	reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 20%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Large
	accelerated filer
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[&nbsp;&nbsp;]
</FONT>
</TD>
<TD STYLE="WIDTH: 25%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated
	filer
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[&nbsp;&nbsp;]
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated
	filer
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[&nbsp;&nbsp;]
	(Do not check if a smaller reporting company)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller
	reporting company
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[X]
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [&nbsp;&nbsp;] No
	[X]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of June 30, 2015 (the last business day of the registrant&rsquo;s most recently completed second fiscal quarter), the aggregate
	market value of the registrant&rsquo;s common stock held by non-affiliates was approximately $20.1 million based upon the closing
	price for shares of the registrant&rsquo;s common stock of $4.45 as reported by the NASDAQ Capital Market on that date. For purposes
	of this calculation, the registrant has assumed that its directors, executive officers and holders of 5% or more of the outstanding
	common stock are affiliates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of March 16, 2016, there were 8,584,661 shares outstanding of the registrant&rsquo;s common stock, par value $0.001 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 27PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	DOCUMENTS
	INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Portions
	of Ritter Pharmaceuticals, Inc.&rsquo;s Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation
	14A for the 2016 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; BORDER-BOTTOM: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	ANNUAL
	REPORT ON FORM 10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	For
	the Year Ended December 31, 2015
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Table
	of Contents
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<A HREF="#FORM10-K_HTM_A_001">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	I
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 0.6IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_002">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Business
</FONT>
</A>
</TD>
<TD STYLE="WIDTH: 0.5IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1A.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_003">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk
	Factors
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	23
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1B.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_004">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unresolved
	Staff Comments
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	44
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	2.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_005">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Properties
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	44
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	3.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_006">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Legal
	Proceedings
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	44
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	4.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_007">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mine
	Safety Disclosures
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	44
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<A HREF="#FORM10-K_HTM_A_008">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	II
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	5.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<A HREF="#FORM10-K_HTM_A_009">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Market
	for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	45
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	6.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_010">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Selected
	Financial Data
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	7.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_011">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	46
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	7A.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_012">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Quantitative
	and Qualitative Disclosures About Market Risk
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	8.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_013">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	Statements and Supplementary Data
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_020">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Changes
	in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	61
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9A.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_021">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Controls
	and Procedures
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	61
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9B.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_022">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other
	Information
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	61
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<A HREF="#FORM10-K_HTM_A_023">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	III
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	10.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_024">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Directors,
	Executive Officers and Corporate Governance
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	62
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	11.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_025">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Compensation
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	62
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	12.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_026">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Security
	Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	62
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	13.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_027">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certain
	Relationships and Related Transactions, and Director Independence
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	62
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	14.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_028">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Principal
	Accountant Fees and Services
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	62
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<A HREF="#FORM10-K_HTM_A_029">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	IV
</B>
</FONT>
</A>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	15.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_030">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits
	and Financial Statement Schedules
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	63
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<A HREF="#FORM10-K_HTM_A_031">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Signatures
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	64
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	SPECIAL
	NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Annual Report on Form 10-K (&ldquo;Annual Report&rdquo;) contains forward-looking statements that involve substantial risks and
	uncertainties. All statements other than statements of historical facts contained in this Annual Report, including statements
	regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives
	of management and expected market growth are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
	&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
	&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo;
	&ldquo;would&rdquo; and similar expressions are intended to identify forward-looking statements, although not all forward-looking
	statements contain these identifying words. These statements involve known and unknown risks, uncertainties and other important
	factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
	or achievements expressed or implied by the forward-looking statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Some
	of the factors that we believe could cause actual results to differ from those anticipated or predicted include:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to obtain additional financing;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	accuracy of our estimates regarding expenses, future revenues and capital requirements;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	success and timing of our preclinical studies and clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to obtain and maintain regulatory approval of RP-G28 and any other product candidates we may develop, and the labeling
	under any approval we may obtain;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	developments in the United States and other countries;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	performance of third-party manufacturers;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to develop and commercialize our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to obtain and maintain intellectual property protection for our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	successful development of our sales and marketing capabilities;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	potential markets for our product candidates and our ability to serve those markets;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	rate and degree of market acceptance of any future products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	success of competing drugs that are or become available; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	loss of key scientific or management personnel.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By
	their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics,
	and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the
	future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each
	forward-looking statement contained in this Annual Report, we caution you that forward-looking statements are not guarantees of
	future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry
	in which we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition, even
	if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent
	with the forward-looking statements contained in this Annual Report, they may not be predictive of results or developments in
	future periods.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	forward-looking statement that we make in this Annual Report speaks only as of the date of such statement, and we undertake no
	obligation to update such statements to reflect events or circumstances after the date of this Annual Report. You should also
	read carefully the factors described in the &ldquo;Risk Factors&rdquo; section of this Annual Report to better understand the
	risks and uncertainties inherent in our business and underlying any forward-looking statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Annual Report includes statistical and other industry and market data that we obtained from industry publications and research,
	surveys and studies conducted by third-parties. Industry publications and third-party research, surveys and studies generally
	indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy
	or completeness of such information. While we believe these industry publications and third-party research, surveys and studies
	are reliable, we have not independently verified such data.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_001">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	I
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_002">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	1. Business
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ritter
	Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.
	We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality
	of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient&rsquo;s health.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	first novel microbiome modulator, RP-G28, an orally administered, high purity galacto-oligosaccharide, is currently under development
	for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing
	bacteria in the colon, thereby effectively adapting the gut microbiome to assist in digesting the lactose that reaches the large
	intestine. RP-G28 has the potential to become the first drug approved by the Food and Drug Administration (&ldquo;FDA&rdquo;)
	for the reduction of symptoms associated with lactose intolerance. RP-G28 has been studied in a Phase 2a clinical trial and is
	a first-in-class compound.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	The
	Gut Microbiome
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	human gut is a relatively under-explored ecosystem but provides a great opportunity for using dietary intervention strategies
	to reduce the impact of gastrointestinal disease. The human body carries about 100 trillion microorganisms in the intestines,
	which is 10 times greater than the number of cells in the human body. This microbial population is responsible for a number of
	beneficial activities such as fermentation, strengthening the immune system, preventing growth of pathogenic bacteria, providing
	nutrients, and providing hormones. The increasing knowledge of how these microbial populations impact human health provides opportunities
	for novel therapies to treat an assortment of diseases such as neurological disease, cardiovascular disease, obesity, irritable
	bowel syndrome, inflammatory bowel disease, colon cancer, allergies, autism and depression.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Platform
	Approach
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	platform is based on selectively colonizing microbiota (increasing beneficial bacteria) in the colon, and thus changing the colon&rsquo;s
	composition of microbiota. This process has been shown to stimulate the growth of endogenous bifidobacteria, which after a short
	feeding period become predominant in the colon. The result is believed to reduce inflammation and improve digestion, thereby potentially
	reducing digestive symptoms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	selectively increases colonization of lactose-metabolizing bacteria in the colon, such as bifidobacteria and lactobacilli, without
	increasing the growth of harmful bacteria, such as Escherichia coli (&ldquo;E. coli&rdquo;). Increased colonization of lactose-metabolizing
	colonic microbiota is associated with increased lactase activity, thereby increasing the fermentation of lactose into galactose,
	glucose and short chain fatty acids. We believe this process could reduce lactose-derived gas production and thereby mitigate
	the symptoms of lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Lactose
	Intolerance
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Studies
	have suggested that lactose intolerance is a widespread condition affecting over one billion people worldwide and over 40 million
	people in the United States (or 15% of the U.S. population), with an estimated nine million of those individuals demonstrating
	moderate to severe symptoms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Current
	annual spending on over-the-counter lactose intolerance aids in the United States has been estimated at approximately $2.45 billion
<I>
	.
</I>
	However, these options are limited and there is no long-term treatment available.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lactose
	intolerance develops in lactose maldigesters when consuming too much lactose or when lactose is added to a previously low-lactose
	diet. People with lactose maldigestion have a low activity level of lactase, the enzyme responsible for breaking down human lactose,
	located in the brush border membrane of the small intestine. Lactose intolerance is characterized by one or more of the cardinal
	symptoms; including abdominal pain/cramps, bloating, gas, and diarrhea following the ingestion of lactose or lactose-containing
	foods.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	lactose maldigesters, unhydrolyzed lactose passes into the large intestine, where it is fermented by the indigenous microflora
	into gases and short chain fatty acids. The excessive gas production and the osmotic effects of excessive undigested lactose cause
	the symptoms of lactose intolerance. Symptoms begin about 30 minutes to two hours after eating or drinking foods containing lactose.
	The severity of symptoms depends on many factors, including the amount of lactose a person can tolerate and a person&rsquo;s age,
	ethnicity, and digestion rate. The symptoms of lactose intolerance are caused by gases and toxins produced by anaerobic bacteria
	in the large intestine. The problem of lactose intolerance has been exacerbated because many foods and drinks contain traces of
	lactose without lactose being clearly stated on the product&rsquo;s label.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Diagnosis
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lactose
	intolerance is often diagnosed by evaluating an individual&rsquo;s clinical history, which reveals a relationship between lactose
	ingestion and onset of symptoms. Hydrogen breath tests may also be utilized to diagnose lactose malabsorption and a milk challenge
	may be used to differentiate between lactose malabsorption and lactose intolerance. Further tests can be conducted to rule out
	other digestive diseases or conditions, including: stool examination to document the presence of a parasite, blood tests to determine
	the presence of celiac disease, and intestinal biopsies to determine mucosal problems leading to malabsorption, such as inflammatory
	bowel disease or ulcerative colitis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Health
	Consequences
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Substantial
	evidence indicates that lactose intolerance is a major factor in limiting calcium intake in the diet of individuals who are lactose
	intolerant. Studies suggest that these individuals avoid milk and dairy products, resulting in an inadequate intake of calcium
	and significant nutritional and health risks.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research
	shows that lactose intolerant individuals have a higher prevalence and risk for osteoporosis, hypertension, decreased bone mineral
	density and several cancers, including colon and breast cancer from the lack of milk consumption
<I>
	.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Decreased
	Calcium Intake Increases the Risk for Hypertension
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Over
	30 published reports show that chronic calcium depletion may lead to increased arterial blood pressure. Many additional papers
	have corroborated this relationship between hypertension and a low calcium intake.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	growing body of evidence indicates that a nutritionally sound diet rich in fruits, vegetables and a generous component of low-fat
	dairy foods (sometimes referred to as the DASH diet) is optimal for reducing the risk of hypertension. Several reports have confirmed
	this finding in middle-aged and elderly women. Further, it appears that the DASH diet with generous low-fat dairy is associated
	with low prevalence of metabolic syndrome. Studies have suggested that the levels of dairy foods (three-four servings per day)
	required to achieve these effects are well above current U.S. averages and even further above that of lactose intolerant individuals
	who are avoiding dairy due to symptoms
<I>
	.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Decreased
	Calcium Intake Increases the Risk for Colon and Breast Cancers
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	national symposium as long ago as 1993 reported that there was a relationship between dietary calcium and both colon and breast
	cancer. Clearly, several other factors are involved, and the role of calcium has not yet been fully elucidated from the others.
	Nonetheless, there is evidence of a relationship.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Our
	History
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	were formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. Our first prototype,
	Lactagen
<SUP>
	&trade;
</SUP>
	, was an alternative lactose intolerance treatment method. In 2004, clinical testing was conducted,
	which included a 60 subject double-blind placebo controlled clinical trial. The results were published in the Federation of American
	Societies for Experimental Biology in May 2005 and demonstrated Lactagen
<SUP>
	&trade;
</SUP>
	to be an effective and safe product
	for reducing symptoms for nearly 80% of the clinical participants who were on Lactagen
<SUP>
	&trade;
</SUP>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	2008, we expanded our focus by developing a prescription drug development program. We initiated the program by developing RP-G28,
	a second generation edition of Lactagen
<SUP>
	&trade;
</SUP>
	. We believe that RP-G28 enables us to state stronger claims, garner
	more medical community support and reach a wider market in the effort to treat lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	To
	help fund the development of RP-G28, we were awarded a grant from the United States government&rsquo;s Health Care Bill program,
	the Qualifying Therapeutic Discovery Project, in 2008. The grant program provides support for innovative projects that are determined
	by the U.S. Department of Health and Human Services to have reasonable potential to result in new therapies that treat areas of
	unmet medical need and/or prevent, detect or treat chronic or acute diseases and conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	September 16, 2008, we converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Our
	Leading Product Candidate &mdash; RP-G28
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Overview
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	is a novel highly purified galacto-oligosaccharide (&ldquo;GOS&rdquo;), which is synthesized enzymatically. The product is being
	developed to reduce the symptoms and frequency of episodes of abdominal pain associated with lactose intolerance. The therapeutic
	is taken orally (a powder solution mixed in water) for 30 consecutive days. The proposed mechanism of action of RP-G28 is to increase
	the intestinal growth and colonization of bacteria that can metabolize lactose to compensate for a patients intrinsic inability
	to digest lactose. Once colonization of bacteria has occurred, it is hypothesized that patients will continue to tolerate lactose
	as long as they maintain their microflora balance. RP-G28 has the potential to become the first FDA-approved drug for the reduction
	of symptoms associated with lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Galacto-oligosaccharides
	(GOS)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	is a &gt;95% purified GOS product. GOS refers to a group of compounds containing &beta;-linkages of 1 to 6 galactose units with
	a single glucose on the terminal end and are found at low levels in human milk. GOS products resist hydrolysis by salivary and
	intestinal enzymes because of the configuration of their glycosidic bonds and reach the colon virtually intact. The undigested
	GOS enhances the growth of beneficial, lactose metabolizing, colonic bacteria that already exist in the subject&rsquo;s digestive
	track, including multiple species and strains of bifidobacteria and lactobacilli. Once colonies of these bacteria have increased,
	continued lactose exposure should maintain tolerability of lactose without further exposure to RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	significance of a higher purity GOS, namely RP-G28, was highlighted in a 2010 study by Klaenhammer. The in vitro study concluded
	that RP-G28 promoted growth of lactobacilli and bifidobacteria, but did not promote multiple strains of E. coli. In contrast,
	lower purity GOS stimulated both bifidobacteria as well as the strains of E. coli evaluated. (As seen below in Figure 1, NCK 430
	(e. coli) grew in the presence of low purity GOS (GOS 2). Alternatively, the higher purity GOS (RP-G28/GOS 1) did not promote
	the growth of E. coli.).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Figure
	1
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/21/0001493152-16-008162_IMAGE_001.JPG" ALT="" STYLE="WIDTH: 395">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Mechanism
	of Action
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	selectively increases colonization of lactose-metabolizing bacteria in the colon, such as bifidobacteria and lactobacilli, without
	increasing the growth of harmful bacteria, such as E. coli
<I>
	.
</I>
	Increased colonization of lactose-metabolizing colonic bacteria
	is associated with increased lactase activity and GOS utilization, thereby increasing the fermentation of lactose into galactose,
	glucose and short chain fatty acids. Digestion of lactose reduces lactose-derived gas production and thereby mitigates the symptoms
	of lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/21/0001493152-16-008162_IMAGE_002.JPG" ALT="" STYLE="HEIGHT: 325; WIDTH: 601">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Safety
	&amp; Toxicology of GOS
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Clinical
	studies of GOS products were reviewed as part of the safety evaluation to support our Investigational New Drug (&ldquo;IND&rdquo;)
	Application for RP-G28. The safety of GOS products in humans has been evaluated in 486 adults at doses of 2.5 to 15 gm/day for
	up to 14 weeks, 342 children at doses of 2.0 &ndash; 2.4 gm/day for up to 1 year, and in 2415 newborns and infants for up to 6
	months. Overall, no reports of severe adverse events attributable to the consumption of GOS were reported in the literature.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Among
	the studies that included tolerance endpoints, side effects were limited to reports of flatulence, fullness, gastronintestinal
	symptoms, and changes in stool consistency and frequency when GOS was consumed on a repeat basis at quantities of between 5.5
	to 15 g/day (Ito 1990; Deguchi 1997; Teuri 1998); however, this effect was not consistently reported in all studies (Teuri and
	Korpela 1998; Depeint 2008; Drakoularako 2010; van de Heuval 1998; van Dokkum 1999; Bouhnik 2004; Sairanen and Piirainen 2007;
	Shadid 2007). Similar observations of increased flatulence have been reported following the consumption of fructooligosaccharides
	(15 gm/day) over a 7-day period (Alles 1996), and this symptom represents a localized effect that is expected in association with
	the consumption of indigestible fiber in large quantities. There were no reports of events in other System Organ Class (SOC) suggestive
	of systemic toxicity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	RP-G28
	Clinical Safety
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to the nonclinical studies evaluating GOS products, the safety of RP-G28 for clinical investigation is supported by clinical
	safety results from our Phase 2a study, G28-001. In this study, RP-G28 was escalated from 1.5 grams per day to 15 grams per day
	over a 35-day dosing period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	was well-tolerated. There were no serious adverse effects. The most common adverse effects were headache, dizziness, nausea, upper
	respiratory tract infection, nasal congestion and pain. All adverse effects were mild or moderate in severity, and event occurrence
	was distributed over the treatment and post-treatment follow-up phase. No clinically significant changes or findings were noted
	from clinical lab evaluations, vital sign measurements, physical exams, or 12-lead electrocardiograms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Our
	Market Opportunity
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Unmet
	Medical Needs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lactose
	intolerance is a challenging condition to manage. According to a market research study conducted by Objective Insights in April
	2012, approximately 60% of lactose intolerant sufferers reported experiencing symptoms daily, or bi-weekly. Not only can symptoms
	be painful and embarrassing, they can also dramatically affect one&rsquo;s quality of life, social activities, and health. Currently
	there are few reliable, or effective, treatments available that provide consistent or satisfactory relief.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Currently,
	there is no approved prescription treatment for lactose intolerance. Most persons with lactose intolerance avoid ingestion of
	milk and dairy products while others substitute non-lactose-containing foods in their diet. However, complete avoidance of lactose-containing
	foods is difficult to achieve (especially for those with moderate to severe symptoms) and can lead to significant long-term morbidity
	(
<I>
	i.e.
</I>
	, dietary deficiencies of calcium and vitamin D).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	At
	the 2010 National Institute of Health (&ldquo;NIH&rdquo;) Consensus Development Conference: Lactose Intolerance and Health, the
	NIH highlighted numerous health risks tied to lactose intolerance such as: osteoporosis; hypertension; and low bone density
<I>
	.
</I>
	There is substantial evidence indicating that lactose intolerance is a major factor in limiting calcium and nutrient intake
	in the diet of people who are lactose intolerant. Adequate calcium intake is essential to reducing the risks of osteoporosis and
	hypertension
<I>
	.
</I>
	In addition, chronic calcium depletion has been linked to increased arterial blood pressure, thereby establishing
	a relationship between hypertension and low calcium intake
<I>
	.
</I>
	Moreover, there is evidence of a correlation between calcium
	intake and both colon and breast cancer
<I>
	.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Treatment
	Options
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Doctors
	generally recommend the following treatments for the management of lactose intolerance: (1) dairy avoidance; (2) lactase supplements;
	(3) probiotics/dietary supplements; and (4) dairy substitutes/lactose free products. Despite educating their patients on all viable
	treatment options, physicians tend to advise their patients to refrain from consuming any dairy products whatsoever. However,
	in a 2008 survey conducted by Engage Health, 47% of lactose intolerance sufferers reported that this method was not effective
	(largely due to hidden dairy products in ingredients), and only 30% of lactose intolerance sufferers reported lactase supplements
	as being effective in managing their lactose intolerance
<I>
	.
</I>
	Further, while probiotics/dietary supplements have been demonstrated
	to aid and support one&rsquo;s digestive system, helping break down general foods consumed, they don&rsquo;t directly help with
	lactose intolerance. The 2008 survey by Engage Health suggests that the majority of lactose intolerance patients are dissatisfied
	with current treatment options.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Patients
	Unsatisfied with Current Management Options
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/21/0001493152-16-008162_IMAGE_003.JPG" ALT="" STYLE="HEIGHT: 325; WIDTH: 241">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Growing
	Awareness
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lactose
	intolerance is a condition that continues to expand as society advances and evolves. Education and awareness have increased, and
	the American diet has greatly changed over the past decade to include more dairy-based goods. As the populace is growing older,
	the prevalence of lactose intolerance is increasing because more people tend to develop lactose intolerance later in life. Increased
	education and diagnosis is making more people aware of their allergies and digestive conditions. Physicians may compound the growth
	of lactose intolerance prevalence and its associated disorders by recommending individuals to avoid dairy products, a practice
	which in and of itself may increase severity of the intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	It
	has been estimated that gastroenterologists see approximately 15 new patients with lactose intolerance each month
<I>
	.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Doctors
	tend to diagnose lactose intolerance in a patient before the patient is able to self-diagnose it
<I>
	.
</I>
	However, patients tend
	to initiate discussion about lactose intolerance with their doctors. This is indicative of broad public awareness of lactose intolerance.
	Doctors often administer two tests for diagnosing lactose intolerance: (i) a symptom history test and (ii) a hydrogen breath test.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Our
	Competitive Strengths
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Market
	Opportunity
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	has the potential to become the first approved drug in the United States and Europe for the reduction of symptoms associated with
	lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Renowned
	Scientific Team and Management Team
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	leadership team has extensive biotechnology/pharmaceutical expertise in discovering, developing, licensing and commercializing
	therapeutic products. We have attracted a scientific team comprised of innovative researchers who are renowned in their knowledge
	and understanding of the host-microbiome in the field of lactose intolerance and gastroenterology.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Substantial
	Patent Portfolio and Product Exclusivity
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have an issued patent in the United Kingdom directed to the composition of non-digestible carbohydrates, and we have issued patents
	in the United States directed to methods of using such compositions for the treatment of lactose intolerance and symptoms. Additional
	worldwide patent applications are pending. The patent applications include claims covering compositions, methods, formulations
	and packaging.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, in July 2015 we acquired the rights, title and interest to certain patents and related patent applications with claims
	covering a process for producing ultra high purity galacto-oligosaccharide active pharmaceutical ingredients, including RP-G28
	from our supplier. See &ldquo;Business&mdash;Clinical Supply and Cooperation Agreement with Ricerche Sperimentali Montale and
	Inalco SpA&rdquo; for additional details regarding the second amendment to the exclusive supply agreement and our exercise of
	the exclusive option.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	See
	&ldquo;Business&mdash;Intellectual Property&rdquo; for additional information regarding our patent portfolio.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Our
	Growth Strategy
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	order to achieve our objective of developing safe and effective applications to treat conditions associated with microbiome disfunctions,
	our near-term and long-term strategies include the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	Complete
	an adaptive design Phase 2b/3 clinical trial and any additional pivotal studies of RP-G28 for the reduction of symptoms associated
	with lactose intolerance;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	seek
	regulatory approval of RP-G28 for the reduction of symptoms associated with lactose intolerance if the clinical trials are
	successful, initially in the United States and subsequently in the rest of the world;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	develop
	and commercialize RP-G28 either by ourselves or in collaboration with others throughout the world;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	explore
	the use of RP-G28 for additional potential therapeutic indications and orphan indications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	establish
	ourselves as a leader in developing therapeutics that modulates the human gut microbiome;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	continue
	to develop a robust and defensible patent portfolio, including those we own and those we plan to in-license in the future;
	and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	continue
	to optimize our product development and manufacturing capabilities both internally and externally through outside manufacturers.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Clinical
	and Regulatory
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	IND
	Application/Phase 1
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	submitted an IND application for RP-G28 to the FDA in June 2010. Because the safety and tolerability profile, pharmacokinetics
	and dose response curve of GOS products is generally well understood, as part of our IND submission, we proposed that the data
	supporting the IND was sufficient to support a Phase 2 proof-of-concept study in a small number of lactose-intolerant patients.
	The FDA agreed with this proposal and the typical Phase 1 clinical program in healthy volunteers was replaced by a Phase 2a program
	in subjects with lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 28, 2010, we received an advice letter from the FDA regarding our IND submission. The FDA suggested that we (1) consider
	expanding our inclusion criteria to include females of childbearing potential who are willing to use appropriate contraception
	throughout the duration of the protocol; (2) follow the FDA&rsquo;s guidance regarding Patient-Reported Outcome Measures; and
	(3) include a pharmacokinetic study in our proposed Phase 2a trial to determine the extent of systemic exposure of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Phase
	2a Study
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	June 2011, we began a Phase 2a clinical trial on RP-G28 to validate the efficacy, safety, and tolerance of RP-G28 compared to
	placebo when administered to subjects with symptoms of lactose intolerance. The clinical results from the study, which concluded
	at the end of 2011, showed that RP-G28 improved lactose digestion versus placebo as measured by the improvement in digestive symptoms
	associated with lactose intolerance and decline in hydrogen production present in a hydrogen breath test.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 12, 2013, we announced positive data from our Phase 2a first-in-human, proof of concept clinical study of RP-G28. The purpose
	of the study was to assess the effectiveness, safety and tolerability of RP-G28 compared to a placebo when administered to subjects
	with symptoms associated with lactose intolerance. The results were presented at Digestive Diseases Week and the New York Academy
	of Sciences Conference on Probiotics, Prebiotics and the Host Microbiome: The Science of Translation, and co-sponsored by the
	Sackler Institute for Nutrition Science and the International Scientific Association of Probiotics and Prebiotics.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	double-blinded, randomized, multi-center, placebo-controlled Phase 2a study evaluated RP-G28 in 62 patients with lactose intolerance
	over a treatment period of 35 consecutive days. Post-treatment, subjects reintroduced dairy into their diets and were followed
	for an additional 30 days to evaluate lactose digestion, as measured by hydrogen production and symptom improvements. In order
	to confirm lactose intolerance and study participation, subjects underwent a 25-gram lactose challenge in the clinic. Lactose
	intolerance symptoms and hydrogen production via hydrogen breath test were assessed for six hours post-lactose dose. Eligible
	subjects were required to demonstrate a minimum symptom score and a &ldquo;positive&rdquo; hydrogen breath test in order to be
	eligible for randomization. A &ldquo;positive&rdquo; breath test was defined as a hydrogen gas elevation of 20 parts per million
	(ppm) at two time-points within the six hours following a lactose-loading dose. The primary endpoints included tracking patients&rsquo;
	gastrointestinal symptoms via a patient-reported symptom assessment instrument (a Likert Scale, measuring individual symptoms
	of flatulence, bloating, cramping, abdominal pain and diarrhea, on a scale of 0 (none) to 10 (worst)) at baseline, day 36 and
	day 66; as well as the measurement of hydrogen gas levels in their breath following a 25-gram lactose challenge.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	was well tolerated, with no significant adverse events reported. The Phase 2a study demonstrated clinically meaningful benefits
	to patients on treatment, whereas treated subjects reported increased tolerance to lactose and dairy foods: reduced lactose intolerance
	symptoms (gas, bloating, cramping and abdominal pain) were reported in subjects on RP-G28, a durable reduction in abdominal pain
	(p=0.019) was reported, and treated patients were six times more likely to describe themselves as lactose tolerant (p=0.039).
	In sum, positive trends were seen when the entire per protocol study population was analyzed, including some statistically significant
	subgroup analysis, suggesting that a therapeutically positive effect is seen. Although there were few primary and secondary efficacy
	endpoints with statistically significant results, the combined data suggest that RP-G28 is exerting a positive therapeutic effect.
	We believe these positive drug effect trends combined with the benign safety profile support continued drug development of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Key
	findings of the Phase 2a study include:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	RP-G28
	was well tolerated with no significant study-drug related adverse effects. The benign adverse event safety profile of RP-G28
	with dose levels up to 15 gm/day observed in this study is consistent with the known safety of GOS products administered up
	to 20 gm/day reported in literature.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	Subjects
	in the RP-G28 group reported a reduction in total symptoms after treatment. Reported symptom improvement continued 30 days
	post-treatment. Improvement in symptoms was assessed in the study using several different measures, including a pain Likert
	scale and a patient global assessment. Subjects receiving RP-G28 had greater improvement in most of their symptoms (cramps,
	bloating and gas) following lactose challenge compared to placebo, but the differences were not statistically significant
	given the small cohort size. However, a clinically meaningful reduction in abdominal pain was seen in subjects receiving RP-G28
	compared to placebo.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	An
	analysis of&thinsp; &ldquo;responders&rdquo; for abdominal pain (defined as subjects who reported a score of zero in abdominal
	pain severity following a lactose challenge at Day 36/Hour 6 and Day 66/Hour 6) was performed. In the 55 subjects who noted
	abdominal pain following the baseline (Day 0) lactose challenge, 50% of RP-G28-treated subjects reported no abdominal pain
	compared to 17% of the placebo-treated subjects. This difference was statistically significant (p = 0.0190). See Figure 2
	below.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	An
	analysis of&thinsp; &ldquo;responders&rdquo; for abdominal pain (defined as subjects who reported a greater than 50% decrease
	in abdominal pain severity following lactose challenge between Day 0/Hour 6 and Day 36/Hour 6) was performed. In the 55 subjects
	who noted abdominal pain following the baseline (Day 0) lactose challenge, 72.2% of RP-G28-treated subjects reported a &gt;50%
	reduction in abdominal pain severity compared to 42.1% of the placebo-treated subjects. This difference was also statistically
	significant (p=0.0288).
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	To
	better explore a meaningful benefit to patients, a global assessment was explored. Six times as many patients in the treatment
	group versus the placebo group described themselves as lactose tolerant and did not report symptoms associated with lactose
	intolerance on Day 66. After completion of study treatment at Day 36, subjects were encouraged to re-introduce dairy foods
	into their diet. Thirty days later (Day 66), subjects were asked to provide an assessment of their symptom status, i.e., whether
	they considered themselves still lactose intolerant compared with subjects receiving placebo (Yes/No). As seen below in Figure
	2 below, in the 58 subjects providing responses, a significantly larger percentage of subjects receiving RP-G28 (30%) considered
	themselves no longer lactose intolerant compared with subjects receiving placebo (5.6%); this result was statistically significant
	(p=0.0389).
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	The
	reduction in total symptoms following a post-treatment lactose challenge was consistent with the improvement in post-treatment
	hydrogen breath test results as compared to baseline (pre-treatment) results. Although rarely used in clinical practice and
	primarily used to identify lactase deficiency, hydrogen measurements were used as an eligibility criterion as well as an outcome
	measure in our Phase 2a proof-of-concept study. Our intent was to better understand how lactose intolerant symptoms and hydrogen
	values correlated and whether a treatment effect could be detected by hydrogen production. In the RP-G28 group, the median
	peak hydrogen production was 113 ppm on Day 0 and 110 ppm on Day 36. In the placebo group, the median peak hydrogen production
	was 94 ppm at Day 0 and 113 on day 36. At Day 0 and Day 36, the median total hydrogen production was 385 ppm and 367 ppm,
	respectively, for the RP-G28 group and 347 and 436 ppm, respectively, for the placebo group. Comparison of the hydrogen breath
	test results between RP-G28 and placebo shows that median hydrogen production was generally similar between the two treatment
	groups at Day 0 while at Day 36, median hydrogen production was lower in the RP-G28 group compared to placebo at the peak
	time points of 2 to 4 hours. While the differences were not large, the RP-G28 group had consistently lower levels of breath
	hydrogen production from Hours 2 to 6 following lactose challenge, but the results did not correlate with clinical symptoms.
	In the Placebo group, differences in hydrogen production following lactose challenge were not apparent.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Figure
	2
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/21/0001493152-16-008162_IMAGE_004.JPG" ALT="" STYLE="HEIGHT: 325; WIDTH: 226">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	the Phase 2a study, changes in the fecal microbiome were investigated using both Terminal Restriction Fragment Length Polymorphisms
	(TRFLP), a molecular biology technique for profiling microbial communities based on the position of a restriction site closest
	to a labeled end of an amplified gene, and microme analysis of 16S rRNA genex by pyrosequencing, a method of DNA sequencing (determining
	the order of nucleotides in DNA).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Figure
	3
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/21/0001493152-16-008162_IMAGE_005.JPG" ALT="" STYLE="HEIGHT: 400; WIDTH: 368">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, Principal Component Analysis (PCA), a multivariate method that helps transform a number of possibly correlated variables
	into a smaller number of uncorrelated variables called principal components, thereby reducing the dimensions of a complex dataset,
	showed statistically significant shifts in the microbiome of subjects fed RP-G28, compared to placebo, at 66 days. Specifically,
	RP-G28 significantly altered the microbiomes of 82% of the study participants who received the treatment. See Figure 3 above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pre-treatment,
	three distinct clusters were identified, whereas post-treatment (Day 66) two distinct clusters were identified, showing a clear
	shift in certain species represented before and after treatment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Principal
	Coordinates Analysis (PCoA), a multivariate method that helps visualize similarities and dissimilarities in large datasets, was
	also utilized to analyze the microbiome data. For analysis of 16S amplicon sequencing data, we created Unweighted Unifrac similarity
	matrices (that is we conducted PCoA) and applied ANOSIM (Analysis of Similarities) and PERMANOVA (Permutational Analysis of Variance)
	statistical analyses. Our analysis showed a significant association between Day (day 0 or baseline, and day 36 and 66 as categories)
	and microbiome composition (ANOSIM R = 0.218, P = 0.0001, PERMANOVA Pseudo-F = 3.4318, P = 0.0001). These data indicate that RP-G28
	and subsequent introduction of lactose into the diet had impacted the fecal microbiome of participants. Further, lactose metabolizing
	bacteria were shown to increase in the treatment group.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	results of our Phase 2a study were published in Nutrition Journal in a manuscript entitled &ldquo;
<I>
	Improving lactose digestion
	and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
</I>
	.&rdquo;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	held a Type C meeting with the FDA&rsquo;s Division of Gastroenterology and Inborn Errors Products on February 20, 2013. The purpose
	of the meeting was to obtain the FDA&rsquo;s feedback on the planned Phase 2 program and Phase 3 programs, inform the FDA of our
	ongoing development plans, gain feedback on relevant clinical trial design and end points related to patient meaningful benefits,
	and to inform the FDA of the status of our product characterization. We believe that this meeting was a significant step forward
	in streamlining the pathway to initial U.S. approval of RP-G28 to reduce symptoms and frequency of symptomatic episodes associated
	with lactose intolerance. The meeting and official meeting minutes provided valuable guidance on the development path of RP-G28:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	The
	FDA agreed with our decision to develop and validate a new analytical assay for RP-G28 drug substance and drug product. This
	adjustment will provide additional information about GOS components and non-GOS impurities, which the FDA agrees should be
	in place before we prepare batches of the drug substance for use in any pivotal Phase 3 clinical trials.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	Based
	on our plan to conduct ICH-compliant GLP embryo-fetal development toxicology studies (in two species) and the ICH standard
	battery of genotoxicity tests using RP-G28, the FDA agreed that no additional nonclinical studies are needed at this time
	to support Phase 3 studies.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	The
	FDA advised us on potential end points and clinical trial design.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	We
	addressed the FDA&rsquo;s recommendation in its June 28, 2010 advice letter that we include a pharmacokinetic study in the
	Phase 2b study to assess the extent of systemic exposure of RP-G28. We explained to the FDA that we did not collect serum
	samples for pharmacokinetic measurement in the Phase 2a study because at the time assays for measuring RP-G28 were not available
	and significant systemic absorption was not anticipated. We then informed the FDA of our plan to evaluate alternatives, as
	a surrogate for RP-G28 systemic exposure as part of our Phase 2b program. The FDA agreed with this approach.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Following
	analysis of the Phase 2a clinical trial, discussions with the FDA in 2013 about our clinical development plan, and further discussions
	with our regulatory consultants, we initiated a Phase 2b/3 clinical trial of RP-G28 in March 2016. We believe this trial could
	serve as one of two pivotal trials should the resulting data and the FDA be supportive of this trial as a pivotal trial. We did
	not discuss the Phase 2b/3 study design and development plan with the FDA, though we did submit a supplement to the IND detailing
	the protocols for the adaptive study. See below for further discussion of our Phase 2b/3 study.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Nonclinical
	Safety Plans
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	the established safety profile of GOS in humans and the lack of significant safety concerns with RP-G28 administered to subjects
	in the Phase 2a study, no additional non-clinical safety studies are planned to support continued evaluation of RP-G28 in the
	Phase 2 program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Guidelines
	adopted by the FDA and established by ICH require nonclinical studies that specifically address female fertility to be completed
	before the inclusion of women of child bearing potential in large-scale or long-duration clinical trials (e.g., Phase 3 trials).
	In the United States, such assessments of embryo-fetal development can be deferred until before Phase 3 using precautions to prevent
	pregnancy in clinical trials. As the FDA recommended in their June 28, 2010 advice letter, we will continue to evaluate females
	of child-bearing potential who are willing to use appropriate contraception throughout the duration of any study. In addition,
	to support Phase 3 studies, we plan to perform ICH-compliant embryo-fetal development toxicology studies of RP-G28. We will then
	confirm any negative findings from these toxicology studies in a standard battery of ICH-compliant genotoxicity tests using RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Phase
	2b/3 Study
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Phase 2b/3 clinical trial of RP-G28 was initiated in March 2016. This study is designed as a multi-center double-blinded, placebo
	controlled clinical trial of approximately 350 subjects to determine the maximum tolerated dose and optimal dose-escalation schedule
	for RP-G28. The trial will assess patients with moderate to severe abdominal pain as measured by a pain Likert scale after a lactose
	challenge. The Phase 2b/3 clinical trial is designed to measure additional lactose intolerance symptoms (gas, bloating, diarrhea,
	cramps) as secondary endpoints. Entry criteria in the Phase 2b/3 study will include a hydrogen breath test to validate lactase
	deficiency. The Phase 2b/3 study design includes a screening phase; a 30-day course treatment phase and a 30-day post-treatment
	evaluation phase. The study is designed to gradually escalate the dose beyond the 15 gm/day dose level evaluated in the Phase
	2a study. Study subjects will abstain from lactose containing food products and then be randomized evenly (1:1:1:1) to receive
	one of three doses of RP-G28 or placebo for 30 days. Subjects will then be followed post-treatment for an additional 30 days while
	lactose containing food products are re-introduced into their diets. The primary endpoint for the Phase 2b/3 clinical study will
	be a durable reduction in abdominal pain, with secondary endpoints measuring changes in individual lactose intolerance symptoms
	(gas, bloating, diarrhea, cramps). The Phase 2b/3 study is also designed to include collection of blood samples to assess systemic
	exposure to RP-G28 using measurement of serum concentrations of a trisaccharide. This is will be monitored as a surrogate to assess
	the systemic bioavailability of orally administered RP-G28. Additionally, the study will require the collection of fecal samples
	from patients enrolled to evaluate the baseline and changes to the patient&rsquo;s microbiome that correlate to symptom reduction
	and lactose tolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	order to gather long-term data on subjects exposed to RP-G28, we also intend for subjects completing the Phase 2b/3 protocol to
	be offered enrollment in an observational extension study, G28-004. As RP-G28 is expected to provide extended relief from lactose
	intolerance symptoms beyond the initial 30-day treatment phase, this extension study for the Phase 2b/3 program is going to assess
	the long-term treatment effect. We intend for the results from this study to guide the need to evaluate an additional 30-day course
	of treatment in Phase 3 in subjects who experience the return of lactose intolerance symptoms after an initial course of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Adaptive
	seamless phase 2b/3 designs, such as the Phase 2b/3 pivotal clinical trial for RP-G28, are aimed at interweaving the two phases
	of full development by combining them into one single, uninterrupted study conducted in two steps. Adaptive seamless phase 2b/3
	designs enable a clinical trial to be conducted in steps with the sample size calculation selected on the basis of data observed
	in the first step to continue along to the second step. The main statistical challenge in such a design is ensuring control of
	the type I error rate. Most methodology for such trials is based on the same endpoint being used for interim and final analyses.
	A type I error is one in which the adaptation process leads to design, analysis, or conduct flaws that introduce bias that increases
	the chance of a false conclusion that a treatment is effective (a type I error). Controlling type I error can be accomplished
	by prospectively specifying and including in the statistical analysis plan all possible adaptation plans that may be considered
	during the course of the trial. We are working with Covance, Inc., a contract research organization (&ldquo;CRO&rdquo;) to control
	type I error in our Phase 2b/3 study.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Research
	and Development Agreement with Kolu Pohaku Technologies and Kolu Pohaku Management, LLC
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	November 30, 2010, we entered into a Research and Development Agreement &amp; License (the &ldquo;R&amp;D Agreement&rdquo;) with
	Kolu Pohaku Technologies, LLC (&ldquo;KPT&rdquo;) and Kolu Pohaku Management, LLC (&ldquo;KPM&rdquo;). The R&amp;D Agreement called
	for KPT to make a series of payments to us totaling $1,750,000 in exchange for us performing certain research and development
	activities in Hawaii for the benefit of KPT (referred to herein as the &ldquo;KP Research&rdquo;), from the effective date of
	the agreement through December 31, 2014. The KP Research consisted of the initial phase of research, including the conduct of
	Phase 2 clinical trials in Hawaii for RP-G28. Under the terms of the R&amp;D Agreement, we maintained sole and exclusive control
	over the manner in which we and our employees and contractors performed the KP Research and ownership of the results of our ongoing
	research related to RP-G28, although KPT maintained ownership of the results of the KP Research. Inventions, developments, and
	improvements arising out of the KP Research were owned by KPT. Under the terms of the R&amp;D Agreement we would bear any costs
	involved in obtaining patents for any inventions, developments or improvements resulting from the KP Research. In exchange for
	the irrevocable, perpetual, exclusive, worldwide right and license to the results of the KP Research, we agreed to pay a quarterly
	royalty payment to KPT of&thinsp; $32,000 commencing March 31, 2015 and continuing through December 31, 2035 or until such time
	as the KPM Option (described below) was exercised. The license included, without limitation, our right to sublicense the KP Research
	and to make, have made, use, sell, offer for sale and import products based, in whole or in part, on the KP Research. The R&amp;D
	Agreement was subsequently amended on, July 6, 2011, September 30, 2011, February 6, 2012 and November 4, 2013 to increase the
	funding to be received by us thereunder and to add royalty payments made by us for years subsequent to the original agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the R&amp;D Agreement, we also granted an option (the &ldquo;KPM Option&rdquo;) to KMP. Pursuant to the terms
	of the KPM Option Agreement, we had the right to put to KPM and KPM had the right to call from us 1,469,994 shares of our then
	authorized Series B preferred stock at any time after December 31, 2014. The number of shares was determined by dividing the $1,750,000
	of payments made by KPT to us under the R&amp;D Agreement by the Series B preferred stock original issue price of&thinsp;$1.19
	per share. On March 26, 2015, we exercised our right to put the KPM Option and issued 1,469,994 shares of Series B preferred stock
	to KPM (the &ldquo;KPM Shares&rdquo;). Pursuant to the terms of the KPM Option Agreement, our issuance of the KPM Shares to KPM
	resulted in the full satisfaction of our obligation to make royalty payments to KPT under the R&amp;D Agreement and also resulted
	in the termination of the R&amp;D Agreement and therefore KPM&rsquo;s and KPT&rsquo;s right, title, and interest in the KP Research
	under the R&amp;D Agreement was assigned to Ritter.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Master
	Service Agreement
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 30, 2015, we entered into a Master Service Agreement with Covance, Inc. (&ldquo;Covance&rdquo;), with an effective date
	of December 29, 2015. Pursuant to the terms of the Master Service Agreement, Covance (or one or more of its affiliates) will provide
	Phase 1, 2, 3, and 4 clinical services for a clinical study or studies to us, and, at our request, assist us with the design of
	such studies, in accordance with the terms of separate individual project agreements to be entered into by the parties. The term
	of the agreement is for three years and will renew automatically for successive one year periods unless Covance is no longer providing
	services under the agreement or either party has terminated the agreement upon written notice. We may terminate the Master Service
	Agreement or any individual project agreement entered into under the Master Service Agreement prior to the applicable study&rsquo;s
	completion at any time for any reason upon 30 days written notice to Covance, except when the reason for termination is the safety
	of subjects, in which case it may be terminated immediately. Covance may not terminate any individual project agreement without
	cause, except when the reason for the termination is the safety of subjects, in which case it may be terminated immediately. In
	the event of a termination of the Master Service Agreement, Covance will be entitled to full payment for (i) work performed on
	the applicable project upon through the date work on such project is concluded and (ii) reimbursement for all non-cancellable
	and non-refundable expenses and financial obligations which Covance (or an affiliate) has incurred or undertaken on our behalf.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Manufacturing
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans to develop
	our own manufacturing operations in the foreseeable future. In December 2009, we entered into a Clinical Supply and Cooperation
	Agreement (the &ldquo;Supply Agreement&rdquo;), with Ricerche Sperimentali Montaleor (&ldquo;RSM&rdquo;) and Inalco SpA (&ldquo;Inalco&rdquo;).
	Pursuant to the terms of the Supply Agreement, RSM has exclusively manufactured for us, and will continue to manufacture for us
	in connection with our Phase 2b/3 study, an improved form of GOS (higher purity) (referred to as &ldquo;Improved GOS&rdquo;).
	RSM also agreed that it will not, except as necessary for RSM to perform its obligations under the Supply Agreement, market or
	sell Improved GOS, or any galacto-oligosaccharides that are of greater purity to any third party. In addition to our payments
	to RSM for the GOS manufactured or to be manufactured by RSM for us in connection with our clinical trials, we agreed to pay RSM
	certain milestone payments including a payment of&thinsp; $50,000 as consideration for its assistance in seeking the necessary
	regulatory approvals for RP-G28 (consisting of a payment of&thinsp; $25,000 upon the effective date of the Supply Agreement and
	a payment of&thinsp; $25,000 upon completion to our satisfaction of the drug master file submission to the FDA related to RP-G28
	or another product using Improved GOS). We also agreed to pay a monthly fee of&thinsp;$7,000 in consideration for the services
	provided by RSM under the agreement, which became payable 30 days after our initial public offering, and will continue until such
	time as the parties agree that RSM&rsquo;s support for regulatory approval is no longer required, which is expected to be after
	the completion of our Phase 3 studies. Pursuant to the terms of the Supply Agreement, we also agreed to reimburse RSM for its
	reasonable costs actually incurred in purchasing certain equipment required to perform its analysis methods for Improved GOS,
	which equipment we will own upon payment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the terms of the Supply Agreement, RSM granted us an exclusive worldwide option to the assignment of all right, title and interest
	to the Improved GOS (the &ldquo;Improved GOS IP&rdquo;), which we could exercise by paying RSM $1,000,000, within 10 days of a
	Financing Receipt (as defined in the Supply Agreement), which included our initial public offering. As additional consideration
	for the assignment of the Improved GOS IP, we agreed to pay RSM an additional $1,000,000 within 10 days of the approval by the
	FDA of the new drug application (&ldquo;NDA&rdquo;) for our first product containing Improved GOS. Under the terms of the Supply
	Agreement, we would continue to make the monthly payments to RSM until such time as the parties agree that RSM&rsquo;s support
	for regulatory approval is no longer required. See the section below entitled &ldquo;Intellectual Property&thinsp;&mdash;&thinsp;Patents
	and Proprietary Rights Covering Our Drug Candidates&rdquo; for additional information regarding the Improved GOS IP.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the terms of the Supply Agreement, the parties agreed that in the event we were able to obtain a Financing Receipt, the parties
	would enter into a further agreement (the &ldquo;Proposed Agreement), for the purpose of clarifying future manufacturing services
	to be provided by RSM to us regarding Improved GOS and payment by us for such services. The Supply Agreement sets forth certain
	terms and conditions that the parties to the agreement agreed would be included in the Proposed Agreement, including, among other
	things, a provision that calls for certain milestone payments to be paid to RSM by us in the event we receive approval from the
	FDA to market RP-G28 or another product using Improved GOS, which milestone payments will be based upon the number of&thinsp;&ldquo;units&rdquo;
	sold by us containing Improved GOS. The Proposed Agreement will terminate upon the expiration of the first patent filed by RSM
	regarding Improved GOS.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Supply Agreement was amended in September 2010. Pursuant to the terms of this amendment, we have paid all obligations to RSM in
	satisfaction of the payment due to RSM upon completion to our satisfaction of the drug master file submission to the FDA related
	to RP-G28 (as described above). The amendment also further defined the terms and conditions of the supply of Improved GOS by RSM
	to us to ensure adequate and timely delivery of Improved GOS to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Supply Agreement was further amended on July 24, 2015 to adopt certain provisions contemplated by the Proposed Agreement. Pursuant
	to the terms of the second amendment to the Supply Agreement, the provisions related to the exclusive worldwide option to the
	assignment of all right, title and interest to the Improved GOS IP were amended to provide that we could exercise the option by
	paying RSM $800,000 within ten days after the effective date of the second amendment to the Supply Agreement. We exercised this
	option on July 30, 2015 and RSM transferred the Improved GOS IP to us. Under the terms of the Supply Agreement, as amended, if
	we fail to make any future option payment required under the terms of the Supply Agreement, we may be required to return the Improved
	GOS IP to RSM. The terms of the second amendment to the Supply Agreement require us to pay RSM $400,000 within 10 days following
	FDA approval of a new drug application for the first product owned or controlled by us using Improved GOS as its active pharmaceutical
	ingredient and to pay RSM the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo as was previously
	required.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	consideration for RSM entering into the second amendment to the Supply Agreement, we issued 100,000 shares of our common stock
	to RSM pursuant to a stock purchase agreement. The shares issued to RSM are subject to a lock-up agreement, pursuant to which
	RSM has agreed that it will not sell these shares for a period ending on the earlier of (i) the public release by us of the final
	results of our Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of a Form 10-Q with the SEC for the fiscal quarter in which
	we receive the results of our Phase 2b/3 clinical trial of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Commercialization
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	our stage of development, we have not yet established a commercial organization or distribution capabilities. RP-G28, if approved,
	is intended to be prescribed to patients suffering from lactose intolerance. These patients are normally under the care of a gastroenterologist
	and/or a primary care physician. Our current plan is to evaluate a possible partnership to commercialize RP-G28 for the reduction
	of symptoms associated with lactose intolerance in patients in the United States and Europe if it is approved. We may also build
	our own commercial infrastructure or utilize contract reimbursement specialists, sales people and medical education specialists,
	and take other steps to establish the necessary commercial infrastructure at such time as we believe that RP-G28 is approaching
	marketing approval. Outside of the United States and Europe, subject to obtaining necessary marketing approvals, we will likely
	seek to commercialize RP-G28 through distribution or other collaboration arrangements for patients suffering from lactose intolerance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Competition
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	biopharmaceutical industry is characterized by intense competition and rapid innovation. Although we know of no drug candidate,
	other than RP-G28, in advanced clinical trials for treating lactose intolerance, other biopharmaceutical companies may be able
	to develop compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational
	pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research
	institutions. Some of the pharmaceutical and biotechnology companies we expect to compete with include microbiome-based development
	companies such as Second Genome, Inc., Seres Health, Inc., Enterome SA, Vedanta Biosciences, Inc., and Microbiome Therapeutics,
	LLC. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
	with large, established companies. We will also compete with providers of a wide variety of lactase supplements (the most widely
	used supplement in the United States being Lactaid
<SUP>
	&reg;
</SUP>
	), probiotic/dietary supplements, and lactose-free and dairy-free
	products. We believe the key competitive factors that will affect the development and commercial success of our product candidates
	are efficacy, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Intellectual
	Property
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	proprietary nature of, and protection for, our product candidates and our discovery programs, processes and know-how are important
	to our business. We have sought patent protection in the United States and internationally for uses of RP-G28 and our discovery
	programs, and any other inventions to which we have rights, where available and when appropriate. Our policy is to pursue, maintain
	and defend patent rights, whether developed internally or licensed from third parties, and to protect the technology, inventions
	and improvements that are commercially important to the development of our business. We also rely on trade secrets that may be
	important to the development of our business. We do not have composition of matter patent protection in the United States for
	RP-G28, which may result in competitors being able to offer and sell products so long as these competitors do not infringe any
	other patents that we hold, including patents directed to methods of manufacturing and purified RP-G28 or directed to methods
	of using RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current
	and future product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents
	against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our
	products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.
	We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent
	applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted
	to us in the future will be commercially useful in protecting our product candidates, discovery programs and processes from commercial
	competition. Furthermore, we cannot be sure that issued patents will not be challenged in court as invalid or in the Patent Office
	as unpatentable. For this and more comprehensive risks related to our intellectual property, please see &ldquo;Risk Factors&thinsp;&mdash;&thinsp;Risks
	Relating to Our Intellectual Property.&rdquo;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Patents
	and Proprietary Rights Covering Our Drug Candidates
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	strive to protect our product candidates and exclusivity rights, as well as both maintain and fortify our position in the field
	of reduction of symptoms associated with lactose intolerance. We believe our intellectual property portfolio consists of early
	and broad filings in the area. We have focused on patents and patent applications relating to use of our products in disease treatment.
	We have sought and continue to seek the strongest possible intellectual property protection available to us in order to prevent
	others from directly competing with us, as well as to exclude competition around our products, their manufacture, and methods
	for use of the products in disease treatment. Our intellectual property portfolio related to RP-G28 contains four issued patents
	relating to RP-G28 and its uses. That portfolio also includes at least 15 other related, pending patent applications in the United
	States and worldwide. We also own a patent family, including claims generally directed to processes for producing an improved
	form of galactoologosaccharides (GOS) mixtures (higher purity); this family includes issued patents in United States (not expiring
	until 2030), Italy (not expiring until 2029), Germany, and the Netherlands (not expiring until 2030), as well as applications
	pending in the United States, China, India, and other jurisdictions that, if issued, will not expire until 2030.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	portfolio includes patents and proprietary rights related to:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	U.S.
	Patent No. 8,486,668, which has a current expiry date of February 17, 2030, includes claims generally directed to methods
	for treating lactose intolerance comprising administering, for a predetermined number of days, a high purity galactooligosaccharides
	(GOS) pharmaceutical composition, and wherein the administration leads to a persistent decrease in at least one symptom of
	lactose intolerance;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	U.S.
	Patent No. 8,492,124, which has a current expiry date of February 17, 2030, includes claims generally directed to methods
	for treating lactose intolerance comprising administering, for a predetermined number of days, a controlled release pharmaceutical
	composition that contains galoctooligosaccharides (GOS), but does not contain a probiotic;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	U.S.
	Patent No. 8,785,160, which has a current expiry date of February 17, 2030, includes claims generally directed to methods
	for treating lactose intolerance comprising administering a hydrogen breath test, diagnosing lactose intolerance based upon
	the hydrogen breath test, and administering a high purity galactooligosaccharides (GOS) pharmaceutical composition;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	U.S.
	Patent No. 9,200,303, which has a current expiry date of August 6, 2030 (subject to the payment of maintenance fee), includes
	claims generally directed to the processes for producing ultra-pure galactooligosaccharides (GOS) pharmaceutical compositions
	by utilizing sequential microbiological purifications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	United
	Kingdom Patent No. GB2480042, which has a current expiry date of February 16, 2030, includes claims generally directed to
	a solid oral unit-dosage form of a high purity galactoologosaccharides (GOS);
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	European
	Patent No. EP 2,462,234, validated in six European countries, including Germany, Great Britain, and France, which has a current
	expiry date of August 6, 2030 (subject to payment of annuities), includes claims generally directed to the processes for producing
	preparing ultra-pure galactooligosaccharides (GOS) pharmaceutical compositions by utilizing sequential microbiological purifications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	Italian
	Patent No. IT 1,395,068, which has a current expiry date of August 7, 2029 (subject to the payment of annuities), includes
	claims generally directed to the production of ultra-pure galactooligosaccharides (GOS) pharmaceutical compositions by utilizing
	sequential microbiological purifications; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	Chinese
	Patent No. ZL 201080035013.2, which has a current expiry date of August 6, 2030 (subject to payment of annuities), includes
	claims generally directed to the production of ultra-pure galactooligosaccharides (GOS) pharmaceutical compositions by utilizing
	sequential microbiological purifications.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -0.25IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are pursuing patent applications. These applications are pending in the United States, Europe, Japan and other jurisdictions,
	and, if they issue as patents, will not expire until at least 2030, and include claims generally directed to (i) oral dosage forms
	of a higher purity galactoologosaccharides (GOS), (ii) use of galactoologosaccharides (GOS) for treating lactose intolerance,
	and (iii) methods of preventing or reducing certain symptoms of lactose intolerance using galactoologosaccharides (GOS) dosage
	forms.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Trade
	Secrets
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and
	know-how can be difficult to protect. We seek to protect our proprietary processes, in part, by confidentiality agreements and
	invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These
	agreements are designed to protect our proprietary information. We also seek to preserve the integrity and confidentiality of
	our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of
	our information technology systems.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Government
	Regulation and Product Approval
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Governmental
	authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
	things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing
	and export and import of products such as those we are developing. Our product candidates must be approved by the FDA through
	the NDA process before they may be legally marketed in the United States and by the European Medicines Agency (the &ldquo;EMA&rdquo;)
	through the Marketing Authorization Application (&ldquo;MAA&rdquo;) process before they may be legally marketed in Europe. Our
	product candidates will be subject to similar requirements in other countries prior to marketing in those countries. The process
	of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
	regulations require the expenditure of substantial time and financial resources.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	United
	States Government Regulation
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	NDA
	Approval Processes
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) and implementing
	regulations. Failure to comply with the applicable U.S. requirements at any time during the product development process or approval
	process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material
	adverse effect on us. These sanctions could include:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	refusal
	to approve pending applications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	withdrawal
	of an approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	imposition
	of a clinical hold;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	warning
	letters;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	product
	seizures and/or condemnation and destruction;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	total
	or partial suspension of production or distribution; or
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	injunctions,
	fines, disgorgement, or civil or criminal penalties.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	process required by the FDA before a drug may be marketed in the United States generally involves the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	completion
	of nonclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices (&ldquo;GLPs&rdquo;)
	or other applicable regulations;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	submission
	to the FDA of an IND, which must become effective before human clinical trials may begin;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	performance
	of adequate and well-controlled human clinical trials according to Good Clinical Practices (&ldquo;GCPs&rdquo;), to establish
	the safety and efficacy of the proposed drug for its intended use;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	submission
	to the FDA of a NDA;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	satisfactory
	completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
	with current Good Manufacturing Practices (&ldquo;cGMPs&rdquo;) to assure that the facilities, methods and controls are adequate
	to preserve the drug&rsquo;s identity, strength, quality and purity; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	FDA
	review and approval of the NDA.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Once
	a pharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical
	tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor
	must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part
	of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the
	nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial,
	the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself
	to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within
	the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding
	concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND, and may affect one
	or more specific studies or all studies conducted under the IND.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must
	be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion
	criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the
	IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must
	timely report to FDA serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected
	adverse reaction over that listed in the protocol or investigation brochure, or any findings from other studies or animal or in
	vitro testing that suggest a significant risk in humans exposed to the drug. An institutional review board, or IRB, at each institution
	participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution
	and must also approve the information regarding the trial and the consent form that must be provided to each research subject
	or the subject&rsquo;s legal representative, monitor the study until completed and otherwise comply with IRB regulations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Human
	clinical trials are typically conducted in three sequential phases that may overlap or be combined:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
<I>
	Phase
	1
</I>
	. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,
	distribution and elimination. In the case of some products for severe or life-threatening diseases, such as cancer, especially
	when the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often
	conducted in patients.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
<I>
	Phase
	2
</I>
	. Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety
	risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance
	and optimal dosage. Although there are no statutory or regulatory definitions for Phase 2a and Phase 2b, Phase 2a is commonly
	used to describe a Phase 2 clinical trial designed to evaluate efficacy, adverse effects and safety risks and Phase 2b is
	commonly used to describe a subsequent Phase 2 clinical trial that also evaluates dosage tolerance and optimal dosage.
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
<I>
	Phase
	3
</I>
	. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population
	at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of
	the product and provide an adequate basis for product labeling.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Adaptive
	seamless phase 2b/3 designs, such as the Phase 2b/3 pivotal clinical trial for RP-G28 that we are contemplating, are aimed at
	interweaving the two phases of full development by combining them into one single, uninterrupted study conducted in two steps.
	Adaptive seamless phase 2b/3 designs enable a clinical trial to be conducted in steps with the sample size calculation selected
	on the basis of data observed in the first step to continue along to the second step. The main statistical challenge in such a
	design is ensuring control of the type I error rate. Most methodology for such trials is based on the same endpoint being used
	for interim and final analyses. A type I error is one in which the adaptation process leads to design, analysis, or conduct flaws
	that introduce bias that increases the chance of a false conclusion that a treatment is effective (a type I error). Controlling
	type I error can be accomplished by prospectively specifying and including in the statistical analysis plan all possible adaptation
	plans that may be considered during the course of the trial. We intend to work with a CRO to determine how best to control type
	I error in our Phase 2b/3 study.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Human
	clinical trials are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or
	the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects
	or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
	trial at its institution if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the
	drug has been associated with unexpected serious harm to patients.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	During
	the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior
	to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may be requested. For
	instance, we held a Type C meeting with the FDA&rsquo;s Division of Gastroenterology and Inborn Errors Products on February 20,
	2013. The purpose of the meeting was to obtain the FDA&rsquo;s feedback on the planned clinical development program and future
	necessary clinical studies, inform the FDA of our ongoing development plans, gain feedback on relevant clinical trial design and
	end points related to patient meaningful benefits, and to inform the FDA of the status of our product characterization. At the
	time of our meeting, we were not contemplating an adaptive design Phase 2b/3 clinical trial. Based on RP-G28&rsquo;s mechanism
	of action, data from the Phase 2a clinical study, and further research conducted after the Type C Meeting in early 2013, however,
	we now intend to conduct our next clinical trial as an adaptive design Phase 2b/3 clinical trial. We do not intend to request
	an additional meeting to seek FDA guidance about this specific clinical development plan although we will submit a supplement
	to the IND detailing the protocols for the adaptive study.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FDA
	meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide
	advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical
	results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the new
	drug. If a Phase 2 clinical trial is the subject of discussion at the end of Phase 2 meeting with the FDA, a sponsor may be able
	to request a Special Protocol Assessment (&ldquo;SPA&rdquo;), the purpose of which is to reach agreement with the FDA on the Phase
	3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	According
	to published guidance on the SPA process, a sponsor which meets the prerequisites may make a specific request for a SPA and provide
	information regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within
	45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request
	for additional information. A SPA request must be made before the proposed trial begins, and all open issues must be resolved
	before the trial begins. If a written agreement is reached, it will be documented and made part of the record. The agreement will
	be binding on the FDA and may not be changed by the sponsor or the FDA after the trial begins except with the written agreement
	of the sponsor and the FDA or if the FDA determines that a substantial scientific issue essential to determining the safety or
	efficacy of the drug was identified after the testing began.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Concurrent
	with clinical trials, sponsors usually complete additional animal safety studies and also develop additional information about
	the chemistry and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product
	in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
	drug and the manufacturer must develop methods for testing the quality, purity and potency of the drug. Additionally, appropriate
	packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not
	undergo unacceptable deterioration over its proposed shelf-life.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process,
	analytical tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part
	of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of user fees, but a waiver
	of such fees may be obtained under specified circumstances. The FDA has 60 days from its receipt of an NDA to determine whether
	the application will be accepted for filing based on the agency&rsquo;s threshold determination of whether it is sufficiently
	complete to permit substantive review. It may request additional information rather than accept an NDA for filing. In this event,
	the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the
	FDA accepts it for filing.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Once
	the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug
	representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA may
	refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data.
	Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA
	reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its
	manufacturing is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether
	the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee,
	but it generally follows such recommendations. Before approving an NDA, the FDA will inspect the facility or facilities where
	the product is manufactured and tested.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Patent
	Term Restoration and Marketing Exclusivity
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Depending
	upon the timing, duration and specifics of FDA marketing approval of RP-G28, one of our U.S. patents may be eligible for limited
	patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman
	Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product
	development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
	beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally one-half the
	time between the effective date of an IND, and the submission date of an NDA, plus the time between the submission date of an
	NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the
	application for extension must be made prior to expiration of the patent. The United States Patent and Trademark Office, in consultation
	with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply
	for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration
	date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Market
	exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides
	a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an
	NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing
	the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity
	period, the FDA may not accept for review an abbreviated new drug application (&ldquo;ANDA&rdquo;), or a 505(b)(2) NDA submitted
	by another company for another version of such drug where the applicant does not own or have a legal right of reference to all
	the data required for approval. However, an application may be submitted after four years if it contains a certification of patent
	invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement
	to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the
	applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages
	or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations
	and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity
	will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct
	or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to
	demonstrate safety and effectiveness.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Pediatric
	Exclusivity and Pediatric Use
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	the Best Pharmaceuticals for Children Act (&ldquo;BPCA&rdquo;), certain drugs may obtain an additional six months of exclusivity,
	if the sponsor submits information requested in writing by the FDA (a Written Request) relating to the use of the active moiety
	of the drug in children. The FDA may not issue a Written Request for studies on unapproved or approved indications or where it
	determines that information relating to the use of a drug in a pediatric population, or part of the pediatric population, may
	not produce health benefits in that population.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have not received a Written Request for such pediatric studies, although we may ask the FDA to issue a Written Request for such
	studies in the future. To receive the six-month pediatric market exclusivity, we would have to receive a Written Request from
	the FDA, conduct the requested studies in accordance with a written agreement with the FDA or, if there is no written agreement,
	in accordance with commonly accepted scientific principles, and submit reports of the studies. A Written Request may include studies
	for indications that are not currently in the labeling if the FDA determines that such information will benefit the public health.
	The FDA will accept the reports upon its determination that the studies were conducted in accordance with and are responsive to
	the original Written Request or commonly accepted scientific principles, as appropriate, and that the reports comply with the
	FDA&rsquo;s filing requirements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, the Pediatric Research Equity Act (&ldquo;PREA&rdquo;) requires all applications (or supplements to an application)
	submitted under section 505 of the FDCA (21 U.S.C. &sect;355) for a new active ingredient, new indication, new dosage form, new
	dosing regimen or new route of administration to contain a pediatric assessment unless the applicant has obtained a waiver or
	deferral. It also authorizes the FDA to require holders of approved NDAs for marketed drugs to conduct pediatric studies under
	certain circumstances. In general, PREA applies only to those drugs developed for diseases and/or conditions that occur in both
	the adult and pediatric populations. Products intended for pediatric-specific indications will be subject to the requirements
	of PREA only if they are initially developed for a subset of the relevant pediatric population.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	part of the Food and Drug Administration Safety and Innovation Act, Congress reauthorized both BPCA and PREA, which were slated
	to expire on September 30, 2012, and made both laws permanent.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Orphan
	Drugs
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition,
	defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient
	population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of
	developing and making available the drug or biologic in the United States will be recovered from sales in the United States for
	that drug or biologic.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for
	the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA
	may not approve any other applications, including a full NDA, to market the same product for the same indication for seven years,
	except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the
	FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities
	of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug
	exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same
	drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for
	certain research and a waiver of the NDA application user fee.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication
	for which it received orphan designation. Orphan drug exclusive marketing rights in the United States also may be lost if the
	FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
	quantities of the product to meet the needs of patients with the rare disease or condition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	intend to explore orphan drug designation for RP-G28 for any orphan indication in which there is a medically plausible basis for
	treatment of the indication through colonic adaptation of gut bacteria.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Post-approval
	Requirements
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Once
	an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems
	occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions
	on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved
	product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review
	and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that
	have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of
	these post-marketing programs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
	among other things:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	compliance
	with current good manufacturing practices;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	record-keeping
	requirements;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	reporting
	of adverse experiences with the drug;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	providing
	the FDA with updated safety and efficacy information;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	drug
	sampling and distribution requirements;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	notifying
	the FDA and gaining its approval of specified manufacturing or labeling changes; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	complying
	with FDA promotion and advertising requirements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Drug
	manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their
	establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some
	state agencies for compliance with cGMP and other laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products.
	Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt
	production or distribution, or require substantial resources to correct.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	From
	time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions
	governing the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance
	are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible
	to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact
	of such changes, if any, may be.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Regulation
	Outside of the United States
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to regulations in the United States, we will be subject to regulations of other countries governing clinical trials and
	commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval
	by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such
	countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market
	products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product
	licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required
	for FDA approval.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized
	procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended
	to treat AIDS, cancer, neurodegenerative disorders or diabetes and optional for those medicines which are highly innovative, provides
	for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure
	provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization
	may submit an application to the remaining member states. Within 90 days of receiving the applications and assessments report,
	each member state must decide whether to recognize approval. If a member state does not recognize the marketing authorization,
	the disputed points are eventually referred to the European Commission, whose decision is binding on all member states.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Reimbursement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sales
	of our products will depend, in part, on the extent to which the costs of our products will be covered by third-party payors,
	such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly
	challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become
	a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state
	legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price
	controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and
	cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could
	further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared
	to other therapies, they may not cover our products after approved as a benefit under their plans or, if they do, the level of
	payment may not be sufficient to allow us to sell our products on a profitable basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &ldquo;MMA&rdquo;) imposed new requirements for the
	distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in
	prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans
	include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage
	plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required
	to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will
	cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category
	and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part
	D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of
	the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated
	prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain.
	Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
	policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result
	in a similar reduction in payments from non-governmental payors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different
	treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the
	Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research
	and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended
	to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the
	sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also
	possible that comparative effectiveness research demonstrating benefits in a competitor&rsquo;s product could adversely affect
	the sales of our product candidates. If third-party payors do not consider our products to be cost-effective compared to other
	available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not
	be sufficient to allow us to sell our products on a profitable basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010
	(collectively, the &ldquo;ACA&rdquo;), enacted in March 2010, is expected to have a significant impact on the health care industry.
	The ACA is expected to expand coverage for the uninsured while at the same time containing overall healthcare costs. With regard
	to pharmaceutical products, among other things, the ACA is expected to expand and increase industry rebates for drugs covered
	under Medicaid programs and make changes to the coverage requirements under the Medicare Part D program. We cannot predict the
	impact of the ACA on pharmaceutical companies, as many of the ACA reforms require the promulgation of detailed regulations implementing
	the statutory provisions which has not yet occurred. In addition, some members of the U.S. Congress have been seeking to overturn
	at least portions of the legislation and we expect they will continue to review and assess this legislation and alternative health
	care reform proposals. Any legal challenges to the ACA, as well as Congressional efforts to repeal the ACA, add to the uncertainty
	of the legislative changes enacted as part of the ACA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed.
	The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options
	for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
	and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
	or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
	on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
	products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched
	in the European Union do not follow price structures of the United States and generally tend to be significantly lower.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Employees
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of the date of this Annual Report, we had eight employees, all of whom were full time employees. None of our employees are represented
	by a labor union, and we consider our relationship with our employees to be good.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Available
	Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	file with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) annual reports on Form 10-K, quarterly reports on Form 10-Q,
	current reports on Form 8-K, proxy and information statements and amendments to reports filed or furnished pursuant to Sections
	13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended. The public may obtain these filings at the SEC&rsquo;s
	Public Reference Room at 100 F Street, NE, Washington, DC 20549 or by calling the SEC at 1-800-SEC-0330. The SEC also maintains
	a website at http://www.sec.gov that contains reports, proxy and information statements and other information regarding Ritter
	Pharmaceuticals, Inc. and other companies that file materials with the SEC electronically. As soon as practicable after filing
	with the SEC, we make copies of our reports on Form 10-K, Forms 10-Q and Forms 8-K available to the public, free of charge, through
	the investor relations tab on our web site,
<U>
	http://www.ritterpharmaceuticals.com/investors
</U>
</FONT>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_003">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	1A. Risk Factors
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	We
	operate in a dynamic and rapidly changing business environment that involves multiple risks and substantial uncertainty. The following
	discussion addresses risks and uncertainties that could cause, or contribute to causing, actual results to differ from expectations
	in material ways. In evaluating our business, investors should pay particular attention to the risks and uncertainties described
	below and in other sections of this Annual Report and in our subsequent filings with the SEC. These risks and uncertainties, or
	other events that we do not currently anticipate or that we currently deem immaterial also may affect our results of operations,
	cash flows and financial condition. The trading price of our common stock could also decline due to any of these risks, and you
	could lose all or part of your investment. The following information should be read in conjunction with Part II, Item 7, &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the financial statements and related notes
	included in Part II, Item 8, &ldquo;Financial Statements and Supplementary Data&rdquo; of this Annual Report.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to Our Financial Position and Need for Additional Capital
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	have incurred net losses in each year since our inception. Currently, we have no products approved for commercial sale. As a result,
	our ability to reduce our losses and reach profitability is unknown, and we may never achieve or sustain profitability.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have incurred net losses in each year since our inception. The accompanying financial statements have been prepared assuming that
	we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities
	in the normal course of business. For the years ended December 31, 2015 and 2014, we had net losses of approximately $8.8 million
	and $2.5 million, respectively, and had net cash used in operating activities of approximately $6.1 million and $1.1 million,
	respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	To
	date, we have devoted most of our financial resources to our corporate overhead and research and development, including our drug
	discovery research, preclinical development activities and clinical trials. We currently have no products that are approved for
	commercial sale. We expect to continue to incur net losses and negative operating cash flow for the foreseeable future, and we
	expect these losses to increase as we continue our development of, and seek regulatory approvals for, RP-G28, and other product
	candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support
	our product development efforts and operations as a public company. We anticipate that any such losses could be significant for
	the next several years as we begin our Phase 2b/3 and any Phase 3 clinical trials for RP-G28 for the reduction of symptoms associated
	with lactose intolerance and related activities required for regulatory approval of RP-G28. If RP-G28 or any of our other product
	candidates fails in clinical trials or does not gain regulatory approval, or if our product candidates do not achieve market acceptance,
	we may never become profitable. These net losses and negative cash flows have had, and will continue to have, an adverse effect
	on our stockholders&rsquo; equity and working capital.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Because
	of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict
	the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses
	could increase if we are required by the FDA or the EMA, to perform studies or trials in addition to those currently expected,
	or if there are any delays in completing our clinical trials or the development of our product candidates. The amount of future
	net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available,
	may require us to delay, limit, reduce or cease our operations.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are currently advancing RP-G28 through clinical development. Developing pharmaceutical products, including conducting preclinical
	studies and clinical trials, is expensive. As of December 31, 2015, we have a total of approximately $15.8 million in cash.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 29, 2015, we closed our initial public offering of 4,000,000 shares of common stock at a public offering price of $5.00 per
	share. Total gross proceeds from our initial public offering were $20.0 million before deducting underwriting discounts and commissions
	and other offering expenses payable by us, resulting in net proceeds of $17.4 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 18, 2015, we entered into a common stock purchase agreement (the &ldquo;Aspire Purchase Agreement&rdquo;) with Aspire
	Capital Fund, LLC (&ldquo;Aspire Capital&rdquo;), which provides that, upon the terms and subject to the conditions and limitations
	set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of our shares of common stock over
	the approximately 30-month term of the Aspire Purchase Agreement. Upon execution of the Aspire Purchase Agreement, we sold 500,000
	shares of common stock to Aspire Capital at $2.00 per share for proceeds of $1.0 million. We may sell an additional 888,835 shares
	of common stock to Aspire Capital in the future pursuant to the terms of the Aspire Purchase Agreement. See Part II, Item 7, &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo; for additional information regarding our financing
	arrangement with Aspire Capital.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expect our existing cash and cash equivalents, together with interest, and any proceeds received from our sale of shares of common
	stock to Aspire Capital in the future pursuant to the Aspire Purchase Agreement, will be sufficient to fund our current operations
	through the first quarter of 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our
	available capital resources sooner than we currently expect. For example, our clinical trials may encounter technical, enrollment
	or other difficulties that could increase our development costs more than we expect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not expect our existing capital resources will be sufficient to enable us to complete the commercialization of RP-G28, if approved,
	or to initiate any clinical trials or additional development work for other product candidates, other than as described above.
	We will need to secure additional financing in order to complete clinical development and commercialize RP-G28 and to generally
	fund our operations. To complete the work necessary to file a NDA and a MAA for RP-G28 as a treatment for patients with lactose
	intolerance, which is currently anticipated to occur in 2019, we estimate that our RP-G28 clinical trials, and our planned clinical
	and nonclinical studies, as well as other work needed to submit RP-G28 for regulatory approval in the United States, Europe and
	other countries, will cost approximately $85 million, including the internal resources needed to manage the program. If the FDA
	or EMA requires that we perform additional nonclinical studies or clinical trials, our expenses would further increase beyond
	what we currently expect and the anticipated timing of any potential NDA or MAA would likely be delayed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or
	development programs. We also could be required to seek funds through arrangements with collaborative partners or otherwise that
	may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable
	to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	extent to which we utilize the Aspire Purchase Agreement with Aspire Capital as a source of funding will depend on a number of
	factors, including the prevailing market price of our common stock, the volume of trading in our common stock and the extent to
	which we are able to secure funds from other sources. The number of shares that we may sell to Aspire Capital under the Aspire
	Purchase Agreement on any given day and during the term of the agreement is limited. Additionally, we and Aspire Capital may not
	effect any sales of shares of our common stock under the Aspire Purchase Agreement during the continuance of an event of default
	or on any trading day that the closing sale price of our common stock is less than $0.50 per share. Even if we are able to access
	the full $10 million under the Aspire Purchase Agreement, we will still need additional capital to fully implement our business,
	operating and development plans.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may sell additional equity or debt securities to fund our operations, which would result in dilution to our stockholders and imposed
	restrictions on our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding,
	commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.
	Additional funding may not be available to us on acceptable terms or at all. To the extent that we raise additional funds by issuing
	equity securities (including any common stock issued to Aspire Capital pursuant to the Aspire Purchase Agreement), our stockholders
	may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability
	to conduct business. If we are not able to raise additional capital when required or on acceptable terms, we may have to (i) significantly
	delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators
	for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise
	be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would
	otherwise seek to develop or commercialize. In addition, the terms of any financing may adversely affect the holdings or the rights
	of our stockholders and the issuance of additional shares by us, or the possibility of such issuance, may cause the market price
	of our shares to decline.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	financial condition and operating results have varied significantly since our formation and are expected to continue to fluctuate
	significantly from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	operations since 2010 have been limited to developing our technology and undertaking preclinical studies and clinical trials of
	our lead product candidate, RP-G28. We have not yet obtained regulatory approvals for RP-G28, or any other product candidate.
	Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had approved
	products on the market. Our financial condition and operating results have varied significantly since our formation and are expected
	to continue to significantly fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are
	beyond our control. Factors relating to our business that may contribute to these fluctuations include:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	any
	delays in regulatory review and approval of our product candidates in clinical development, including our ability to receive
	approval from the FDA and the EMA for RP-G28 for the reduction of symptoms associated with lactose intolerance in patients
	based on our Phase 2b/3 and any Phase 3 trials of RP-G28, and our other completed and planned clinical and nonclinical studies
	and other work, as the basis for review and approval of RP-G28 for the reduction of symptoms associated with lactose intolerance
	in patients;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	delays
	in the commencement, enrollment and timing of clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	difficulties
	in identifying and treating patients suffering from our target indications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	success of our clinical trials through all phases of clinical development, including our Phase 2b/3 and any Phase 3 trials
	of RP-G28 for the reduction of symptoms associated with lactose intolerance in patients;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	potential
	side effects of our product candidates that could delay or prevent approval or cause an approved drug to be taken off the
	market;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to obtain additional funding to develop our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to identify and develop additional product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	market
	acceptance of our product candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to establish an effective sales and marketing infrastructure directly or through collaborations with third parties;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	competition
	from existing products or new products that may emerge;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to adhere to clinical study requirements directly or with third parties such as CROs;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	dependency on third-party manufacturers to manufacture our products and key ingredients;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to establish or maintain collaborations, licensing or other arrangements;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	costs to us, and our ability and our third-party collaborators&rsquo; ability to obtain, maintain and protect our intellectual
	property rights;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	costs
	related to and outcomes of potential intellectual property litigation;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to adequately support future growth;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	ability to attract and retain key personnel to manage our business effectively; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	potential
	product liability claims.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accordingly,
	the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to Regulatory Review and Approval of Our Product Candidates
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	are substantially dependent on the success of our current product candidate, RP-G28.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. We currently
	invest nearly all of our efforts and financial resources in the research and development of RP-G28, which is currently our only
	product candidate. Our business currently depends entirely on the successful development and commercialization of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	cannot be certain that RP-G28 will receive regulatory approval, and without regulatory approval we will not be able to market
	RP-G28 as a prescription drug.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the
	FDA in the United States, the EMA in Europe, and regulatory authorities in other countries, with regulations differing from country
	to country. We are not permitted to market our product candidates in the United States or Europe until we receive approval of
	a NDA from the FDA or a MAA from the EMA, respectively. We have not submitted any marketing applications for RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	NDAs
	and MAAs must include extensive preclinical and clinical data and supporting information to establish the product candidate&rsquo;s
	safety and effectiveness for each desired indication. NDAs and MAAs must also include significant information regarding the chemistry,
	manufacturing and controls for the product. Obtaining approval of a NDA or a MAA is a lengthy, expensive and uncertain process,
	and we may not be successful in obtaining approval. The FDA and the EMA review processes can take years to complete and approval
	is never guaranteed. If we submit a NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing.
	We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions,
	such as the EMA, have their own procedures for approval of product candidates. Even if a product is approved, the FDA or the EMA,
	as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product
	labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities
	in countries outside of the United States and Europe also have requirements for approval of drug candidates with which we must
	comply prior to marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country
	does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections
	of marketing applications in the United States, Europe or other countries may be based upon many factors, including regulatory
	requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different
	interpretations of data and results, changes in regulatory policy during the period of product development and the emergence of
	new information regarding our product candidates or other products. Also, regulatory approval for any of our product candidates
	may be withdrawn.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have completed one Phase 2a trial for RP-G28. Before we submit a NDA to the FDA or a MAA to the EMA for RP-G28 for the treatment
	of pain and the reduction in the frequency of symptomatic episodes of lactose intolerance, we must successfully complete a Phase
	2b/3 trial and Phase 3 trials. Following analysis of the Phase 2a clinical trial, discussions with the FDA during the Type C meeting
	in 2013 about our clinical development plan, and further discussions with our regulatory consultants, we intend to conduct our
	planned Phase 2b clinical trial as an adaptive design Phase 2b/3 clinical trial. A trial that is designed as an adaptive seamless
	clinical trial refers to a trial that combines the objectives of what are typically separate trials into a single uninterrupted
	trial with multiple objectives.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Neither
	the FDA nor any other comparable governmental agency has considered this Phase 2b/3 study or our current development plan for
	RP-G28, and we do not intend to request a meeting with the FDA to discuss these matters. Regulatory authorities in the United
	States and Europe have both published guidance documents on the use and implementation of adaptive design trials. These documents
	include description of adaptive trials and include a requirement for prospectively written standard operating procedures and working
	processes for executing adaptive trials and a recommendation that sponsor companies engage with CROs that have the necessary experience
	in running such trials. In addition, the regulations governing INDs are extensive and involve numerous notification requirements
	including that, generally, an IND supplement must be submitted to and cleared by the FDA before a sponsor or an investigator may
	make any change to the investigational plan that may affect its scientific soundness or the rights, safety or welfare of human
	subjects. We intend to comply with these requirements and believe we will need to submit an IND supplement containing amended
	protocols for the Phase 2b/3 adaptive trial. There can be no assurance that the FDA will provide clearance for an amended IND
	for a Phase 2b/3 trial in a timely manner, if at all, and that this trial and other trials will not be delayed or disrupted as
	a result.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, guidelines adopted by the FDA and established by the International Conference on Harmonization of Technical Requirements
	for Registration of Pharmaceuticals for Human Use (ICH) require nonclinical studies that specifically address female fertility
	to be completed before the inclusion of women of child bearing potential in large-scale or long-duration clinical trials (e.g.,
	Phase 3 trials). In the United States, such assessments of embryo-fetal development can be deferred until before Phase 3 using
	precautions to prevent pregnancy in clinical trials. As the FDA recommended in their June 28, 2010 advice letter, we will continue
	to evaluate females of child-bearing potential who are willing to use appropriate contraception throughout the duration of any
	study. To support any Phase 3 study, we plan to perform ICH-compliant embryo-fetal developmental toxicology studies (in two species)
	and the ICH-recommended standard battery of genotoxicity tests using RP-G28. We also intend to perform work on the characterization
	of compounds and analytical specifications for RP-G28. The design of our Phase 2b/3 trial will need to account for these FDA and
	ICH requirements, and we may need to complete all nonclinical studies that specifically address female fertility before we complete
	a Phase 2b/3 clinical trial. We cannot predict whether our future trials and studies will be successful or whether regulators
	will agree with our conclusions regarding the preclinical studies and clinical trials we have conducted to date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	we are unable to obtain approval from the FDA, the EMA or other regulatory agencies for RP-G28, or if, subsequent to approval,
	we are unable to successfully commercialize RP-G28, we will not be able to generate sufficient revenue to become profitable or
	to continue our operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	statements in this document indicating that RP-G28 has demonstrated preliminary evidence of efficacy are our own and are not based
	on the FDA&rsquo;s or any other comparable governmental agency&rsquo;s assessment of RP-G28 and do not indicate that RP-G28 will
	achieve favorable efficacy results in any later stage trials or that the FDA or any comparable agency will ultimately determine
	that RP-G28 is effective for purposes of granting marketing approval.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	The
	FDA and other regulatory agencies outside the United States, such as the EMA, may not agree to our proposed endpoint for approval
	of RP-G28 for the reduction of symptoms associated with lactose intolerance in patients, in which case we would need to complete
	an additional clinical trial in order to seek approval outside the United States.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	During
	our Type C Meeting with the FDA in February 2013, we had proposed that future studies with RP-G28 in subjects with lactose intolerance
	would utilize a total lactose intolerance symptom score, measured by a patient reporting instrument that we were going to develop,
	as the primary, stand-alone endpoint. However, based on RP-G28&rsquo;s mechanism of action, data from the Phase 2a clinical study,
	further research conducted after the Type C Meeting with the FDA along with FDA guidance and products under the review of the
	Division of Gastroenterology and Inborn Errors Products, we now intend to use abdominal pain, measured by an 11-point validated
	scale, as the primary endpoint for the Phase 2b/Phase 3 study that assesses RP-G28 for the management of lactose intolerant patients
	with moderate to severe abdominal pain associated with lactose intake. We believe that evaluation of abdominal pain is a reliable
	clinical assessment of treatment response and treatment benefit in a lactose intolerant patient. Although no FDA-approved product
	exists for lactose intolerance, the use of a pain scale as a primary endpoint has been used as a validated primary measurement
	in many approved products, including other gastrointestinal products used to treat diseases such as Irritable Bowel Syndrome (IBS).
	We have not consulted with the FDA about our intent to use abdominal pain as a primary endpoint or our plan to convert our Phase
	2b clinical trial into an adaptive design Phase 2b/3 pivotal clinical trial.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not know if the FDA, the EMA or regulatory authorities in other countries will agree with our final primary endpoint for approval
	of RP-G28. The FDA, the EMA and regulatory authorities in other countries in which we may seek approval for and market RP-G28,
	may require additional nonclinical studies and/or clinical trials prior to granting approval. It may be expensive and time consuming
	to conduct and complete additional nonclinical studies and clinical trials that the EMA and other regulatory authorities may require
	us to perform. As such, any requirement by the EMA or other regulatory authorities that we conduct additional nonclinical studies
	or clinical trials could materially and adversely affect our business, financial condition and results of operations. Furthermore,
	even if we receive regulatory approval of RP-G28 for the reduction of symptoms associated with lactose intolerance in patients,
	the labeling for RP-G28 in the United States, Europe or other countries in which we seek approval may include limitations that
	could impact the commercial success of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	The
	results from our planned Phase 2b/3 trial with adaptive design may not be sufficiently robust to support the submission of marketing
	approval for RP-G28.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	intend to conduct our planned Phase 2b clinical trial as an adaptive design seamless Phase 2b/3 clinical trial. We do not intend
	to meet with the FDA to discuss the Phase 2b/3 study design or current development plan for RP-G28. The FDA standard for traditional
	approval of a drug generally requires two well-controlled Phase 3 studies. If the FDA disagrees with our choice of primary endpoint
	for our Phase 2b/3 trial or the results for the primary endpoint are not robust or significant relative to control, are subject
	to confounding factors, or are not adequately supported by other study endpoints, the FDA may not recognize the Phase 2b/3 trial
	as one of the required pivotal trials required for FDA approval. If the FDA or other regulatory authorities do not recognize this
	trial as a pivotal trial, we would incur increased costs and delays in the marketing approval process, which would require us
	to expend more resources than we have available.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Delays
	in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our
	ability to obtain regulatory approval for RP-G28 or our other product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Delays
	in the commencement, enrollment and completion of clinical trials could increase our product development costs or limit the regulatory
	approval of RP-G28 or other product candidates we may develop in the future. Although we believe that our existing cash and cash
	equivalents, together with interest, and any proceeds received from our sale of shares of common stock to Aspire Capital in the
	future pursuant to the pursuant to the Aspire Purchase Agreement should be sufficient to fund our projected operating requirements
	through the completion of the Phase 2b/3 and any Phase 3 trials of RP-G28, we may not be able to complete these trials on time
	or we may be required to conduct additional clinical trials or nonclinical studies not currently planned to receive approval for
	RP-G28 as a treatment for lactose intolerance. The commencement, enrollment and completion of clinical trials may be delayed or
	suspended for a variety of reasons, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to obtain sufficient funds required for a clinical trial;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive
	negotiation and may vary significantly among different CROs and trial sites;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	clinical
	holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval
	to commence a clinical trial in countries that require such approvals;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	discussions
	with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial
	programs, including some that may be for the same indications targeted by our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to obtain approval from institutional review boards, or IRBs, to conduct a clinical trial at their respective sites;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	severe
	or unexpected drug-related adverse effects experienced by patients;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to timely manufacture sufficient quantities of the product candidate required for a clinical trial;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	difficulty
	recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including meeting the enrollment
	criteria for our study and competition from other clinical trial programs for the same indications as our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to get FDA approval of our end points; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	inability
	to retain enrolled patients after a clinical trial is underway.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Changes
	in regulatory requirements and guidance may also occur and we may need to amend clinical trial protocols to reflect these changes
	with appropriate regulatory authorities. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination,
	which may impact the costs, timing or successful completion of a clinical trial. In addition, a clinical trial may be suspended
	or terminated at any time by us, our future collaborators, the FDA or other regulatory authorities due to a number of factors,
	including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	failure or the failure of our potential future collaborators to conduct the clinical trial in accordance with regulatory requirements
	or our clinical protocols;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	unforeseen
	safety issues or any determination that a clinical trial presents unacceptable health risks;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	lack
	of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	a
	breach of the terms of any agreement with, or for any other reason by, future collaborators who have responsibility for the
	clinical development of our product candidates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, if we or any of our potential future collaborators are required to conduct additional clinical trials or other nonclinical
	studies of our product candidates beyond those contemplated, our ability to obtain regulatory approval of these product candidates
	and to generate revenue from their sales would be similarly harmed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Clinical
	failure can occur at any stage of clinical development. The results of earlier clinical trials are not necessarily predictive
	of future results and any product candidate we or our potential future collaborators advance through clinical trials may not have
	favorable results in later clinical trials or receive regulatory approval.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Clinical
	failure can occur at any stage of our clinical development. Clinical trials may produce negative or inconclusive results, and
	we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies.
	In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret
	our data as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical studies and early
	clinical trials does not ensure that subsequent clinical trials will generate the same or similar results or otherwise provide
	adequate data to demonstrate the efficacy and safety of a product candidate. A number of companies in the pharmaceutical industry,
	including those with greater resources and experience than us, have suffered significant setbacks in Phase 2b and/or Phase 3 clinical
	trials, including adaptive seamless clinical trials even after seeing promising results in earlier clinical trials.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the
	design of a clinical trial may not become apparent until the clinical trial is well-advanced. We may be unable to design and execute
	a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal that it is not practical
	or feasible to continue development efforts.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	RP-G28, or any of our other product candidates, is found to be unsafe or lack efficacy, we will not be able to obtain regulatory
	approval for it and our business would be harmed. For example, if the results of our Phase 2b/3 and any Phase 3 trials of RP-G28
	do not achieve the primary efficacy endpoints or demonstrate expected safety, the prospects for approval of RP-G28 would be materially
	and adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
	candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations,
	adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not
	know whether any Phase 2, Phase 3 or other clinical trials we or any of our potential future collaborators may conduct will demonstrate
	the consistent or adequate efficacy and safety that would be required to obtain regulatory approval and market RP-G28. The adaptive
	Phase 2b/3 clinical trial for RP-G28 that we intend to conduct may not be deemed to be a pivotal trial by the FDA or may not provide
	sufficient support for NDA approval. The FDA may require us to make changes to the proposed study design for this adaptive trial
	or may require us to conduct one or more additional clinical trials, possibly involving a larger sample size or a different clinical
	trial design, or may require longer follow-up periods, particularly if the FDA does not find the results from an adaptive Phase
	2b/3 clinical trial to be sufficiently persuasive as one of the required pivotal trials required for FDA approval. If we are unable
	to bring RP-G28 to market, our ability to create long-term stockholder value will be limited.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	product candidates may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received,
	require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unforeseen
	side effects from RP-G28, or other product candidates we may develop in the future, could arise either during clinical development
	or, if approved, after the approved product has been marketed. The most common side effects observed in clinical trials of RP-G28
	were headache (nine out of 57), nausea (three out of 57), upper respiratory tract infection (two of 57), nasal congestion (two
	of 57), and pain (two out of 57). No patients were withdrawn from the study for these side effects.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	results of future clinical trials may show that RP-G28 causes undesirable or unacceptable side effects, which could interrupt,
	delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory
	authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	RP-G28, or any other product candidate we develop in the future, receives marketing approval and we or others later identify undesirable
	or unacceptable side effects caused by such product:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	regulatory
	authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians
	and pharmacies;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	we
	may be required to change instructions regarding the way the product is administered, conduct additional clinical trials or
	change the labeling of the product;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	we
	may be subject to limitations on how we may promote the product;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	sales
	of the product may decrease significantly;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	regulatory
	authorities may require us to take our approved product off the market;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	we
	may be subject to litigation or product liability claims; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	our
	reputation may suffer.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	of these events could prevent us or our potential future collaborators from achieving or maintaining market acceptance of the
	affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us
	from generating significant revenues from the sale of our products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Reimbursement
	decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement
	for our products, it is less likely that they will be widely used.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Market
	acceptance and sales of RP-G28, or any other product candidates we develop in the future, if approved, will depend on reimbursement
	policies and may be affected by, among other things, future healthcare reform measures. Government authorities and third-party
	payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish
	payment levels. We cannot be certain that reimbursement will be available for RP-G28 or any other product candidates that we may
	develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products.
	If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize RP-G28,
	or other product candidates that we develop.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &ldquo;MMA&rdquo;), changed
	the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare
	coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that
	will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices
	for physician-administered drugs. Any negotiated prices for our products covered by a Part D prescription drug plan will likely
	be lower than the prices we might otherwise obtain in the United States. Moreover, while the MMA applies only to drug benefits
	for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own
	payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental
	payors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory
	proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy
	makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
	with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States,
	the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative
	initiatives. We expect to experience pricing pressures in connection with the sale of RP-G28, and any other product candidates
	that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and
	additional legislative proposals.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
	Act (collectively, the &ldquo;ACA&rdquo;) became law in the United States. The goal of the ACA is to reduce the cost of health
	care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict
	what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA may
	result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of RP-G28 or any
	other product candidates that we may develop. In addition, some members of the U.S. Congress have been seeking to overturn at
	least portions of the legislation and we expect they will continue to review and assess this legislation and alternative health
	care reform proposals. We cannot predict whether new proposals will be made or adopted, when they may be adopted or what impact
	they may have on us if they are adopted.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	If
	we do not obtain protection under the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent
	terms and obtaining data exclusivity for our product candidates, our business may be materially harmed.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Depending
	upon the timing, duration and specifics of FDA marketing approval of RP-G28, one of our U.S. patents may be eligible for a limited
	Patent Term Extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (which is sometimes referred to
	as the &ldquo;Hatch-Waxman Act&rdquo;), provided our U.S. patent claims a method of treating lactose intolerance that is approved
	by the FDA. The Hatch-Waxman Act, 35 U.S.C. &sect;156, permits a patent extension of up to five years as compensation for patent
	term lost during the FDA regulatory review process. The scope of protection afforded by the patent during the extended term is
	not commensurate with the scope of the unextended portion of the patent; for example, the &ldquo;rights derived&rdquo; from a
	method of use patent during the extended period are &ldquo;limited to any use claimed by the patent and approved for the product.&rdquo;
	35 U.S.C. &sect;156(b)(2). We may not be granted an extension because of, for example, failing to apply for the extension within
	applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable statutory
	and/or regulatory requirements including, for example, the requirement that the patent to be extended &ldquo;claim&rdquo; the
	approved product or a method of using the approved product. Moreover, the applicable period of extension could be less than we
	request. If we are unable to obtain patent term extension or if the term of any such extension is shorter than we request, the
	period during which we will be able to exclude others from marketing their versions of our product will be shortened and our competitors
	may obtain approval of generic products following our patent expiration, and our revenue could be reduced, possibly materially.
	Similar concerns are associated with obtaining Supplemental Protection Certificates (SPCs) of certain patents issued in Europe
	and owned by Inalco, to which we have an exclusive options of assignment, based upon patent terms lost during European regulatory
	review processes. In the event that we are unable to obtain any patent term extension, the issued patents for RP-G28 are expected
	to expire in 2030, assuming they withstand any challenge toothier validity and/or patentability.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	If
	we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws,
	we may be subject to civil or criminal penalties.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws,
	commonly referred to as &ldquo;fraud and abuse&rdquo; laws, have been applied in recent years to restrict certain marketing practices
	in the pharmaceutical industry. Other jurisdictions such as Europe have similar laws. These laws include false claims and anti-kickback
	statutes. If we market our products and our products are paid for by governmental programs, it is possible that some of our business
	activities could be subject to challenge under one or more of these laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Federal
	false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the
	federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare
	program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
	remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare
	item or service covered by Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
	to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers or formulary managers
	on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities
	from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
	prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Most
	states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which apply to
	items and services covered by Medicaid and other state programs, or, in several states, apply regardless of the payor. Administrative,
	civil and criminal sanctions may be imposed under these federal and state laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Over
	the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety
	of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other
	monetary benefits to prescribers; reporting inflated average wholesale prices that were then used by federal programs to set reimbursement
	rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce
	liability for Medicaid rebates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Any
	delay or disruption in the manufacture and supply of RP-G28 may negatively impact our operations.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not intend to manufacture the pharmaceutical products that we plan to sell. We have an agreement with RSM, our contract manufacturer,
	for the production of Improved GOS, the active pharmaceutical ingredient in RP-G28, and the formulation of sufficient quantities
	of Improved GOS for our Phase 2b/3 and any Phase 3 trials of RP-G28 and the other trials and nonclinical studies that we believe
	we will need to conduct prior to seeking regulatory approval. However, we do not have agreements for commercial supplies of RP-G28
	and we may not be able to reach agreements with these or other contract manufacturers for sufficient supplies to commercialize
	RP-G28 if it is approved.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Reliance
	on third-party manufacturers entails risks, to which we would not be subject if we manufactured the product candidates ourselves,
	including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; WIDTH: 0.25IN; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	possibility that we are unable to enter into a manufacturing agreement with a third party to manufacture our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; LINE-HEIGHT: 107%">
	the
	possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified
	replacement third-party manufacturer.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: -20.15PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs
	or prevent us from commercializing our product candidates successfully. Furthermore, if RP-G28 or other product candidates are
	approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and
	at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially
	equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand
	for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for
	our product candidates and to have any such new source approved by the government agencies that regulate our products. In the
	event we do need to identify alternative manufacturing partners, we may have to secure licenses to manufacturing and/or purification
	technologies, including third-party patent licenses, to allow us to manufacture RP-G28 that is suitable for the late-stage regulatory
	review process and/or adequate to manufacture commercial quantities of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	If
	the FDA and EMA and other regulatory agencies do not approve the manufacturing facilities of our future contract manufacturers
	for commercial production, we may not be able to commercialize any of our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	facilities used by any contract manufacturer to manufacture RP-G28, or other product candidates we may develop in the future,
	must be the subject of a satisfactory inspection before the FDA or the regulators in other jurisdictions approve the product candidate
	manufactured at that facility. We are completely dependent on these third-party manufacturers for compliance with the requirements
	of U.S. and non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture
	material that conform to our specifications and current good manufacturing practice requirements of any governmental agency whose
	jurisdiction to which we are subject, our product candidates will not be approved or, if already approved, may be subject to recalls.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Even
	if our product candidates receive regulatory approval, we may still face future development and regulatory difficulties.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RP-G28
	and any other product candidates we develop in the future, if approved, will be subject to ongoing regulatory requirements for
	labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information.
	In addition, approved products, manufacturers and manufacturers&rsquo; facilities are required to comply with extensive FDA and
	EMA requirements and requirements of other similar agencies, including ensuring that quality control and manufacturing procedures
	conform to current cGMPs. As such, we and our contract manufacturers are subject to continual review and periodic inspections
	to assess compliance with cGMPs. Accordingly, we and others with whom we work must continue to expend time, money and effort in
	all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report
	certain adverse reactions and production problems, if any, to the FDA and EMA and other similar agencies and to comply with certain
	requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs
	are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&rsquo;s
	approved label. Accordingly, we may not promote our approved products, if any, for indications or uses for which they are not
	approved.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or
	frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling
	of a product, it may impose restrictions on that product or us, including requiring withdrawal of the product from the market.
	If our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	issue
	warning letters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	mandate
	modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	require
	us or our potential future collaborators to enter into a consent decree or permanent injunction, which can include imposition
	of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	impose
	other administrative or judicial civil or criminal penalties;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	withdraw
	regulatory approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	refuse
	to approve pending applications or supplements to approved applications filed by us or our potential future collaborators;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	impose
	restrictions on operations, including costly new manufacturing requirements; or
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	detain,
	seize and/or condemn and destroy products.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to the Commercialization of Our Products
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Even
	if approved, our product candidates may not achieve broad market acceptance among physicians, patients and healthcare payors,
	and as a result our revenues generated from their sales may be limited.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	commercial success of RP-G28, if approved, will depend upon its acceptance among the medical community, including physicians,
	health care payors and patients. The degree of market acceptance of RP-G28, or other product candidates we may develop in the
	future, will depend on a number of factors, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	limitations
	or warnings contained in our product candidates&rsquo; FDA-approved labeling;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	changes
	in the standard of care or availability of alternative therapies at similar or lower costs for the targeted indications for
	such product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	limitations
	in the approved clinical indications for such product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	demonstrated
	clinical safety and efficacy compared to other products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	lack
	of significant adverse side effects;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	sales,
	marketing and distribution support;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	availability
	of reimbursement from managed care plans and other third-party payors;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	timing
	of market introduction and perceived effectiveness of competitive products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	degree of cost-effectiveness;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	availability
	of alternative therapies at similar or lower cost, including generics and over-the-counter products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	enforcement
	by the FDA and EMA of laws and rulings that prohibit the illegal sale of RP-G28 (or any other product candidate) as a dietary
	supplement;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	extent to which our product candidates are approved for inclusion on formularies of hospitals and managed care organizations;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	whether
	our product candidates are designated under physician treatment guidelines for the treatment of or reduction of symptoms associated
	with the indications for which we have received regulatory approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	adverse
	publicity about our product candidates or favorable publicity about competitive products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	convenience
	and ease of administration of our product candidates; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	potential
	product liability claims.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients, the medical community
	and healthcare payors, sufficient revenue may not be generated from these products and we may not become or remain profitable.
	In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require
	significant resources and may never be successful.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	have no internal sales, distribution and/or marketing capabilities at this time and we will have to invest significant resources
	to develop those capabilities or enter into acceptable third-party sales and marketing arrangements.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have no internal sales, distribution and/or marketing capabilities at this time. To develop these capabilities, we will have to
	invest significant amounts of financial and management resources, some of which will be committed prior to any confirmation that
	RP-G28 will be approved. For product candidates for which we decide to perform sales, marketing and distribution functions ourselves
	or through third parties, we could face a number of additional risks, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we
	or our third-party sales collaborators may not be able to attract and build an effective marketing or sales force;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	cost of securing or establishing a marketing or sales force may exceed the revenues generated by any products; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	direct sales and marketing efforts may not be successful.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues
	may depend heavily on the success of the efforts of these third parties.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely
	affect our ability to develop RP-G28 or other product candidates and our financial condition and operating results.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Because
	developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities
	and marketing approved products are expensive, we may seek to enter into collaborations with companies that have more experience.
	Additionally, if RP-G28, or any other product candidate we develop in the future, receives marketing approval, we may enter into
	sales and marketing arrangements with third parties with respect to our unlicensed territories. If we are unable to enter into
	arrangements on acceptable terms, we may be unable to effectively market and sell our products in our target markets. We expect
	to face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming
	to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful in our efforts
	to establish and implement collaborations or other alternative arrangements for the development of our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	When
	we collaborate with a third party for the development and commercialization of a product candidate, we can expect to relinquish
	some or all of the control over the future success of that product candidate to the third party. For example, we may relinquish
	the rights to RP-G28 in jurisdictions outside of the United States. Our collaboration partner may not devote sufficient resources
	to the commercialization of our product candidates or may otherwise fail in their commercialization. The terms of any collaboration
	or other arrangement that we establish may not be favorable to us. In addition, any collaboration that we enter into may be unsuccessful
	in the development and commercialization of our product candidates. In some cases, we may be responsible for continuing preclinical
	and initial clinical development of a product candidate or research program under a collaboration arrangement, and the payment
	we receive from our collaboration partner may be insufficient to cover the cost of this development. If we are unable to reach
	agreements with suitable collaborators for our product candidates, we would face increased costs, we may be forced to limit the
	number of our product candidates we can commercially develop or the territories in which we commercialize them and we might fail
	to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations,
	our operating results and financial condition will be materially and adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	pipeline of product candidates beyond RP-G28 is limited.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	intend to develop and commercialize drug candidates in addition to RP-G28 through our research program. Even if we are successful
	in completing preclinical and clinical development and receiving regulatory approval for one commercially viable drug for the
	treatment of one disease, we cannot be certain that we will be able to develop and receive regulatory approval for other drug
	candidates for the treatment of other forms of that disease or other diseases. If we fail to develop and commercialize RP-G28
	for the reduction of symptoms associated with lactose intolerance, we will not be successful in developing a pipeline of potential
	drug candidates to follow RP-G28, and our business prospects could be significantly limited.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to Our Business and Strategy
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to
	compete effectively.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Although
	we know of no other drug candidates in advanced clinical trials for treating lactose intolerance, the biotechnology and pharmaceutical
	industries are intensely competitive and subject to rapid and significant technological change. We have potential competitors
	in the United States, Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology
	companies, specialty pharmaceutical and generic drug companies and universities and other research institutions. Many of these
	potential competitors have greater financial and other resources, such as larger research and development staff and more experienced
	marketing and manufacturing organizations. Large pharmaceutical companies, in particular, have extensive experience in clinical
	testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have
	significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading
	companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and
	development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete.
	As a result of all of these factors, these potential competitors may succeed in obtaining patent protection and/or FDA approval
	or discovering, developing and commercializing drugs for the diseases that we are targeting before we do. Smaller or early-stage
	companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established
	companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include microbiome based development
	companies: Second Genome, Inc., Seres Health, Inc., Enterome SA, Vedanta Biosciences, Inc., and Microbiome Therapeutics, LLC.
	In addition, many universities and private and public research institutes may become active in our target disease areas. These
	potential competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products
	that are more effective or less costly than RP-G28 or any other product candidates that we are currently developing or that we
	may develop, which could render our products obsolete and noncompetitive.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	believe that our ability to successfully compete will depend on, among other things:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	results of our and our potential strategic collaborators&rsquo; clinical trials and preclinical studies;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to recruit and enroll patients for our clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	efficacy, safety and reliability of our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	speed at which we develop our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to design and successfully execute appropriate clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to maintain a good relationship with regulatory authorities;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	ability to get FDA approval of our end points;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	timing and scope of regulatory approvals, if any;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to commercialize and market any of our product candidates that receive regulatory approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	price of our products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	adequate
	levels of reimbursement under private and governmental health insurance plans, including Medicare;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to protect intellectual property rights related to our products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to manufacture and sell commercial quantities of any approved products to the market; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	acceptance
	of our product candidates by physicians and other health care providers.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	our competitors market products that are more effective, safer or less expensive than ours, or that reach the market sooner than
	ours, we may not achieve commercial success. In addition, the biopharmaceutical industry is characterized by rapid technological
	change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes
	in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological
	advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive
	or not economical.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	depend on third-party contractors for a substantial portion of our operations and may not be able to control their work as effectively
	as if we performed these functions ourselves.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	outsource substantial portions of our operations to third-party service providers, including the conduct of preclinical studies
	and clinical trials, collection and analysis of data, and manufacturing. Our agreements with third-party service providers and
	CROs are on a study-by-study and project-by-project basis. Typically, we may terminate the agreements with notice and are responsible
	for the supplier&rsquo;s previously incurred costs. In addition, any CRO that we retain will be subject to the FDA&rsquo;s and
	EMA&rsquo;s regulatory requirements and similar standards outside of the United States and Europe and we do not have control over
	compliance with these regulations by these providers. Consequently, if these providers do not adhere to applicable governing practices
	and standards, the development and commercialization of our product candidates could be delayed or stopped, which could severely
	harm our business and financial condition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Because
	we have relied on third parties, our internal capacity to perform these functions is limited to management oversight. Outsourcing
	these functions involves the risk that third parties may not perform to our standards, may not produce results in a timely manner
	or may fail to perform at all. Although we have not experienced any significant difficulties with our third-party contractors,
	it is possible that we could experience difficulties in the future. In addition, the use of third-party service providers requires
	us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.
	There are a limited number of third-party service providers that specialize or have the expertise required to achieve our business
	objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming
	and cause delays in our development programs. We currently have a small number of employees, which limits the internal resources
	we have available to identify and monitor third-party service providers. To the extent we are unable to identify, retain and successfully
	manage the performance of third-party service providers in the future, our business may be adversely affected, and we may be subject
	to the imposition of civil or criminal penalties if their conduct of clinical trials violates applicable law.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	A
	variety of risks associated with our possible international business relationships could materially adversely affect our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may enter into agreements with other third parties for the development and commercialization of RP-G28, or other product candidates
	we develop in the future, in international markets. International business relationships subject us to additional risks that may
	materially adversely affect our ability to attain or sustain profitable operations, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	differing
	regulatory requirements for drug approvals internationally;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	potentially
	reduced protection for intellectual property rights;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	potential
	third-party patent rights in the United States and/or in countries outside of the United States;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	potential for so-called &ldquo;parallel importing,&rdquo; which is what occurs when a local seller, faced with relatively
	high local prices, opts to import goods from another jurisdiction with relatively low prices, rather than buying them locally;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	unexpected
	changes in tariffs, trade barriers and regulatory requirements;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	economic
	weakness, including inflation, or political instability, particularly in non-U.S. economies and markets, including several
	countries in Europe;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	compliance
	with tax, employment, immigration and labor laws for employees traveling abroad;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	taxes
	in other countries;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	foreign
	currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident
	to doing business in another country;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	workforce
	uncertainty in countries where labor unrest is more common than in the United States;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	production
	shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	business
	interruptions resulting from geo-political actions, including war and terrorism, or natural disasters, including earthquakes,
	volcanoes, typhoons, floods, hurricanes and fires.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	we increase the number of ongoing product development programs and advance our product candidates through preclinical studies
	and clinical trials, we will need to increase our product development, scientific and administrative headcount to manage these
	programs. In addition, to meet our obligations as a public company, we will need to increase our general and administrative capabilities.
	Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively
	manage our operations, growth and various projects requires that we:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	successfully
	attract and recruit new employees or consultants with the expertise and experience we will require;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	manage
	our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	develop
	a marketing and sales infrastructure; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	continue
	to improve our operational, financial and management controls, reporting systems and procedures.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the
	intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are
	not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints
	that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our
	ability to implement our business strategy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are highly dependent on the development, regulatory, commercialization and business development expertise of Michael D. Step,
	our Chief Executive Officer, Andrew J. Ritter, our Founder and President, and Ira E. Ritter, our Executive Chairman and Chief
	Strategic Officer. If we were to lose one or more of these key employees, our ability to implement our business strategy successfully
	could be seriously harmed. Any of our executive officers may terminate their employment at any time. Replacing any of these persons
	would be difficult and could take an extended period of time because of the limited number of individuals in our industry with
	the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	There
	is also a risk that other obligations could distract our officers and employees from our business, which could have negative impact
	on our ability to effectuate our business plans.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, we have scientific and clinical advisors and consultants who assist us in formulating our research, development and
	clinical strategies. Competition to hire and retain consultants from a limited pool is intense. Further, because these advisors
	are not our employees, they may have commitments to, or consulting or advisory contracts with, other entities that may limit their
	availability to us, and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between
	their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements
	with other companies to assist those companies in developing products or technologies that may compete with ours.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Failure
	to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the
	financial reporting and internal controls requirements for publicly traded companies.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	a public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley
	Act of 2002, as amended (the &ldquo;Sarbanes-Oxley Act&rdquo;), and the related rules and regulations of the SEC, expanded disclosure
	requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley
	Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and
	procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent
	financial fraud.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have begun implementing our system of internal controls over financial reporting and preparing the documentation necessary to
	perform the evaluation needed to comply with Section 404(a) of the Sarbanes-Oxley Act. As we continue to operate as a public company,
	we will continue improving our financial infrastructure with the retention of additional financial and accounting capabilities,
	the enhancement of internal controls and additional training for our financial and accounting staff.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Section
	404(a) of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial
	reporting, starting with the second annual report that we would expect to file with the SEC. However, for as long as we remain
	an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;),
	we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
	that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being required to comply with the auditor
	attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We may take advantage of these reporting exemptions until
	we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an emerging growth company until the earlier of&thinsp;
	(i) the last day of the fiscal year (a) following the fifth anniversary of the date we completed our initial public offering,
	which was June 29, 2015, (b) in which we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed
	to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700.0
	million as of the prior June 30
<SUP>
	th
</SUP>
	, and (ii) the date on which we have issued more than $1.0 billion in non-convertible
	debt during the prior three-year period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Until
	we are able to expand our finance and administrative capabilities and establish necessary financial reporting infrastructure,
	we may not be able to prepare and disclose, in a timely manner, our financial statements and other required disclosures or comply
	with the Sarbanes-Oxley Act or existing or new reporting requirements. If we cannot provide reliable financial reports or prevent
	fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
	and insider trading, which could significantly harm our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply
	with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply
	with health care fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately
	or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry
	are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive
	practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
	sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper
	use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our
	reputation. We have adopted an employee handbook, but it is not always possible to identify and deter employee misconduct, and
	the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or
	losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
	these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or
	asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines
	or other sanctions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability
	for a product candidate and may have to limit its commercialization.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	use of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval expose
	us to the risk of product liability claims. Product liability claims may be brought against us or our potential future collaborators
	by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling our
	products. If we cannot successfully defend ourselves against any such claims, we would incur substantial liabilities. Regardless
	of merit or eventual outcome, product liability claims may result in:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	withdrawal
	of clinical trial participants;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	termination
	of clinical trial sites or entire trial programs;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	costs
	of related litigation;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	substantial
	monetary awards to patients or other claimants;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	decreased
	demand for our product candidates and loss of revenues;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	impairment
	of our business reputation;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	diversion
	of management and scientific resources from our business operations; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	inability to commercialize our product candidates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have product liability insurance coverage for our Phase 2b/3 clinical trials in the United States and in selected other jurisdictions
	where we intend to conduct clinical trials at levels we believe are sufficient and consistent with industry standards for companies
	at our stage of development. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for
	any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we
	may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due
	to product liability. We intend to expand our insurance coverage for products to include the sale of commercial products if we
	obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product
	liability insurance for any products approved for marketing. Large judgments have been awarded in class action lawsuits based
	on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly
	if judgments exceed our insurance coverage, could decrease our cash resources and adversely affect our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured
	liabilities.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain
	include general liability ($2.0 million coverage), employment practices liability, workers&rsquo; compensation, and directors&rsquo;
	and officers&rsquo; insurance at levels we believe are typical for a company in our industry and at our stage of development.
	We currently carry clinical trial liability insurance for our Phase 2b/3 clinical trials at levels we believe are sufficient and
	consistent with industry standards for companies at our stage of development. We do not know, however, if we will be able to maintain
	insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which
	would adversely affect our financial position and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	If
	we engage in an acquisition, reorganization or business combination, we will incur a variety of risks that could adversely affect
	our business operations or our stockholders.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	From
	time to time we have considered, and we will continue to consider in the future, strategic business initiatives intended to further
	the expansion and development of our business. These initiatives may include acquiring businesses, technologies or products or
	entering into a business combination with another company. If we pursue such a strategy, we could, among other things:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	issue
	equity securities that would dilute our current stockholders&rsquo; percentage ownership;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	incur
	substantial debt that may place strains on our operations;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	spend
	substantial operational, financial and management resources to integrate new businesses, technologies and products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	assume
	substantial actual or contingent liabilities;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	reprioritize
	our development programs and even cease development and commercialization of our product candidates; or
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	merge
	with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash and/or
	shares of the other company on terms that certain of our stockholders may not deem desirable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Although
	we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements
	or understandings with respect to any acquisition, reorganization or business combination at this time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to Our Intellectual Property
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	It
	is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position
	does not adequately protect our product candidates, others could compete against us more directly, which would harm our business,
	possibly materially.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	commercial success will depend in part on obtaining, maintaining and enforcing patent protection and on developing, preserving
	and enforcing current trade secret protection. In particular, it will depend in part on our ability to obtain, maintain and enforce
	patents, especially those related to methods of using our current product, RP-G28, and other future drug candidates, and those
	related to the methods used to develop and manufacture our products, as well as successfully defending these patents against third-party
	challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends
	on the extent to which we have rights under valid and enforceable patents (and/or trade secrets) that cover these activities.
	We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent
	applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted
	to us in the future will withstand subsequent challenges to their validity and or patentability, or if they will be commercially
	useful in protecting our product candidates, discovery programs and processes. Furthermore, we cannot be sure that our existing
	patents and patent applications will embrace (or &ldquo;claim&rdquo;) the particular uses for RP-G28 that will be approved by
	FDA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	The
	patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions
	for which important legal principles remain unresolved.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	No
	consistent policy regarding the patentability and/or validity of patent claims related to pharmaceutical patents has emerged,
	to date, in the United States or in most jurisdictions outside of the United States. Changes in either the patent laws (be they
	substantive or procedural) or in the interpretations of patent laws in the United States and other countries may diminish the
	value of our intellectual property. Accordingly, we cannot predict the breadth of claims that will issue or will be enforceable
	in the patents that have or may be issued from the patents and applications we currently own or may in the future own or license
	from third parties. Further, if any patents we obtain, or to which we obtain licenses, are deemed invalid, unpatentable and unenforceable,
	our ability to commercialize or license our technology could be adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	the future others may file patent applications covering products, uses for products, and manufacturing techniques and related
	technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent
	application owned by a third party will not have priority over patent applications filed or in-licensed by us in the future, or
	that we or our licensors will not be involved in interference, opposition, inter partes review or invalidity proceedings before
	U.S. or non-U.S. patent offices or courts.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may
	not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	others
	may be able to develop a platform similar to, or better than, ours in a way that is not covered by the claims of our patents;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	others
	may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	others
	may be able to manufacture compounds that are similar or identical to our product candidates using processes that are not
	covered by the claims of our method of making patents;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	others
	may obtain regulatory approval for uses of compounds, similar or identical to our product, that are not covered by the claims
	of our method of use patents;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we
	may not be able to obtain licenses for patents that are essential to the process of making the product;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we
	might not have been the first to make the inventions covered by our pending patent applications;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we
	might not have been the first to file patent applications for these inventions;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	others
	may independently develop similar or alternative technologies or duplicate any of our technologies;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	any
	patents that we obtain may not provide us with any competitive advantages;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	we
	may not develop additional proprietary technologies that are patentable; or
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	patents of others may have an adverse effect on our business.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Patents
	covering methods of using RP-G28 expire in 2030 if the appropriate maintenance fee renewal, annuity, or other government fees
	are paid, unless a patent term extension based on regulatory delay is obtained. We expect that expiration in 2030 of some of our
	method-of-use patents covering use of RP-G28 for treating lactose intolerance will have a limited impact on our ability to protect
	our intellectual property in the United States, where we have additional issued patents covering this use that extend until 2030.
	In other countries, our pending patent applications covering use of RP-G28 for treating other indications, if issued, would expire
	in 2030. We will attempt to mitigate the effect of patent expiration by seeking data exclusivity, or the foreign equivalent thereof,
	in conjunction with product approval, as well as by filing additional patent applications covering improvements in our intellectual
	property.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expect that the other patent applications for the RP-G28 portfolio, if issued, and if the appropriate maintenance, renewal, annuity
	or other governmental fees are paid, would expire in 2030. We own pending applications in the United States and Europe covering
	RP-G28 analogs, and uses of such analogs as therapeutics to treat a variety of disorders, including lactose intolerance. Patent
	protection, to the extent it issues, would be expected to extend to 2030, unless a patent term extension based on regulatory delay
	is obtained.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Due
	to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not
	obtain patent coverage for all of our product candidates or methods involving these candidates in the parent patent application.
	We plan to pursue divisional patent applications or continuation patent applications in the United States and other countries
	to obtain claim coverage for inventions which were disclosed but not claimed in the parent patent application.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate
	or feasible. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets,
	our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully
	disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade
	secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes
	less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	RP-G28
	does not have composition of matter patent protection.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Although
	we own certain patents and patent applications with claims directed to specific methods of using RP-G28 to treat lactose intolerance,
	RP-G28 has no composition of matter patent protection in the United States or elsewhere. As a result, we may be limited in our
	ability to list our patents in the FDA&rsquo;s Orange Book if the use of our product, consistent with its FDA-approved label,
	would not fall within the scope of our patent claims. Also, our competitors may be able to offer and sell products so long as
	these competitors do not infringe any other patents that we (or third parties) hold, including patents with claims directed to
	the manufacture of RP-G28 and/or method of use patents. In general, method of use patents are more difficult to enforce than composition
	of matter patents because, for example, of the risks that FDA may approve alternative uses of the subject compounds not covered
	by the method of use patents, and others may engage in off-label sale or use of the subject compounds. Physicians are permitted
	to prescribe an approved product for uses that are not described in the product&rsquo;s labeling. Although off-label prescriptions
	may infringe our method of use patents, the practice is common across medical specialties and such infringement is difficult to
	prevent or prosecute. FDA approval of uses that are not covered by our patents would limit our ability to generate revenue from
	the sale of RP-G28, if approved for commercial sale. Off-label sales would limit our ability to generate revenue from the sale
	of RP-G28, if approved for commercial sale.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property
	rights.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or
	company may seek a post grant review (including inter parte review) of our patents, and has the right to ask the court to rule
	that such patents are invalid or should not be enforced against that third party. These lawsuits and administrative proceedings
	are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we
	were successful in stopping the infringement of such patents. In addition, there is a risk that the court or administrative body
	will decide that such patents are not valid or unpatentable and that we do not have the right to stop the other party from using
	the inventions. There is also the risk that, even if the validity/patentability of such patents is upheld, the court will refuse
	to stop the other party on the ground that such other party&rsquo;s activities do not infringe our rights to such patents. In
	addition, the U.S. Supreme Court and the Court of Appeals for the Federal Circuit have recently articulated and/or modified certain
	tests used by the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;), in assessing patentability and by the courts in
	assessing validity and claim scope, which may decrease the likelihood that we will be able to obtain patents and increase the
	likelihood that others may succeed in challenging any patents we obtain or license.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
	from commercializing or increase the costs of commercializing our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We cannot guarantee
	that our products, our methods of manufacture, or our uses of RP-G28 (or our other product candidates), will not infringe third-party
	patents. Furthermore, a third party may claim that we or our manufacturing or commercialization collaborators are using inventions
	covered by the third party&rsquo;s patent rights and may go to court to stop us from engaging in our normal operations and activities,
	including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert
	the attention of managerial and scientific personnel. There is a risk that a court would decide that we or our commercialization
	collaborators are infringing the third party&rsquo;s patents and would order us or our collaborators to stop the activities covered
	by the patents. In that event, we or our commercialization collaborators may not have a viable way around the patent and may need
	to halt commercialization of the relevant product. In addition, there is a risk that a court will order us or our collaborators
	to pay the other party damages for having violated the other party&rsquo;s patents. In the future, we may agree to indemnify our
	commercial collaborators against certain intellectual property infringement claims brought by third parties. The pharmaceutical
	and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including
	us, which patents cover various types of products or methods of use. The scope of coverage of a patent is subject to interpretation
	by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, the patentee would need to
	demonstrate, by a preponderance of the evidence that our products or methods infringe the patent claims of the relevant patent,
	and we would need to demonstrate either that we do not infringe or, by clear and convincing evidence, that the patent claims are
	invalid; we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity
	requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if
	we are successful in these proceedings, we may incur substantial costs and divert management&rsquo;s time and attention in pursuing
	these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of
	others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity
	of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions
	to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend
	an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter
	significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we
	were the first to invent the technology, because:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	some
	patent applications in the United States may be maintained in secrecy until the patents are issued;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	patent
	applications in the United States are typically not published until at least 18 months after the earliest asserted priority
	date; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	publications
	in the scientific literature often lag behind actual discoveries.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent
	application may have priority over our patent applications, which could further require us to obtain rights to issued patents
	covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to
	participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs
	of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the
	other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our
	U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications,
	and may be entitled to priority over our applications in such jurisdictions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Some
	of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
	substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation
	could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Obtaining
	and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
	requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
	with these requirements.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Periodic
	maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to
	be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime
	of the patents and/or applications. We employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S.
	patent agencies and this outside firm has systems in place to ensure compliance on payment of fees. The USPTO and various non-U.S.
	governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions
	during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases,
	an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However,
	there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting
	in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to
	enter the market and this circumstance would have a material adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
	If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology
	and products could be significantly diminished.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology
	or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees,
	or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers.
	Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation
	could result in substantial costs and be a distraction to management.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate
	or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees,
	consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other
	proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide
	an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently
	discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently
	considering whether to make additional information publicly available on a routine basis, including information that we may consider
	to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&rsquo;s disclosure policies
	may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope
	of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business
	position.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Failure
	to secure trademark registrations could adversely affect our business.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have not developed a trademark for our RP-G28 product. Hence, we do not currently own any actual or potential trademark rights
	associated with our RP-G28 product. If we seek to register additional trademarks, including trademarks associated with our RP-G28
	product, our trademark applications may not be allowed for registration or our registered trademarks may not be maintained or
	enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond
	to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many
	other jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered
	trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such
	proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against
	third parties than we otherwise would.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Risks
	Relating to Our Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	An
	active trading market for our common stock may not develop or be sustained.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Prior
	to our initial public offering, there was no public market for our common stock. Since our initial public offering in June 2015,
	there has been, and we expect that there will continue to be, only a limited volume of trading in our common stock. An active
	trading market in our common stock may not develop or, if developed, may not be sustained. The lack of an active market may impair
	your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an
	active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital
	to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using
	our shares as consideration.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	share price may be volatile, which could subject us to securities class action litigation and prevent you from being able to sell
	your shares at or above your purchase price.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this
	section, and others beyond our control, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	results
	of our clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	results
	of clinical trials of our competitors&rsquo; products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	regulatory
	actions with respect to our products or our competitors&rsquo; products;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	actual
	or anticipated fluctuations in our financial condition and operating results;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	actual
	or anticipated changes in our growth rate relative to our competitors;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	actual
	or anticipated fluctuations in our competitors&rsquo; operating results or changes in their growth rate;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	competition
	from existing products or new products that may emerge;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	announcements
	by us, our potential future collaborators or our competitors of significant acquisitions, strategic collaborations, joint
	ventures, or capital commitments;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	issuance
	of new or updated research or reports by securities analysts;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	fluctuations
	in the valuation of companies perceived by investors to be comparable to us;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	share
	price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	additions
	or departures of key management or scientific personnel;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	disputes
	or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent
	protection for our technologies;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	announcement
	or expectation of additional financing efforts;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	sales
	of our common stock by us, our insiders or our other stockholders;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	market
	conditions for biopharmaceutical stocks in general; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	general
	economic and market conditions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Furthermore,
	the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market
	prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating
	performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market
	conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market
	price of shares of our common stock. In addition, such fluctuations could subject us to securities class action litigation, which
	could result in substantial costs and divert our management&rsquo;s attention from other business concerns, which could seriously
	harm our business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	executive officers, directors and principal stockholders maintain the ability to exert substantial influence over all matters
	submitted to stockholders for approval.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	executive officers, directors and principal stockholders beneficially own shares representing approximately 48.1% of our outstanding
	capital stock. As a result, if these stockholders were to choose to act together, they would be able to exert substantial influence
	over all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons,
	if they choose to act together, would exert substantial influence over the election of directors and approval of any merger, consolidation
	or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of
	our Company on terms that other stockholders may desire.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Being
	a public company has increased our expenses and administrative burden.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	a public company, we have incurred and will continue to incur significant legal, insurance, accounting and other expenses that
	we did not incur as a private company. In addition, our administrative staff is required to perform tasks they did not perform
	when we were a private company. For example, as a public company, we must bear all of the internal and external costs of preparing
	and distributing periodic public reports in compliance with our obligations under the securities laws. In addition, laws, regulations
	and standards applicable to public companies relating to corporate governance and public disclosure, including the Sarbanes-Oxley
	Act and related regulations implemented by the SEC and NASDAQ, create uncertainty for public companies, increasing legal and financial
	compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying
	interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over
	time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance
	matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We have invested and will continue
	to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general
	and administrative expenses and may divert management&rsquo;s time and attention from product development activities. If our efforts
	to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to
	ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.
	In the future, it may become more expensive for us to maintain director and officer liability insurance, and we may be required
	to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult
	for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation
	committee, and qualified executive officers.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	are an &ldquo;emerging growth company&rdquo; and will be able to avail ourselves of reduced disclosure requirements applicable
	to emerging growth companies, which could make our common stock less attractive to investors.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are an &ldquo;emerging growth company,&rdquo; as defined in the JOBS Act and we intend to take advantage of certain exemptions
	from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
	including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act,
	reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from
	the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
	payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely
	on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
	for our common stock and our stock price may be more volatile.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	may take advantage of these reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain
	an emerging growth company until the earlier of&thinsp; (i) the last day of the fiscal year (a) following the fifth anniversary
	of the date we completed our initial public offering, which was June 29, 2015, (b) in which we have total annual gross revenue
	of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
	stock that is held by non-affiliates exceeded $700.0 million as of the prior June 30
<SUP>
	th
</SUP>
	, and (ii) the date on which
	we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Future
	sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline,
	even if our business is doing well.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sales
	by our stockholders of a substantial number of shares of our common stock in the public market could occur in the future. These
	sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could
	reduce the market price of our common stock. We had 8,582,004 outstanding shares of common stock as of December 31, 2015, which
	does not include the 888,835 shares we may issue to Aspire Capital in the future pursuant to the terms of the Aspire Purchase
	Agreement. Of the shares outstanding, a total of 5,859,983 shares may be resold in the public market at any time and the remaining
	2,722,021 shares are currently restricted under securities laws.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the Aspire Capital financing transaction, we registered for resale up to 1,577,699 shares of our common stock
	by Aspire Capital (including the shares we have already issued to Aspire Capital under the Aspire Purchase Agreement and an additional
	888,835 shares that we may issue to Aspire Capital in the future under the terms of the Aspire Purchase Agreement). The number
	of shares ultimately offered for sale by Aspire Capital is dependent upon the number of shares we elect to sell to Aspire Capital
	under the Aspire Purchase Agreement. Aspire Capital may sell all, some or none of our shares that it holds or comes to hold under
	the Aspire Purchase Agreement. The sale of a substantial number of shares of our common stock by Aspire Capital, or anticipation
	of such sales, could cause the trading price of our common stock to decline or make it more difficult for us to sell equity or
	equity-related securities in the future at a time and at a price that we might otherwise desire. However, we have the right under
	the Aspire Purchase Agreement to control the timing and amount of sales of our shares to Aspire Capital, and the Aspire Purchase
	Agreement may be terminated by us at any time at our discretion without any penalty or cost to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have also registered 2,111,682 shares of common stock that we may issue under our equity compensation plans. These shares can
	be sold in the public market upon issuance and once vested.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	If
	securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our
	share price and trading volume could decline.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	trading market for our common stock will depend on the research and reports that securities or industry analysts publish about
	us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide
	favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our
	share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish
	reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	failure to meet the continued listing requirements of NASDAQ could result in a de-listing of our common stock.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	we fail to satisfy the continued listing requirements of NASDAQ, such as the corporate governance requirements or the minimum
	closing bid price requirement, NASDAQ may take steps to de-list our common stock. Such a de-listing would likely have a negative
	effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do
	so. In the event of a de-listing, we would take actions to restore our compliance with NASDAQ&rsquo;s listing requirements, but
	we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the
	market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ minimum bid
	price requirement or prevent future non-compliance with NASDAQ&rsquo;s listing requirements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Provisions
	in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to
	our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Provisions
	in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent
	a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions
	in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might
	be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition,
	because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate
	or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders
	to replace members of our board of directors. Among other things, these provisions provide that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	authorized number of directors can be changed only by resolution of our board of directors;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	bylaws may be amended or repealed by our board of directors or our stockholders;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	stockholders
	may not call special meetings of the stockholders or fill vacancies on the board of directors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	board of directors is authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined
	at the discretion of the board of directors and that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the
	stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	stockholders do not have cumulative voting rights, and therefore our stockholders holding a majority of the shares of common
	stock outstanding will be able to elect all of our directors; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	stockholders must comply with advance notice provisions to bring business before or nominate directors for election at a stockholder
	meeting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 40.3PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Moreover,
	because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation
	Law (the &ldquo;DGCL&rdquo;), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging
	or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15%
	of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Claims
	for indemnification by our directors and officers may reduce our available funds to satisfy successful stockholder claims against
	us and may reduce the amount of money available to us.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	permitted by Section 102(b)(7) of the DGCL, our amended and restated certificate of incorporation limits the liability of our
	directors to the fullest extent permitted by law. In addition, as permitted by Section 145 of the DGCL, our amended and restated
	certificate of incorporation and our amended and restated bylaws provide that we shall indemnify, to the fullest extent authorized
	by the DGCL, each person who is involved in any litigation or other proceeding because such person is or was a director or officer
	of our company or is or was serving as an officer or director of another entity at our request, against all expense, loss or liability
	reasonably incurred or suffered in connection therewith. Our amended and restated certificate of incorporation provides that the
	right to indemnification includes the right to be paid expenses incurred in defending any proceeding in advance of its final disposition,
	provided, however, that such advance payment will only be made upon delivery to us of an undertaking, by or on behalf of the director
	or officer, to repay all amounts so advanced if it is ultimately determined that such director is not entitled to indemnification.
	If we do not pay a proper claim for indemnification in full within 60 days after we receive a written claim for such indemnification,
	except in the case of a claim for an advancement of expenses, in which case such period is 20 days, our restated certificate of
	incorporation and our restated bylaws authorize the claimant to bring an action against us and prescribe what constitutes a defense
	to such action.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Section
	145 of the DGCL permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney&rsquo;s
	fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or
	proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted
	in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation,
	and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful.
	In a derivative action, (
<I>
	i.e.
</I>
	, one brought by or on behalf of the corporation), indemnification may be provided only for
	expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action
	or suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the
	best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to
	be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine
	that the defendant is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	rights conferred in the restated certificate of incorporation and the restated bylaws are not exclusive, and we are authorized
	to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify
	such persons. We have entered into indemnification agreements with each of our officers and directors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	above limitations on liability and our indemnification obligations limit the personal liability of our directors and officers
	for monetary damages for breach of their fiduciary duty as directors by shifting the burden of such losses and expenses to us.
	Although we plan to increase the coverage under our directors&rsquo; and officers&rsquo; liability insurance, certain liabilities
	or expenses covered by our indemnification obligations may not be covered by such insurance or the coverage limitation amounts
	may be exceeded. As a result, we may need to use a significant amount of our funds to satisfy our indemnification obligations,
	which could severely harm our business and financial condition and limit the funds available to stockholders who may choose to
	bring a claim against our company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	We
	have never paid dividends on our common stock and do not anticipate paying dividends for the foreseeable future, and accordingly,
	stockholders must rely on stock appreciation for any return on their investment.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have never paid dividends on our common stock and we do not anticipate paying dividends on our common stock for the foreseeable
	future. Accordingly, any return on an investment in our common stock will be realized, if at all, only when stockholders sell
	their shares. In addition, our failure to pay dividends may make our stock less attractive to investors, adversely impacting trading
	volume and price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Our
	ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015, we had federal net operating loss carryforwards, or NOLs, of approximately $15.0 million which begin to
	expire in 2028. Our ability to utilize our NOLs may be limited under Section 382 and 383 of the Internal Revenue Code. The limitations
	apply if an ownership change, as defined by Section 382, occurs. Generally, an ownership change occurs when certain shareholders
	increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period
	(typically three years). Although we have not undergone a Section 382 analysis, it is possible that the utilization of the NOLs,
	could be substantially limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be utilized against
	future taxes. As a result, we may not be able to take full advantage of these carryforwards for federal and state tax purposes.
	Future changes in stock ownership may also trigger an ownership change and, consequently, a Section 382 limitation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_004">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	1B. Unresolved Staff Comments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_005">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	2. Properties
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	July 9, 2015, we entered into a new lease with Century Park, pursuant to which we are leasing approximately 2,780 square feet
	of office space in Los Angeles, California for our headquarters. The lease provides for a term of sixty-one (61) months, which
	commenced October 1, 2015. We paid no rent for the first month of the term and will pay base rent of $9,174 per month for months
	two through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of the lease to a
	maximum of $10,325 per month for months 50 through 61. We have the option to extend the term of the lease for one five-year term,
	provided that the rent would be subject to market adjustment at the beginning of the renewal term. We believe that our facility
	is suitable and adequate for our current needs.
</FONT>
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_006">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	3. Legal Proceedings
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	From
	time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of our business.
	We are not presently a party to any material litigation.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_007">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	4. Mine Safety Disclosures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Not
	Applicable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_008">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	II
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_009">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	5. Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	common stock began trading on the NASDAQ Capital Market under the ticker symbol &ldquo;RTTR&rdquo; on June 24, 2015. Prior to
	that date, there was no public market for our common stock. Our initial public offering was priced at $5.00 per share on June
	24, 2015. The table sets forth, for the periods indicated below, the high and low intra-day sales prices per share of our common
	stock as reported on the New York Stock Exchange since June 24, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	High
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-INDENT: -0.25IN; PADDING-LEFT: 0.25IN">
	Second quarter (beginning June 24, 2015)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	5.50
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	3.80
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.25IN; PADDING-LEFT: 0.25IN">
	Third quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -0.25IN; PADDING-LEFT: 0.25IN">
	Fourth quarter
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.63
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Holders
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of March 16, 2016 there were approximately 41 registered holders of record of our common stock. This number does not include beneficial
	owners whose shares are held by nominees in street name.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Dividends
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our
	common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development
	and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and
	will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual
	restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. See &ldquo;Risk
	Factors &mdash; Risks Relating to Our Common Stock&mdash; We have never paid dividends on our common stock and do not anticipate
	paying dividends for the foreseeable future, and accordingly, stockholders must rely on stock appreciation for any return on their
	investment.&rdquo;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Recent
	Sales of Unregistered Securities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 18, 2015, we entered into a common stock purchase agreement (the &ldquo;Aspire Purchase Agreement&rdquo;) with Aspire
	Capital Fund, LLC (&ldquo;Aspire Capital&rdquo;), which provides that, upon the terms and subject to the conditions and limitations
	set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of our common stock over
	a 30-month period. Upon execution of the Aspire Purchase Agreement, we sold 500,000 shares of common stock (the &ldquo;Initial
	Purchase Shares&rdquo;) at $2.00 per share to Aspire Capital for proceeds of $1,000,000. In consideration for entering into the
	Aspire Purchase Agreement, we also issued to Aspire Capital 188,864 shares of our common stock (the &ldquo;Commitment Shares&rdquo;)
	concurrently with the execution of the Aspire Purchase Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	issuance of the Initial Purchase Shares and the Commitment Shares were exempt from registration under the Securities Act of 1933,
	as amended (the &ldquo;Securities Act&rdquo;), pursuant to the exemption for transactions by an issuer not involving any public
	offering under Section 4(a)(2) of the Securities Act. On December 31, 2015, we filed a registration statement on Form S-1 to register
	the Initial Purchase Shares, Commitment Shares and up to 888,835 additional shares that we may sell to Aspire from time to time
	under the Aspire Purchase Agreement. The registration statement (No. 333-208818) was declared effective on February 11, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Use
	of Proceeds from Initial Public Offering of Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 24, 2015, our registration statement on Form S-1 (File No. 333-202924) relating to our initial public offering of our common
	stock was declared effective by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Our initial public offering closed
	on June 29, 2015, and 4,000,000 shares of our common stock were sold at an initial public offering price of $5.00 per share, for
	aggregate gross proceeds to us of $20 million and net proceeds to us, after deducting underwriting discounts and commissions and
	offering expenses, of approximately $17.4 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Proceeds
	from the initial public offering have been used to fund our Phase 2b/3 trials and product development, including a $0.8 million
	payment to exercise an option with a research and development supplies. A portion of the proceeds ($227,250) was used to pay the
	annual bonuses earned by Andrew and Ira Ritter for 2015, based upon the achievement of specific performance goals, pursuant to
	the terms of their respective offer letters. Remaining proceeds from the initial public offering have been spent to support general
	corporate purposes, general and administrative expenses, capital expenditures, working capital and prosecution and maintenance
	of our intellectual property.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Purchases
	of Equity Securities by the Issuer and Affiliated Purchasers
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	None.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_010">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	6. Selected Financial Data
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Not
	applicable.
</FONT>
</P>
</EFX_FINANCIAL_DATA>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_011">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	The
	following discussion and analysis should be read together with our financial statements and the related notes appearing elsewhere
	in this Annual Report. This discussion contains forward-looking statements reflecting our current expectations that involve risks
	and uncertainties. See &ldquo;Special Note Regarding Forward-Looking Statements and Industry Data&rdquo; for a discussion of the
	uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially
	from those discussed in our forward-looking statements as a result of many factors, including those set forth under &ldquo;Risk
	Factors&rdquo; and elsewhere in this Annual Report.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ritter
	Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.
	We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality
	of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient&rsquo;s health. We have completed
	a Phase 2a clinical trial of our leading product candidate, RP-G28, an orally administered, high purity oligosaccharide.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have devoted substantially all of our resources to development efforts relating to RP-G28, including conducting clinical trials
	of RP-G28, providing general and administrative support for these operations and protecting our intellectual property. We currently
	do not have any products approved for sale and we have not generated any revenue from product sales since our inception. From
	our inception through June 28, 2015, we funded our operations primarily through the private placement of preferred stock, common
	stock and promissory notes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 24, 2015, our registration statement on Form S-1 (File No. 333-202924) relating to our initial public offering of common
	stock was declared effective by the SEC. The shares began trading on the NASDAQ Capital Market on June 24, 2015. The initial public
	offering closed on June 29, 2015, and 4,000,000 shares of common stock were sold at an initial public offering price of $5.00
	per share, for aggregate gross proceeds to us of $20 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering.
	In addition, we incurred expenses of approximately $1.0 million in connection with the offering. Thus, the net offering proceeds
	to us, after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4 million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have incurred net losses in each year since our inception, including net losses of approximately $8.8 million for the year ended
	December 31, 2015. We had an accumulated deficit of approximately $27.1 million as of December 31, 2015. Substantially all our
	net losses resulted from costs incurred in connection with our research and development programs, stock-based compensation, and
	from general and administrative costs associated with our operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate
	that our expenses will increase substantially as we:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	complete
	the development of our lead product candidate, RP-G28, for the reduction of symptoms associated with lactose intolerance in
	patients;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	seek
	to obtain regulatory approvals for RP-G28;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	outsource
	the commercial manufacturing of RP-G28 for any indications for which we receive regulatory approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	contract
	with third parties for the sales, marketing and distribution of RP-G28 for any indications for which we receive regulatory
	approval;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	maintain,
	expand and protect our intellectual property portfolio;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	continue
	our research and development efforts; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	add
	operational, financial and management information systems and personnel, including personnel to support our product development
	and commercialization efforts.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	do not expect to generate revenue from product sales unless and until we successfully complete development and obtain marketing
	approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant
	uncertainty. Accordingly, we anticipate that we will need to raise additional capital in addition to the net proceeds received
	in our initial public offering, and any proceeds received from our sale of shares of common stock to Aspire Capital pursuant to
	the Aspire Purchase Agreement, prior to the commercialization of RP-G28 or any other product candidate. Until such time, if ever,
	as we can generate substantial revenue from product sales, we expect to finance our operating activities through a combination
	of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements
	and other collaborations, strategic alliances and licensing arrangements. However, we may be unable to raise additional funds
	or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such
	other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our product
	candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Financial
	Overview
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Revenue
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have not generated any revenue since our inception. Our ability to generate revenue in the future will depend almost entirely
	on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize RP-G28 in the United
	States. In the event we choose to pursue a partnering arrangement to commercialize RP-G28 or other products outside the United
	States, we would expect to initiate additional research and development and clinical trial activities in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Research
	and Development Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Since
	our inception, we have focused our resources on our research and development activities, including conducting nonclinical studies
	and clinical trials, manufacturing development efforts and activities related to regulatory filings for RP-G28. Our research and
	development expenses consist primarily of:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	fees
	paid to consultants and CROs, including in connection with our nonclinical and clinical trials, and other related clinical
	trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management, clinical
	trial material management and statistical compilation and analysis;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	costs
	related to acquiring and manufacturing clinical trial materials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	depreciation
	of equipment, computers and furniture and fixtures;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	costs
	related to compliance with regulatory requirements; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	overhead
	expenses for personnel in research and development functions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	From
	inception through December 31, 2015, we have incurred approximately $6.0 million in research and development expenses. We plan
	to increase our research and development expenses for the foreseeable future as we continue the development of RP-G28 for the
	reduction of symptoms associated with lactose intolerance in patients and other indications, subject to the availability of additional
	funding.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing
	or costs of the efforts that will be necessary to complete the development of RP-G28 or the period, if any, in which material
	net cash inflows from RP-G28 may commence. This is due to the numerous risks and uncertainties associated with developing drugs,
	including the uncertainty of:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development
	activities;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	future
	clinical trial results; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	timing and receipt of any regulatory approvals.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant
	change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory
	authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion
	of clinical development of a product candidate or if we experience significant delays in enrollment in any of our clinical trials,
	we could be required to expend significant additional financial resources and time on the completion of clinical development.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	RP-G28
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	research and development resources are focused on the Phase 2b and Phase 3 RP-G28 trials and our other planned clinical and nonclinical
	studies and other work needed to submit RP-G28 for the reduction of symptoms associated with lactose intolerance in patients for
	regulatory approval in the United States and Europe. We have incurred and expect to continue to incur expenses in connection with
	these efforts, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	conducting
	our Phase 2b/3 clinical trials as an adaptive design Phase 2b/3 clinical trials;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	working
	with our CRO to prepare for launch of the Phase 2b/3 and Phase 3 trials; and
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	working
	with our third-party drug formulator to produce sufficient drug product for the adaptive design Phase 2b/3 clinical trials
	and other contemplated trials.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Patent
	Costs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Patent
	costs consist primarily of professional fees for legal services to prosecute patents and maintain patent rights.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	General
	and Administrative Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	General
	and administrative expenses include allocation of facilities costs, salaries, benefits, and stock-based compensation for employees,
	professional fees for directors, fees for independent contractors and accounting and legal services.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expect that our general and administrative expenses will increase as we continue to operate as a public company and will increase
	further if RP-G28 is approved for commercialization. We believe that these increases will likely include increased costs for director
	and officer liability insurance, and increased fees for outside consultants, lawyers and accountants, among other expenses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Interest
	Income and Interest Expense
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Interest
	income consists of interest earned on our cash.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Interest
	expense pertains to interest accrued on our promissory notes outstanding prior to our initial public offering.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Critical
	Accounting Estimates
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	discussion and analysis is based on our financial statements, which have been prepared in accordance with generally accepted accounting
	principles in the United States (&ldquo;U.S. GAAP&rdquo;). The preparation of these financial statements requires us to make estimates
	and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent
	assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those
	related to fair value of financial instruments, research and development costs, accrued expenses and stock-based compensation.
	We base our estimates on historical experience, known trends and events and various other factors we believe to be reasonable
	under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
	that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
	conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	While
	our significant accounting policies are more fully described in Note 3 to our financial statements appearing in &ldquo;Item 8.
	Financial Statements and Supplementary Data,&rdquo; we believe that the following accounting policies are the most critical to
	aid you in fully understanding and evaluating our financial condition and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Fair
	Value of Financial Instruments
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Fair
	value measurement guidelines are prescribed by GAAP to value financial instruments. The guidance includes a definition of fair
	value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair
	value and expands disclosures about the use of fair value measurements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained
	from independent sources, while unobservable inputs reflect internal market assumptions. Assets are classified in their entirety
	based on the lowest level of input that is significant to the fair value measurement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	These
	two types of inputs create the following fair value hierarchy:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	1 &mdash; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access
	at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such
	as exchange-traded instruments and listed equities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	2 &mdash; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly
	or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models
	consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial
	instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or
	are supported by observable levels at which transactions are executed in the marketplace.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3 &mdash; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values
	are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption
	or input is unobservable
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	carrying amounts reported in the balance sheet for cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses,
	and the notes payable approximate the fair values due to the short-term nature of the instruments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Research
	and Development Costs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expense the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing
	research and development activities, including clinical study costs, contracted services, and other external costs. Nonrefundable
	advance payments for goods and services that will be used in future research and development activities are expensed when the
	activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,
<I>
	Research
	and Development
</I>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Accrued
	Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves
	reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service
	performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual
	cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones
	are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and
	circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make
	adjustments if necessary. The significant estimates in our accrued research and development expenses include fees due to service
	providers.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	base our expenses on our estimates of the services received and efforts expended pursuant to quotes and contracts with our service
	providers that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation,
	vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors
	will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service
	fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period.
	If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly.
	Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status
	and timing of services performed relative to the actual status and timing of services performed may vary and could result in us
	reporting amounts that are too high or too low in any particular period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Stock-Based
	Compensation
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	June 2015, we adopted a new equity incentive plan, or the 2015 Equity Incentive Plan, to replace our prior 2008 Stock Plan and
	2009 Stock Plan. Terms of our share-based compensation are governed by the 2015 Equity Incentive Plan, 2009 Stock Plan and 2008
	Stock Plan (collectively, the &ldquo;Plans&rdquo;). The Plans permit us to grant non-statutory stock options, incentive stock
	options and other equity awards to our employees, outside directors and consultants; however, incentive stock options may only
	be granted to our employees. Beginning June 29, 2015, no further awards may be granted under the 2009 Stock Plan or 2008 Stock
	Plan. As of December 31, 2015, the aggregate number of shares of common stock available for issuance under the 2015 Equity Incentive
	Plan was 172,448. However, to the extent awards under the 2008 Plan or 2009 Plan are forfeited or lapse unexercised or are settled
	in cash, the common stock subject to such awards will be available for future issuance under the 2015 Equity Incentive Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	exercise price for options issued under the Plans is determined by our board of directors, but will be (i) in the case of an incentive
	stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the
	fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value
	per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair market value
	per share on the date of grant. The options awarded under the Plans shall vest as determined by our board of directors but shall
	not exceed a ten-year period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 238PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Issued to Directors and Employees as Compensation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3.1PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the terms of the Plans, from inception to December 31, 2014, we issued options to purchase an aggregate of 1,996,712 shares
	to our executive officers and non-executive employees and to our non-employee directors for their services on the board of directors
	and its committees. Of these, 82,107 options were expired or exercised and 1,914,605 options were outstanding as of December 31,
	2014. The exercise prices of these option grants, as determined by our board of directors, range from $0.79 to $13.23 per share,
	and a portion of the shares underlying these options vest subject to certain performance conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3.05PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	2015, we granted an aggregate of 30,000 non-qualified 10-year term options to purchase our common stock to our board of directors
	and an aggregate of 41,957 options to purchase our common stock were automatically terminated due to certain performance conditions
	not being met. As of December 31, 2015, we had a total of 1,902,648 options issued to our executive officers, non-executive employees
	and non-employee directors outstanding. The exercise prices of the outstanding options, as determined by our board of directors,
	range from $0.79 to $13.23 per share, and a portion of these vest subject to certain performance conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3.05PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3.05PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	recognize stock-based compensation expense for these services within general and administrative expense in the accompanying statements
	of operations of approximately $2.9 million and $0.7 million for the years ended December 31, 2015 and 2014, respectively. As
	of December 31, 2015, there was approximately $2.1 million of total unrecognized compensation cost related to un-vested stock-based
	compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.5 years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3.05PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Issued to Nonemployees for Services Received
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have issued options to purchase an aggregate of 106,573 shares of our common stock since inception to 2014 to nonemployee consultants
	under the Plans. Of these, 68,662 options were expired or exercised and 37,911 options were outstanding as of December 31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	2015, we granted an aggregate of 4,000 non-qualified 10-year term options to purchase our common stock to our nonemployee contractors.
	During 2015, 6,025 options were expired or exercised and 35,886 options remain outstanding as of December 31, 2015. The exercise
	prices of the outstanding options, as determined by our board of directors, range from $0.72 to $2.25 per share. These outstanding
	options, with the exception of an option to purchase 7,272 shares granted to a consultant, vest 25% upon the first anniversary
	of the vesting commencement date with the remaining options vesting monthly in equal amounts over 36 months. We recognized an
	expense for these services of approximately $1,300 and $13,000 for the years ended December 31, 2015 and 2014 respectively, within
	research and development expense in the accompanying statements of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Valuation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	calculate the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing
	method. If we determine that other methods are more reasonable, or other methods for calculating these assumptions are prescribed
	by regulators, the fair value calculated for our stock options could change significantly. Higher volatility and longer expected
	lives would result in an increase to stock-based compensation expense to non-employees determined at the date of grant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock-based
	compensation expense to non-employee consultants affects our general and administrative expenses and research and development
	expenses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	The
	fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors
	incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as
	follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	Years ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 46%">
	Expected dividend yield
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 25%">
	0.00%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: CENTER">
	0.00%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected stock-price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	51.45% - 67.08%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	51.45% - 64.24%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	0.77% - 2.27%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	0.88% - 3.04%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Term of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	10
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5 - 10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Stock price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	$1.70 - $5.86
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	$1.14 - $5.86
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	dividend yield.
</I>
	The expected dividend is assumed to be zero as we have never paid dividends and have no current plans
	to pay any dividends on our common stock.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	stock-price volatility.
</I>
	As our common stock only recently became publicly traded, the expected volatility is derived from
	the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to
	our business over a period approximately equal to the expected term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Risk-free
	interest rate.
</I>
	The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero
	coupon U.S. Treasury notes with maturities approximately equal to the expected term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	term.
</I>
	The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical
	share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a
	lack of sufficient data. Therefore, we estimate the expected term by using the simplified method provided by the SEC. The
	simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to the assumptions used in the Black-Scholes option-pricing model, we also estimate a forfeiture rate to calculate the
	stock-based compensation for our equity awards. We will continue to use judgment in evaluating the expected volatility, expected
	terms and forfeiture rates utilized for our stock-based compensation calculations on a prospective basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Significant
	factors, assumptions and methodologies used in determining the estimated fair value of our common stock
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value
	calculations using the Black-Scholes option-pricing model. Our board of directors, with the assistance of management, determined
	the fair value of our common stock on each grant date. Option grants are based on the estimated fair value of our common stock
	on the date of grant, which is determined by taking into account several factors, including the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	prices at which we sold our convertible preferred stock and the rights, preferences, and privileges of the convertible preferred
	stock relative to those of our common stock, including the liquidation preferences of the convertible preferred stock;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	important
	developments in our operations;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	actual operating results and financial performance;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	conditions
	in our industry and the economy in general;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	stock
	price performance of comparable public companies;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	estimated likelihood of achieving a liquidity event, such as an initial public offering or an acquisition of the our company,
	given prevailing market conditions; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	illiquidity of the common stock underlying stock options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	table below presents the prices received from sales to third parties of our common stock and various classes of our preferred
	stock from inception to date:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Share Class
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Price per Share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 25%">
	2005
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Common
	Stock
<SUP>
	(a)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: RIGHT">
	1.79
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2006
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series A-2 Preferred
	Stock
<SUP>
	(a)(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2008&thinsp;&ndash;&thinsp;2009
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series A-3 Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2010&thinsp;&ndash;&thinsp;2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series B Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series C Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	After
	giving effect to our conversion from an limited liability company to a corporation.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Each
	share of preferred stock is convertible into shares of our common stock on a 7.15-for-1 basis, after giving effect to our
	reverse stock split, which was effected on June 17, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	options issued from inception to 2013, in determining the estimated fair value of our common stock, our board of directors, with
	the assistance of management, used the market approach to estimate the enterprise value of the Company in accordance with the
	American Institute of Certified Public Accountants (&ldquo;AICPA&rdquo;) Accounting and Valuation Guide, Valuation of Privately-Held
	Company Equity Securities Issued as Compensation (the &ldquo;AICPA Guide&rdquo;) for the three valuation dates of November 7,
	2013, July 31, 2012, and December 31, 2010. The Market Approach is one of the three approaches (along with the Income Approach
	and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using comparable companies
	in determining the value of the entity. Both public and private companies, if publicly available information exists, are considered
	in the market approach. Two information points commonly available&thinsp;&mdash;&thinsp;company valuation and transaction value&thinsp;&mdash;&thinsp;are
	used for their respective methodologies. There are a number of different methods within the Market Approach that may be used:
	the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline Transactions Method; and the Backsolve
	Method.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	our early stage of development, the Backsolve Method was used to estimate the fair value of our securities. This method derives
	an implied market value of invested capital from a transaction involving a company&rsquo;s own securities. The price of a company&rsquo;s
	security that was involved in a recent arms-length transaction is used as a reference point in an allocation of value. We first
	raised additional capital through our sale of limited liability company units (&ldquo;LLC units&rdquo;). These units later converted
	into common shares and preferred shares upon our conversion to a corporation. Subsequent to our corporation conversion, we raised
	additional capital through the sales of our Series A-1, Series A-2, Series A-3, Series B, and Series C preferred shares at the
	price of&thinsp; $0.07, $0.40, $0.62, $1.19, and $1.30, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	valued LLC units and common stock (after converting to a corporation) from inception through 2009 by reference to our sales of
	units and/or common stock and preferred stock over the period. Beginning in 2010, we valued the our common stock using the Backsolve
	Method. The Backsolve Method requires considering the rights and preferences of each class of equity and solving for the total
	market value of invested capital that is consistent with a recent transaction in our own securities, considering the rights and
	preferences of each class of equity. However, management has decided that the liquidation preferences between our preferred shares
	and common shares are immaterial for a pre-revenue company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Per
	the AICPA Guide, the Backsolve Method is generally the most reliable indicator of value of early-stage enterprises with no product
	revenue or cash flow, if relevant and reliable transactions have occurred in our equity securities. This methodology is also prescribed
	by the AICPA when a valuation is conducted in close proximity to the date of a financing transaction, and when other methodologies
	are deemed less reliable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	stage of development of RP-G28 was reflected in our selection of the term and volatility estimates used in the analysis. The estimate
	of the term considers our existing cash runway and the time to the next potential financing or liquidity event, while the volatility
	estimate reflects the relative riskiness of our equity securities (or asset base) relative to the general stock market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	estimated the implied market value of our invested capital by backsolving for the purchase price of our preferred shares for one
	common share through the option-pricing method. The premise of this method is that the transaction implied a market price for
	a share which in turn implied values for the other classes of equity based on relative claims on equity value, such as liquidation
	preferences and conversion rights. The application of the backsolve method considering our capital structure yielded a total market
	value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million, of which approximately $819,000, $870,000,
	and $670,000 were allocated to the total value of common stock as of our three valuation dates of November 7, 2013, July 31, 2012,
	and December 31, 2010, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	the three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, after estimating the market value of invested
	capital, we allocated it to the various equity classes comprising the subject company&rsquo;s capitalization table. This process
	ultimately results in creating a final estimate of value for the subject company&rsquo;s underlying equity interests. While there
	are many different value allocation methods, these various methods can be grouped into three general categories as defined by
	the AICPA Guide, one of which is the Option-Pricing Method (OPM).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	used the OPM to allocate market value of invested capital to the various equity classes and debt comprising our capitalization
	structure. We chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty related to market
	conditions, and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled as a call option
	with a distinct claim on our equity. The option&rsquo;s exercise price is based on our total equity value available for each participating
	equity holder. The characteristics of each equity class determine the equity class&rsquo; claim on the total equity value. By
	constructing a series of options in which the exercise price is set at incremental levels of value, which correspond to the equity
	value necessary for each level of equity to participate, we determined the incremental option value of each series. When multiplied
	by the percentage of ownership of each equity class participating under that series, the result is the incremental value allocated
	to each class under that series.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	OPM relies on the Black-Scholes option-pricing model to value the call options on our invested capital. The following inputs were
	applied in the Black-Scholes calculations of the OPM:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="10" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	Valuation Dates
</B>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	November 7, 2013
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	July 31, 2012
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<B>
	December 31, 2010
</B>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: LEFT">
	Risk-free rate
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	0.55
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	0.57
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	2.01
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Maturity (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Discounts
	ranging from 35.8% to 40% were applied for lack of control and lack of marketability for the common stock. The calculation resulted
	in a fair value for the common stock of&thinsp;$1.17, $1.19, and $1.03 per share as of our three valuation dates of November 7,
	2013, July 31, 2012, and December 31, 2010, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	options issued in 2014, given our distinct possible exit scenarios of an initial public offering, we used the probability weighted
	expected return method (PWERM) to estimate the fair value of our common equity. Under this method, an analysis of future values
	of a company is performed for several likely liquidity scenarios. The value of the common stock is determined for each scenario
	at the time of each future liquidity event and discounted back to the present using a risk-adjusted discount rate. The present
	values of the common stock under each scenario are then weighted based on the probability of each scenario occurring to determine
	the value for the common stock. Our management determined the probability weighting of potential liquidity events to be 45% for
	an initial public offering and 55% for other scenarios, which represents all other likely outcomes for us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	estimated the implied market value of our invested capital by backsolving for the purchase price of our preferred shares for one
	common share through the use of OPM. The application of the backsolve method considering the our capital structure yielded a total
	market value of invested capital of approximately $25.2 million, of which approximately $1.4 million was allocated to the total
	value of common stock as of our valuation date of October 31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	the lack of marketability for the common stock, we applied a discount of 21.4% for using the average strike put option approach.
	This resulted in a probability weighted common share value, after adjustment, of&thinsp;$5.86 per share as of valuation date of
	October 31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Stock-based
	Compensation Summary Tables
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Information
	regarding our stock option grants to employees and non-employees, along with the estimated fair value per share of the underlying
	common stock, for stock options granted since 2005 is summarized as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Grant Date
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Number of Common
<BR>
	Shares Underlying
<BR>
	Options Granted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Exercise Price per
<BR>
	Common Share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Estimated Fair Value
<BR>
	per Share of Common
<BR>
	Stock
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Intrinsic
	Value
</B>
</FONT>
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Per
	Option
</B>
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: LEFT">
	2005
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	58,321
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	0.07
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	1.79
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	1.72
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2009
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,559
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.72
	- $0.79
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.71
	- $3.64
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2011
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,846
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.03
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2012
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,019
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.14
	- $1.30
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,626,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.86
	- $13.23
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.86
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following represents a summary of the options granted to employees and non-employees outstanding at December 31, 2015 and changes
	during the period then ended:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Weighted Average
<BR>
	Exercise Price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%">
	Outstanding at December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	1,952,516
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	7.022
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Exercised/Expired/Forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(47,982
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(1.246
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Outstanding at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,938,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	7.081
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Exercisable at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	697,832
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5.285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Expected to be vested
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,240,702
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	8.091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Jumpstart
	Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can
	take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the
	Securities Act), for complying with new or revised accounting standards. In other words, an &ldquo;emerging growth company&rdquo;
	can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have
	elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of
	the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective
	dates for public and private companies until those standards apply to private companies. As a result of this election, our financial
	statements may not be comparable to companies that comply with public company effective dates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the
	JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an &ldquo;emerging growth company,&rdquo; we intend to rely
	on certain of these exemptions, including without limitation, (i) providing an auditor&rsquo;s attestation report on our system
	of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any
	requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report
	providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We
	will remain an emerging growth company until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary
	of the date we completed our initial public offering, which was June 29, 2015, (b) in which we have total annual gross revenue
	of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common
	stock that is held by non-affiliates exceeded $700.0 million as of the prior June 30th, and (ii) the date on which we have issued
	more than $1.0 billion in non-convertible debt during the prior three-year period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Results
	of Operations
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Comparison
	of the years ended December 31, 2015 and 2014
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following table summarizes the results of our operations for the years ended December 31, 2015 and 2014, together with the changes
	in those items in dollars and as a percentage:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	For the Years Ended
<BR>
	December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	Dollar
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	Percentage
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	Change
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	Change
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Statement of Operations Data:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Operating costs and expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 36%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,260,297
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	113,931
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,146,366
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	1,884
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Patent costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	243,463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	197,731
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,732
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	6,404,643
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,969,960
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	4,434,683
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	225
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 20PT">
	Total operating costs and expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	8,908,403
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,281,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	6,626,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	290
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Loss from operations
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(8,908,403
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(2,281,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(6,626,781
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	290
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest income (expense), net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,876
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(212,991
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	253,867
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	119
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Other income
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	79,756
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	21,148
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	58,608
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	277
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 20PT">
	Total other income (expense)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	120,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(191,843
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	312,475
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	163
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,787,771
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(2,473,465
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,314,306
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	255
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Research
	and Development Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research
	and development expenses were approximately $2.3 million and $114,000 for the years ended December 31, 2015 and 2014, respectively.
	The increase in research and development expenses of approximately $2.1 million, or 1,884%, was primarily attributable to $1.2
	million of manufacturing ramp-up costs to prepare product for clinical trials and the remaining $0.9 million due to fees paid
	to consultants and clinical research organizations in preparation and support for clinical trials.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Patent
	Costs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Patent
	costs were approximately in $243,000 and $198,000 for the years ended December 31, 2015 and 2014, respectively, representing an
	increase of approximately $45,000, or 23%. This increase was primarily due to our transition to a new service provider and increased
	activity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	General
	and Administrative Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	General
	and administrative expenses were approximately $6.4 million and $2.0 million for the years ended December 31, 2015 and 2014, respectively.
	The increase in general and administrative expenses during this period was $4.4 million, or 225%. This increase in general and
	administrative expenses was primarily due to the increase in stock-based compensation that totaled $2.9 million related to the
	options granted to our executives and non-executive employees, most which were granted on December 2, 2014. There was also an
	increase in headcount and in salary for our officers in 2015, expenses related to the closing of our initial public offering,
	and the increase in costs of being a public company that contributed to the overall increase during the 2015 year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Other
	Income
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	increase in net interest income was approximately $254,000, or 119%. Net interest income for the year ended December 31, 2015
	was approximately $41,000, which was primarily a result of increased cash resulting from the net proceeds of our initial public
	offering. Net interest expense for the year ended December 31, 2014 was approximately $213,000, which primarily represented interest
	costs associated with outstanding promissory notes that were converted into Series C preferred stock in December 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other
	income was approximately $80,000 and $21,000 for the years ended December 31, 2015 and 2014, respectively. The increase in other
	income was approximately $59,000, or 277%, and was the result of a settlement of accounts payable.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Liquidity
	and Capital Resources
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Sources
	of Liquidity
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Since
	our inception, we have incurred net losses and negative cash flows from operations, and, as of December 31, 2015, we had an accumulated
	deficit of approximately $27.1 million. Substantially all our net losses resulted from costs incurred in connection with our research
	and development programs, stock-based compensation, and from general and administrative costs associated with our operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	At
	December 31, 2015, after consummation of our initial public offering, we had working capital of $14.7 million, and cash of $15.8
	million. We have not generated any product revenues and have not achieved profitable operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Aspire
	Capital Financing Arrangement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 18, 2015, we entered into the Aspire Purchase Agreement with Aspire Capital, which provides that, upon the terms and
	subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0
	million of our shares of common stock over the approximately 30-month term of the Aspire Purchase Agreement. Upon execution of
	the Aspire Purchase Agreement, we sold 500,000 shares of common stock to Aspire Capital at $2.00 per share for proceeds of $1.0
	million. We may sell an additional 888,835 shares of common stock to Aspire Capital in the future pursuant to the terms of the
	Aspire Purchase Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	February 24, 2016, the conditions necessary for us to sell an additional 888,835 shares of our common stock to Aspire under the
	Aspire Purchase Agreement were satisfied. On any trading day on which the closing sale price of our common stock exceeds $0.50,
	we have the right, in our sole discretion, to present Aspire Capital with a purchase notice (each a &ldquo;Purchase Notice&rdquo;),
	directing Aspire Capital (as principal) to purchase up to 100,000 shares of our common stock per trading day, for up to $9.0 million
	of our common stock in the aggregate at a per share price (the &ldquo;Purchase Price&rdquo;), calculated by reference to the prevailing
	market price of our common stock (as provided in the Aspire Purchase Agreement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, on any date on which we submit a Purchase Notice for 100,000 shares to Aspire Capital and the closing sale price of
	our stock is equal to or greater than $0.50 per share of common stock, we also have the right, in our sole discretion, to present
	Aspire Capital with a volume-weighted average price purchase notice (each a &ldquo;VWAP Purchase Notice&rdquo;), directing Aspire
	Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on the Nasdaq Capital
	Market on the next trading day (the &ldquo;VWAP Purchase Date&rdquo;), subject to a maximum number of shares we may determine
	(the &ldquo;VWAP Purchase Share Volume Maximum&rdquo;), and a minimum trading price (the &ldquo;VWAP Minimum Price Threshold&rdquo;)
	(as more specifically described below). The purchase price per share pursuant to such VWAP Purchase Notice (the &ldquo;VWAP Purchase
	Price&rdquo;) is calculated by reference to the prevailing market price of our common stock (as provided in the Aspire Purchase
	Agreement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Aspire Purchase Agreement provides that we and Aspire Capital will not effect any sales under the Aspire Purchase Agreement on
	any purchase date where the closing sale price of our common stock is less than $0.50 per share (the &ldquo;Floor Price&rdquo;).
	This Floor Price and the respective prices and share numbers in the preceding paragraphs will be appropriately adjusted for any
	reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. There are
	no trading volume requirements or restrictions under the Aspire Purchase Agreement, and we will control the timing and amount
	of any sales of our common stock to Aspire Capital. Aspire Capital has no right to require any sales by us, but is obligated to
	make purchases from us as we direct in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial
	or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated
	damages in the Aspire Purchase Agreement. Aspire Capital may not assign its rights or obligations under the Purchase Agreement.
	The Purchase Agreement may be terminated by us at any time, at our discretion, without any penalty or cost to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	expect to use the Aspire facility to complement, rather than replace, other financing that may be required during the next twelve
	months to continue our operations and support our capital needs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Cash
	Flows
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following table sets forth the significant sources and uses of cash for the periods set forth below:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	For the Year Ended
<BR>
	December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net cash (used in) provided by:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Operating activities
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(5,721,565
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; TEXT-ALIGN: RIGHT">
	(1,157,385
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16,999
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	18,810,882
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	3,457,573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net increase in cash
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	13,072,318
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	2,299,022
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Operating
	Activities
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash used in operating activities of approximately $5.7 million during the year ended December 31, 2015 was primarily a result
	of our net loss of approximately $8.8 million, offset by stock-based compensation of approximately $2.9 million, $416,000 for
	the issuance of common stock to a supplier, an increase in prepaid and other assets of approximately $132,000, a decrease in accounts
	payable of approximately $344,000, and an increase in accrued expenses of approximately $232,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash used in operating activities of approximately $1.2 million during the year ended December 31, 2014 was primarily a result
	of our net loss of approximately $2.5 million offset by stock-based compensation of approximately $707,000 and a non-cash charge
	of approximately $184,000 to interest expense related to the conversion of convertible promissory notes and an increase of approximately
	$249,000 in accounts payable and an increase in accrued expenses of approximately $160,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Investing
	Activities
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash used in investing activities of approximately $17,000 during the year ended December 31, 2015 was the result of our purchasing
	office furniture and equipment for our new office and computer equipment purchases for new employees.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash used in investing activities of approximately $1,000 during the year ended December 31, 2014 primarily reflected our use
	of cash to purchase equipment, offset partially by our proceeds from the disposal of property and equipment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Financing
	Activities
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash provided by financing activities of approximately $18.8 million during the year ended December 31, 2015 mainly resulted from
	net proceeds received upon closing of our initial public offering, selling 4,000,000 shares of our common stock for gross proceeds
	of $20.0 million, offset partially by underwriting discounts, commissions and issuance costs of approximately $2.6 million, for
	net proceed of approximately $17.4 million. Additionally, proceeds of $1.0 million were received in connection with the sale of
	shares of our common stock to Aspire Capital pursuant to the Aspire Purchase Agreement entered into in December 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net
	cash provided by financing activities of approximately $3.5 million in the year ended December 31, 2014 mainly resulted from approximately
	$3.0 million in net proceeds received on sales of preferred stock subject to redemption and warrants to purchase common stock
	and approximately $605,000 in net proceeds from the sale of convertible notes offset partially by deferred offering costs of approximately
	$143,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Future
	Funding Requirements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	To
	date, we have not generated any revenue. We do not know when, or if, we will generate any revenue from product sales. We do not
	expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize
	RP-G28 or any of our other product candidates. At the same time, we expect our expenses to increase in connection with our ongoing
	development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval
	for, our product candidates. Additionally, we have incurred and will continue to incur additional costs associated with operating
	as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur
	significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will
	need substantial additional funding in connection with our continuing operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Based
	upon our current operating plan, we believe that our existing cash and cash equivalents, together with interest and any proceeds
	received from our sale of shares of common stock to Aspire Capital in the future pursuant to the Aspire Purchase Agreement, will
	enable us to fund our operating expenses and capital expenditure requirements through the first quarter of 2017. We intend to
	devote our existing financial resources to fund the continued clinical development of RP-G28 for the reduction of symptoms associated
	with lactose intolerance, including our anticipated Phase 2b/3 trials; to fund expenses associated with the manufacture and product
	development of RP-G28; to explore potential orphan indications; and for general corporate purposes, general and administrative
	expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	future capital requirements will depend on many factors, including:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	progress, costs, results of and timing of implementing a Phase 2b/3 clinical trials for the reduction of symptoms associated
	with lactose intolerance in patients;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	willingness of the EMA or other regulatory agencies outside the United States to accept our Phase 2b/3 and any Phase 3 trials
	of RP-G28, as well as our other completed and planned clinical and nonclinical studies and other work, as the basis for review
	and approval of RP-G28 in the European Union for the reduction of symptoms associated with lactose intolerance in patients;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	outcome, costs and timing of seeking and obtaining FDA, EMA and any other regulatory approvals;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	ability of our product candidates to progress through clinical development successfully;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	need to expand our research and development activities;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	costs associated with securing and establishing commercialization and manufacturing capabilities;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	market
	acceptance of our product candidates;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of
	any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense
	and enforcement of any patents or other intellectual property rights;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	need and ability to hire additional management and scientific and medical personnel;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	effect of competing technological and market developments;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	our
	need to implement additional internal systems and infrastructure, including financial and reporting systems;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or
	other arrangements into which we may enter in the future; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	costs of operating as a public company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Until
	such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination
	of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements
	and other collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through
	the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the
	terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders.
	Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific
	actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through
	government or other third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic
	alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
	revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Contractual
	Obligations and Commitments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Master
	Services Agreement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 30, 2015, we entered into a Master Service Agreement with Covance, Inc. (&ldquo;Covance&rdquo;), with an effective date
	of December 29, 2015. Pursuant to the terms of the Master Service Agreement, Covance (or one or more of its affiliates) will provide
	Phase 1, 2, 3, and 4 clinical services for a clinical study or studies to us, and, at our request, assist us with the design of
	such studies, in accordance with the terms of separate individual project agreements to be entered into by the parties. The term
	of the agreement is for three years and will renew automatically for successive one year periods unless Covance is no longer providing
	services under the agreement or either party has terminated the agreement upon written notice. We may terminate the Master Service
	Agreement or any individual project agreement entered into under the Master Service Agreement prior to the applicable study&rsquo;s
	completion at any time for any reason upon 30 days written notice to Covance, except when the reason for termination is the safety
	of subjects, in which case it may be terminated immediately. Covance may not terminate any individual project agreement without
	cause, except when the reason for the termination is the safety of subjects, in which case it may be terminated immediately. In
	the event of a termination of the Master Service Agreement, Covance will be entitled to full payment for (i) work performed on
	the applicable project upon through the date work on such project is concluded and (ii) reimbursement for all non-cancellable
	and non-refundable expenses and financial obligations which Covance (or an affiliate) has incurred or undertaken on our behalf.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Clinical
	Supply and Cooperation Agreement with Ricerche Sperimentali Montale (&ldquo;Ricerche&rdquo;) and Inalco SpA (&ldquo;Inalco&rdquo;)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Effective
	July 24, 2015, we entered into an amended Clinical Supply and Cooperation Agreement (the &ldquo;Amended Supply Agreement&rdquo;)
	with Ricerche and Inalco (collectively, &ldquo;RSM&rdquo;). The Amended Supply Agreement amends certain terms of the Clinical
	Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010 (the &ldquo;Existing Supply Agreement&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	the Existing Supply Agreement, RSM granted us an exclusive worldwide option in a specified field and territory to assignment of
	all right, title and interest to a purified Galacto-oligosaccharides product (&ldquo;Improved GOS&rdquo;), the composition of
	matter of the Improved GOS and any information relating to the Improved GOS, including certain specified technical information
	and other intellectual property rights (the &ldquo;Improved GOS IP&rdquo;). Pursuant to the amended terms, we could exercise the
	option by paying RSM $800,000 within ten days after the effective date of the Amended Supply Agreement. We exercised this option
	on July 30, 2015 and RSM transferred the Improved GOS IP to us. Under the terms of the Existing Supply Agreement, if a further
	option payment of $1 million due in the future is not made, we may be required to return the Improved GOS IP to RSM.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Amended Supply Agreement also provides that we must pay RSM $400,000 within 10 days following FDA approval of a new drug application
	for the first product owned or controlled by us using Improved GOS as its active pharmaceutical ingredient. In addition, we agreed
	to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo
	as under the Existing Supply Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	consideration for RSM entering into the Amended Supply Agreement, we issued 100,000 shares of our common stock, par value $0.001
	per share (the &ldquo;RSM Shares&rdquo;), to RSM on November 30, 2015. Fair value of these shares totaling $416,000 was recognized
	in stockholders&rsquo; equity in the balance sheet as of December 31, 2015. The stock purchase agreement includes a lock-up agreement
	by RSM in our favor pursuant to which RSM will not be able to sell the RSM Shares for a period ending on the earlier of (i) the
	public release by us of the final results of our Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of our Form 10-Q with
	the Securities and Exchange Commission for the fiscal quarter in which we receives the results of our Phase 2b/3 clinical trial
	of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Lease
	Agreement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	lease office space for our headquarters in California. Until September 30, 2015, we leased office and storage space pursuant to
	a two-year agreement which called for a minimum monthly rent of approximately $5,000 and an annual increase of 3%.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	July 9, 2015, we entered into a lease with Century Park, a California limited partnership, pursuant to which we are leasing approximately
	2,780 square feet of office space in Los Angeles, California for our headquarters. The lease provides for a term of sixty-one
	(61) months, commencing on October 1, 2015. We paid no rent for the first month of the term and will pay base rent of $9,174 per
	month for months 2 through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of
	the lease to a maximum of $10,325 per month for months 50 through 61. The base rent payments do not include our proportionate
	share of any operating expenses, including real estate taxes. We have the option to extend the term of the lease for one five-year
	term, provided that the rent would be subject to market adjustment at the beginning of the renewal term. We will recognize rent
	expense on a straight-line basis over the lease term.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Rent
	expense, recognized on a straight-line basis, was approximately $74,000 and $60,000 for the years ended December 31, 2015 and
	2014, respectively, and is recorded in general and administrative expenses in the accompanying statement of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Employment
	Agreements
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Michael
	D. Step
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 2, 2014, Michael D. Step accepted an offer letter from us setting forth the terms of his employment as Chief Executive
	Officer. The offer letter provides that Mr. Step is entitled to an annual base salary of $360,000 and a total of three grants
	of options to purchase our common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	first two options entitle Mr. Step to purchase 646,537 and 73,377 of our shares, respectively, for an exercise price of&thinsp;$5.86
	per share. Each of these options was immediately exercisable in full as of the date of the grant, with 44/48
<SUP>
	ths
</SUP>
	of
	the total number of shares covered by each option subject to a right of repurchase by us upon termination of Mr. Step&rsquo;s
	employment with us for any reason. This right of repurchase lapses over a period of 44 months, with 1/44
<SUP>
	th
</SUP>
	of the total
	number of shares subject to the right of repurchase lapsing on January 1, 2015 and on the first day of each month thereafter.
	In addition, the right of repurchase will lapse in its entirety upon a termination of the employment under certain circumstances.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	third option became exercisable upon the closing of our initial public offering on June 29, 2015. The option is for a total of
	163,799 shares of our common stock, which, together with the shares subject to the first option, represent 7.5% of the shares
	of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis, after giving effect to the number of shares
	subject to the third option. Seventy-five percent of the shares subject to the third option are subject to a right of repurchase
	by us upon termination of Mr. Step&rsquo;s employment for any reason. This right of repurchase lapses with respect to 1/36
<SUP>
	th
</SUP>
	of the total number of shares subject to the right of repurchase on the first day of each month following the date on which
	the third option becomes exercisable. In addition, the right of repurchase will lapse in its entirety upon Mr. Step&rsquo;s termination
	of employment under certain circumstances.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additionally,
	under the terms of his Executive Severance and Change in Control Agreement, also effective on December 2, 2014, Mr. Step is entitled
	to receive certain payments in the event his employment is terminated under certain scenarios.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Andrew
	Ritter and Ira Ritter
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	September 25, 2013, our board of directors approved the Executive Compensation Plan (the &ldquo;Compensation Plan&rdquo;) setting
	forth certain compensation to be paid to Andrew Ritter, our current President and former Chief Executive Officer, and Ira Ritter,
	our current Chief Strategic Officer (&ldquo;CSO&rdquo;), for their respective contributions to our company. Effective June 29,
	2015, in connection with our initial public offering, Andrew Ritter and Ira Ritter accepted offer letters from us setting forth
	the terms of their employment as President and CSO, respectively, of the Company. The offer letters superseded the Compensation
	Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Their
	respective offer letters provide that that Andrew Ritter is entitled to an annual base salary of $310,000 and Ira Ritter is entitled
	to an annual base salary of $295,000. In accordance with his offer letter, Andrew Ritter also became entitled to receive up to
	$180,000 payable over a three year period for tuition reimbursement. As of December 31, 2015, we paid an aggregate of $105,000
	and have an accrual of $75,000 in tuition reimbursement for Andrew Ritter and recognized such amount in general and administrative
	expenses in the accompanying statements of operations for the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additionally,
	under the terms of their Executive Severance and Change in Control Agreements, also effective on June 29, 2015, each of Andrew
	Ritter and Ira Ritter is entitled to receive certain payments in the event their employment is terminated under certain scenarios.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to their respective offer letters, Andrew Ritter and Ira Ritter each have the opportunity to earn an annual bonus based upon a
	percentage of their base salary and the achievement of specific performance as determined by the Company. The initial target bonus
	opportunities are 40% and 35% of the base salary for Andrew Ritter and Ira Ritter, respectively. The board of directors determined
	that the specific performance requirements were met for fiscal year 2015 and accordingly, Andrew Ritter received 40% of his base
	salary, or $124,000 and Ira Ritter received 35% of his base salary, or $103,250. These bonus payments are recognized in general
	and administrative expense in the accompanying statements of operations for the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the Compensation Plan, as in effect prior to entering into their offer letters, Andrew Ritter and Ira Ritter had bonus opportunities
	to, upon the satisfaction of the events described below, each potentially receive the following cash payments and each potentially
	receive the following options to purchase up to 48,951 shares of our common stock (the &ldquo;Executive Options&rdquo;) pursuant
	to the 2008 Stock Plan:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	FDA
	Meeting Bonus Opportunities
</I>
	. Each executive was entitled to receive, and in April 2013 each executive received, a one-time
	cash bonus of $10,000 for a milestone associated with meeting with the FDA regarding RP-G28&rsquo;s path to FDA approval.
	In addition, upon satisfaction of this milestone, the executives became entitled to 3,496 of the Executive Options. 2,360
	shares of the Executive Options vested and became exercisable as of the grant date of September 25, 2013, with the balance
	of the 1,136 shares vesting ratably in 36 equal monthly installment beginning on September 30, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Clinical
	Trial Funding Commitment Bonus Opportunities
</I>
	. Each executive was entitled to receive a one-time cash bonus of $75,000
	upon our receipt of a commitment by a third party to fund a Phase 2 or later clinical trial; provided, however, that no such
	bonus would be paid at any time we had less than $2,000,000 in available cash. In addition, upon the satisfaction of this
	milestone, 35% of 10,489 shares of the Executive Options would vest and become exercisable, with the balance of the 10,489
	shares vesting in 36 equal monthly installments beginning on the last day of the following month. The board of directors determined
	that this milestone was satisfied; accordingly, each executive received a bonus of $75,000 which has been recognized in general
	and administrative expenses in the accompanying statements of operations for the year ended December 31, 2015. In addition,
	3,671 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 6,818 shares
	vesting ratably on a monthly basis beginning July 31, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Fundraising
	Bonus Opportunities
</I>
	. Each executive was entitled to receive (i) a one-time cash bonus of $50,000 upon the sale of additional
	equity capital for cash, in one or more closings after July 17, 2012, and/or the actual deployment of funds by a third party
	for a clinical trial in an aggregate amount in excess of $2,000,000 and (ii) a one-time cash bonus of $150,000 upon the sale
	of additional equity capital for cash, in one or more closings after July 17, 2012 and/or the actual deployment of funds by
	a third party for a clinical trial in an aggregate amount in excess of $10,000,000 (which such bonus would be reduced by any
	cash bonus paid under subsection (i)); provided, however, that no bonus under subsection (i) or (ii) would be paid at any
	time we had less than $2,000,000 in available cash. In addition, upon the satisfaction of the milestone described in subsection
	(i), 35% of 6,993 shares of the Executive Options would vest and become exercisable, with the balance of the 6,993 shares
	vesting in 36 equal monthly installments beginning on the last day of the following month, and, upon satisfaction of the milestone
	described in subsection (ii), 35% of 13,986 shares of the Executive Options would vest and become exercisable, with the balance
	of the 13,986 shares vesting in 36 monthly installments beginning on the last day of the following month. The board of directors
	determined that this milestone as described in subsection (ii) above was satisfied upon the closing of our initial public
	offering on June 29, 2015 raising approximately $17.4 million, net of offering costs; accordingly, each executive received
	a bonus of $150,000 which has been recognized in general and administrative expenses in the accompanying statements of operations
	for the year ended December 31, 2015. In addition, 4,895 shares of the Executive Options vested and became exercisable as
	of June 29, 2015, with the balance of 9,091 shares vesting ratably on a monthly basis beginning July 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	License
	Event Bonus Opportunities
</I>
	. Each executive was entitled to receive the following bonus payments in connection with the
	closing of an exclusive license of RP-G28 and/or any future product candidate developed by the Company from time to time during
	the term of the Compensation Plan by and/or any option to exclusively license such product candidate to a third party (referred
	to under the Compensation Plan as a &ldquo;License Event&rdquo;) with a minimum upfront payment to the Company of $2,000,000:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.5IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#111;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined in the Compensation Plan) up to $5,000,000;
	(ii) 4% of the Initial Period License Payment in excess of $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period
	License Payment in excess of $10,000,000. In addition, upon our receipt of an Initial Period License Payment of more than
	$2,000,000, 35% of 45,454 shares of their Executive Options will vest and become exercisable, with the balance of the 45,454
	shares vesting in 36 monthly installments beginning on the last day of the following month.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#111;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined in the Compensation Plan); provided, however that
	no such bonus may be paid at any time the Company has less than $1,000,000 in available cash. In addition, upon our receipt
	of an Annual Excess Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become exercisable, with
	the balance of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the following month.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015, 27,972 of the maximum 48,951 Executive Options potentially issuable to each executive had been issued to
	each executive subject to the vesting conditions described above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Off-Balance
	Sheet Arrangements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC
	rules.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Recent
	Accounting Pronouncements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	November 20, 2015, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
	No. 2015-17,
<I>
	Balance Sheet Classification of Deferred Taxes.
</I>
	ASU 2015-17 simplifies the presentation of deferred income
	taxes and requires that deferred tax assets and liabilities, as well as any related valuation allowance, be classified as noncurrent
	in a classified statement of financial position. The adoption of ASU 2015-17 is not expected to impact our financial statements
	as we have no net deferred income taxes presented on its balance sheets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	August 2014, the FASB issued ASU No. 2014-15,
<I>
	Presentation of Financial Statements &mdash; Going Concern (Subtopic 205-40)
	&mdash; Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
</I>
	, which provides guidance
	regarding management&rsquo;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a
	going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and
	interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that
	raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements
	are issued (or within one year after the date that the financial statements are available to be issued when applicable). This
	ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.
	Management is currently evaluating the new guidance and has not determined the impact this standard may have on our financial
	statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Other
	accounting standards updates effective after December 31, 2015, are not expected to have a material effect on our financial position,
	annual results of operations and/or cash flows.
</FONT>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_012">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	7A. Quantitative and Qualitative Disclosures about Market Risk
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Not
	applicable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET_RISK>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_013">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	8. Financial Statements and Supplementary Data.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	INDEX
	TO FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.1IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.5IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_014">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Report
	of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	F-1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	Statements:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_015">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Balance
	Sheets as of December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	F-2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_016">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Statements
	of Operations for the years ended December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_017">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Statements
	of Changes in Securities Subject to Redemption and Stockholders&rsquo; Equity (Deficit) for the years ended December 31, 2015
	and 2014
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	F-4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_018">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Statements
	of Cash Flows for the years ended December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#FORM10-K_HTM_A_019">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Notes
	to Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-6
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_014">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	REPORT
	OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	To the Board of Directors and Stockholders
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 261PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 261PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 261PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have audited the accompanying balance sheets of Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2015
	and 2014, and the related statements of operations, statements of changes in securities subject to redemption and stockholders&rsquo;
	equity (deficit), and cash flows for each of the years in the two year period ended December 31, 2015, and the related notes to
	the financial statements. These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility
	is to express an opinion on these financial statements based on our audits.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
	standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are
	free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
	over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing
	audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness
	of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining,
	on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing
	the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
	presentation. We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Ritter
	Pharmaceuticals, Inc. as of December 31, 2015 and 2014, and results of its operations and its cash flows for each of the years
	in the two year period ended December 31, 2015, in conformity with accounting principles generally accepted in the United States
	of America.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
	in Note 2 to the financial statements, the Company has incurred recurring operating losses and is dependent on additional financing
	to fund operations. These conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
	Management&rsquo;s plans in regard to these matters are described in Note 2 to the financial statements. The financial statements
	do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the
	amounts and classification of liabilities that may result from the outcome of this uncertainty.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 3PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Mayer Hoffman McCann P.C.
</I>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Orange
	County, California
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	March 21, 2016
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_015">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	BALANCE
	SHEETS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	15,819,566
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,747,248
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	189,136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	57,115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,008,702
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,804,363
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,326
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred offering costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	143,454
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Property and equipment, net
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	20,688
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Total Assets
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	16,039,716
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,963,320
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	739,357
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,083,597
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	614,141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	168,635
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,223
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,518
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,354,721
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,254,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Preferred stock subject to redemption, $0.001 par value; 0 shares authorized, issued and outstanding as of December 31,
	2015; 16,378,646 shares authorized, 13,399,668 shares issued and outstanding as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,203,612
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Stockholders&rsquo; equity (deficit)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Preferred stock, $0.001 par value; 5,000,000 and 8,887,500 shares authorized as of December 31, 2015 and December 31,
	2014, respectively; 0 shares and 8,887,500 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,888
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Common stock, $0.001 par value; 25,000,000 and 50,000,000 shares authorized as of December 31, 2015 and December 31, 2014,
	respectively; 8,582,004 and 465,384 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,582
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	465
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,759,355
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,399,924
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Accumulated deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(27,082,942
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(17,904,319
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Total stockholders&rsquo; equity (deficit)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	14,684,995
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(14,495,042
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Total Liabilities and Stockholders&rsquo;
	Equity (Deficit)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	16,039,716
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,963,320
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_016">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	STATEMENTS
	OF OPERATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Years Ended December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Operating costs and expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,260,297
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	113,931
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Patent costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	243,463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	197,731
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	6,404,643
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,969,960
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total operating costs and expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,908,403
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,281,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,908,403
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,281,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Other income (expense)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,876
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(213,516
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Other income
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	79,756
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	21,148
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Other income (expense), net
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	120,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(191,843
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(8,787,771
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(2,473,465
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cumulative preferred stock dividends
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(327,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(589,462
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Accretion of discount of Series C preferred stock
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(63,283
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(8,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 2.5PT">
	Net loss attributable to common stockholders
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(9,178,623
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(3,071,507
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss attributable to common stockholders per share, basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(3.11
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	(6.79
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Weighted average shares outstanding, basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	2,946,792
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	452,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_017">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	STATEMENTS
	OF CHANGES IN SECURITIES SUBJECT TO REDEMPTION AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Preferred
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="22" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Stockholders&rsquo;
	Equity (Deficit)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Stock
	Subject to Redemption
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Preferred
	Stock
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Common
	Stock
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Additional
	Paid-in
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Accumulated
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Total
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Stockholders&rsquo;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Shares
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Capital
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Deficit
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	Equity&nbsp;Deficit)
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 20%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Balance
	at December 31, 2013
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	10,408,652
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	12,413,876
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,887,500
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,888
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	451,398
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	451
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,059,347
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(14,832,812
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(12,764,126
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Conversion
	of notes payable into preferred stock subject to redemption and warrants to purchase common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	621,788
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	660,635
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	136,733
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	136,733
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Issuance
	of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,369,228
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,531,059
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	482,068
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	482,068
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Exercise
	of options on common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	13,986
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	14
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	14,386
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	14,400
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Stock-based
	compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	707,390
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	707,390
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Cumulative
	dividends on Series B preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	589,462
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(589,462
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(589,462
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Accretion
	of discount on Series C preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,580
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,580
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,580
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Net
	loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(2,473,465
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(2,473,465
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Balance
	at December 31, 2014
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	13,399,668
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	16,203,612
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,887,500
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,888
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	465,384
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	465
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	3,399,924
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(17,904,319
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(14,495,042
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Exercise
	of prepaid forward sale of Series B preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	1,469,994
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Cumulative
	dividends on Series B preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	327,569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(327,569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(327,569
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Accretion
	of discount on Series C preferred stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	63,283
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(63,283
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(63,283
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Conversion
	of all outstanding preferred stock to common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,887,500
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,888
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	1,243,002
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	1,243
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	7,645
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Conversion
	of all outstanding preferred stock subject to redemption to common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(14,869,662
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(16,594,464
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,079,650
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,080
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	16,592,384
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	16,594,464
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Common
	stock subject to repurchase
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(180
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(180
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Issuance
	of common stock upon closing of initial public offering
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	4,000,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	4,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	19,996,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	20,000,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Commissions
	and offering costs of initial public offering
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(2,551,390
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(2,551,390
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Issuance
	of common stock upon closing of common stock purchase agreement
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	500,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	500
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	999,500
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	1,000,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Issuance
	of common stock for commitment fee
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	188,864
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	189
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(189
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Issuance
	of common stock to supplier
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	100,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	100
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	415,900
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	416,000
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Exercise
	of options on common stock
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	5,104
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	5
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	5,252
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	5,257
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Stock-based
	compensation
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,894,509
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	2,894,509
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Net
	loss
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,787,771
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(8,787,771
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	Balance
	at December 31, 2015
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,582,004
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	8,582
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	41,759,355
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	(27,082,942
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	)
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	14,684,995
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_018">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	STATEMENTS
	OF CASH FLOWS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Years Ended December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from operating activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(8,787,771
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	(2,473,465
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
	Depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,939
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,479
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,894,509
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	707,390
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Gain on disposal of equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(456
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Issuance of shares of common stock to supplier
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	416,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accretion of debt discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,192
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Non-cash interest on conversion of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	184,445
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Changes in fair value of put embedded in convertible debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,148
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(132,021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Other assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,028
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(344,240
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	249,101
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	231,950
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	160,071
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; PADDING-BOTTOM: 1.5PT">
	Other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(1,475
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(1,999
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(5,721,565
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,157,385
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from investing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Purchases of property and equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(16,999
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(1,166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(16,999
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,166
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Cash flows from financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Commissions and issuance costs of initial public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,194,375
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds from issuance of shares upon closing of initial public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds from the issuance of shares from common stock purchase agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds from exercise of options on common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,257
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,400
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred offering costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(143,454
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds of borrowing under notes payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	605,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Repayment of borrowing under note payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(31,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Net proceeds from issuance of preferred stock subject
	to redemption and warrants to purchase common stock
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	3,013,127
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	18,810,882
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,457,573
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Net increase in cash and cash equivalents
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	13,072,318
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,299,022
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Cash and cash equivalents at beginning of year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2,747,248
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	448,226
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Cash and cash equivalents at end of year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	15,819,566
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	2,747,248
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Supplemental disclosure of cash flow information
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash paid for interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash paid for taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Supplemental disclosure of noncash financing activities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrual of commissions and issuance costs of the initial public offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	213,561
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred offering costs reclassified to additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	665,603
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Conversion of all outstanding preferred stock into common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,888
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Conversion of all outstanding preferred stock subject to redemption into
	common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,594,464
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Common stock subject to repurchase
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cumulative preferred stock dividends
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	327,569
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	589,462
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accretion of discount on Series C preferred stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	63,283
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Common stock issued as commitment fee for stock purchase agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	400,392
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Conversion of notes payable into preferred stock subject to redemption and
	warrants to purchase common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	612,923
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying notes are an integral part of these financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	RITTER
	PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_019">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTES
	TO FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	1 &mdash; ORGANIZATION AND PRINCIPAL ACTIVITIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ritter
	Pharmaceuticals, Inc. (&ldquo;Ritter&rdquo; or the &ldquo;Company&rdquo;) is a Delaware corporation headquartered in Los Angeles,
	California. The Company was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences,
	LLC, and converted into a Delaware corporation on September 16, 2008.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ritter
	Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.
	The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality
	of prebiotic-based therapeutics. The Company&rsquo;s lead compound, RP-G28 is currently under development for the treatment of
	lactose intolerance. There currently is no drug approved by the Food and Drug Administration (&ldquo;FDA&rdquo;) for the treatment
	of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company currently operates in one business segment focusing on the development and commercialization of RP-G28. The Company is
	not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision
	maker, the Chief Executive Officer. The Company does not currently operate any separate lines of business or separate business
	entities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Initial
	Public Offering
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 24, 2015, the Company&rsquo;s registration statement on Form S-1 (File No. 333-202924) relating to its initial public offering
	of its common stock was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;). The shares began trading
	on the NASDAQ Capital Market on June 24, 2015. The initial public offering closed on June 29, 2015, and 4,000,000 shares of common
	stock were sold at an initial public offering price of $5.00 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company paid to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering.
	In addition, the Company incurred expenses of approximately $1 million in connection with the offering. Thus, the net offering
	proceeds to the Company, after deducting underwriting discounts and commissions and offering expenses, were approximately $17.4
	million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Capitalization
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the Company&rsquo;s initial public offering in June 2015, the Company effected a 1&ndash;for-7.15 reverse split
	of its common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share
	amounts in these financial statements and notes to financial statements have been adjusted to reflect the reverse split on a retroactive
	basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	2 &mdash; BASIS OF PRESENTATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United
	States of America (&ldquo;GAAP&rdquo;) and include all adjustments necessary for the fair presentation of the Company&rsquo;s
	financial position for the periods presented.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Going
	Concern and Liquidity
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,
	among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has
	not generated any product revenue and has not achieved profitable operations. The Company had net losses of approximately $8.8
	million and $2.5 million for the years ended December 31, 2015 and 2014, respectively, and had net cash used in operating activities
	of approximately $5.7 million and $1.2 million, for the years ended December 31, 2015 and 2014, respectively. There is no assurance
	that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development
	activities, clinical and pre-clinical testing, and commercialization of the Company&rsquo;s products will require significant
	financing. These matters, among others, raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Since
	inception, the operations of the Company have been funded through the sale of common shares, preferred shares and convertible
	debt. Management cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that
	the Company raises additional funds by issuing equity securities, the Company&rsquo;s stockholders may experience significant
	dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company&rsquo;s ability to conduct
	business. If the Company is not able to raise additional capital when required or on acceptable terms, the Company may have to
	(i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates;
	(ii) seeks collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less
	favorable than might otherwise be available; (iii) relinquish or otherwise dispose of rights to technologies, product candidates
	or products that the Company would otherwise seek to develop or commercialize.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	3 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Use
	of Estimates
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect
	the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial
	statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
	estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by
	management include among others; the valuation allowance of deferred tax assets resulting from net operating losses and the valuation
	of options on the Company&rsquo;s common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Cash
	and Cash Equivalents
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Cash
	consists of amounts held in a financial institution and consists of immediately available fund balances. The funds were maintained
	at a stable financial institution, generally at amounts in excess of federally insured limits, which represents a concentration
	of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Deferred
	Offering Costs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Deferred
	offering costs as of December 31, 2014 primarily consist of direct, incremental banking, legal and accounting fees related to
	the public offering of the Company&rsquo;s common stock, and are classified within long term assets. The deferred offering costs
	were reclassified to additional paid-in capital upon the consummation of the offering on June 29, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Property
	and Equipment
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Property
	and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method (see Note
	4). Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts
	and any resulting gain or loss is credited or charged to income. Maintenance and repairs are charged to expense as incurred while
	expenditures for refurbishments and improvements that significantly add to the productive capacity or extend the useful life of
	an asset are capitalized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Impairment
	of Long-Lived Assets
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company periodically assesses the impairment of long lived assets in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;)
	Topic 360,
<I>
	Property Plant and Equipment.
</I>
	When indicators of impairment are present, the Company evaluates the carrying
	value of these assets in relation to the operating performance of the business and future undiscounted cash flows expected to
	result from the use of these assets. No such impairments have been recognized during the years ended December 31, 2015 or 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Accrued
	Expenses
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company incurs periodic expenses such as research and development, salaries, and professional fees. An accrual is necessary when
	expenses have been incurred by the Company prior to them being paid. When a vendor&rsquo;s invoice is not received, the Company
	is required to estimate its accrued expense. This process involves reviewing quotations and contracts, identifying services that
	have been performed on the Company&rsquo;s behalf and estimating the level of service performed and the associated cost incurred
	for the service when the Company has not yet been invoiced or otherwise been notified of the actual cost. The majority of the
	Company&rsquo;s service providers invoice monthly in arrears for services performed or when contractual milestones are met. The
	Company estimates accrued expenses at each balance sheet date based on facts and circumstances known at that time. The Company
	periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Research
	and Development
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in
	performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical
	materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods
	and services that will be used in future research and development activities are expensed when the activity is performed or when
	the goods have been received, rather than when payment is made, in accordance with ASC Topic 730,
<I>
	Research and Development
</I>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Patent
	Costs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution
	costs. Therefore, patent costs are expensed as incurred. Should the Company experience a legal cost to defend a patent in the
	future, that cost would be capitalized only when it is part of the cost of retaining and obtaining the future economic benefit
	of the patent. Costs related to an unsuccessful outcome would be expensed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Stock-based
	Compensation
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock-based
	compensation cost for stock awards issued to employees, members of the Company&rsquo;s board of directors and non-employees, is
	measured at the grant date based on the fair value of the award and is recognized as expense over the required service period,
	which is generally equal to the vesting period. Stock-based compensation is recognized only for those awards that are ultimately
	expected to vest. Common stock, stock options or warrants issued to non-employees, including consultants and members of the Company&rsquo;s
	Scientific Advisory Board as consideration for goods or services received by the Company, are accounted for based on the fair
	value of the equity instruments issued unless the fair value consideration received can be more reliably measured. The fair value
	of stock options is determined using the Black-Scholes option-pricing model. The fair value of any options issued to non-employees
	is recorded as expense over the vesting period. See Note 9 for further information.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Fair
	Value Measurements
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework
	for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a
	recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset
	or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement
	that should be determined based on assumptions that market participants would use in pricing an asset or liability.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs
	used in measuring fair value as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.6IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	1:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Observable
	inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	2:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	InpInputs
	other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted
	prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities
	in markets that are not active.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unobservable
	inputs that reflect the reporting entity&rsquo;s own assumptions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015 and 2014, the carrying amounts of cash and cash equivalents, prepaid expenses, accounts payable and accrued
	expenses are generally considered to be representative of their fair value because of the short term nature of these instruments.
	No transfers between levels have occurred during the periods presented.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Accounting
	for Income Taxes
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Deferred
	tax assets and liabilities are recognized for the expected future consequences of events that have been reflected in the financial
	statements. Deferred tax assets and liabilities are determined based on the differences between the book and tax basis of assets
	and liabilities and operating loss carryforwards, using tax rates expected to be in effect for the years in which the differences
	are expected to reverse. Such differences arise primarily from stock-based compensation and net operating loss carryforwards.
	The Company records a valuation allowance to reduce deferred income tax assets when it is more likely than not that some portion
	or all of the deferred tax asset will not be realized. Prior to September 15, 2008, the Company was a limited liability company
	and the Company&rsquo;s tax losses and credits generally flowed directly to the members.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Net
	Loss Per Share
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Basic
	net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted
	net loss per share is calculated by dividing net loss by the weighted-average common shares outstanding during the period using
	the treasury stock method or the two-class method, whichever is more dilutive. The potentially dilutive stock options issued under
	the 2015 Equity Incentive Plan (described in Note 9) and warrants on the Company&rsquo;s common stock (described in Note 8) are
	not considered in the computation of diluted net loss per share because they would be anti-dilutive.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	common share amounts and per share amounts have been adjusted to reflect a 1-for-7.15 reverse stock split of the Company&rsquo;s
	common stock effected in June 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Comprehensive
	Income (Loss)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Comprehensive
	income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner
	sources. The Company is required to record all components of comprehensive loss in the financial statements in the period in which
	they are recognized. Net income (loss) and other comprehensive loss, including foreign currency translation adjustments and unrealized
	gains and losses on investments are reported, net of their related tax effect, to arrive at a comprehensive loss. For the years
	ended December 31, 2015 and 2014, comprehensive loss was equal to the net loss.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Recent
	Accounting Pronouncements
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	November 20, 2015, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
	No. 2015-17,
<I>
	Balance Sheet Classification of Deferred Taxes.
</I>
	ASU 2015-17 simplifies the presentation of deferred income
	taxes and requires that deferred tax assets and liabilities, as well as any related valuation allowance, be classified as noncurrent
	in a classified statement of financial position. The adoption of ASU 2015-17 is not expected to impact the Company&rsquo;s financial
	statements as the Company has no net deferred income taxes presented on its balance sheets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	August 2014, the FASB issued ASU No. 2014-15,
<I>
	Presentation of Financial Statements &mdash; Going Concern (Subtopic 205-40)
	&mdash; Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
</I>
	, which provides guidance
	regarding management&rsquo;s responsibility to assess whether substantial doubt exists regarding the ability to continue as a
	going concern and requires related footnote disclosures. In connection with preparing financial statements for each annual and
	interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that
	raise substantial doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the
	financial statements are issued (or within one year after the date that the financial statements are available to be issued when
	applicable). This ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods
	thereafter. Management is currently evaluating the new guidance and has not determined the impact this standard may have on the
	Company&rsquo;s financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Other
	accounting standards updates effective after December 31, 2015, are not expected to have a material effect on the Company&rsquo;s
	financial position, annual results of operations and/or cash flows.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	4 &mdash; PROPERTY AND EQUIPMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Property
	and equipment consists of the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Useful Life (Years)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 41%; TEXT-ALIGN: LEFT">
	Furniture and fixtures
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: CENTER">
	7
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	15,840
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	4,270
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Computer equipment
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	9,696
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,487
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,536
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,757
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Less: Accumulated depreciation and amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(4,848
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(4,585
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Property and equipment, net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	20,688
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	5,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Depreciation
	expense of approximately $1,900 and $3,500 was recognized for the years ended December 31, 2015 and 2014, respectively, and is
	classified in general and administrative expense in the accompanying Statements of Operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	5 &mdash; CONVERTIBLE NOTES PAYABLE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	2014, the Company issued a combination of convertible notes payable and a note payable for a total principal balance of $605,000
	(the &ldquo;2014 Notes&rdquo;) to two investors and converted all of these outstanding notes, plus accrued interest, into Series
	C preferred stock and warrants to purchase the Company&rsquo;s common stock. These notes were convertible upon a qualified equity
	financing, pursuant to which the Company sold, with the principal purpose of raising capital, a new class of preferred stock with
	an aggregate sales price of not less than $3,000,000, including the principal and accrued but unpaid interest of any notes which
	are converted into the preferred securities (&ldquo;Qualified Equity Financing&rdquo;), or upon a change of control.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	convertible notes payables with a principal balance of&thinsp;$535,000 settle by providing the holder with a variable number of
	the Company&rsquo;s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the
	value that the holder receives at settlement does not vary with the value of the Company&rsquo;s equity shares, the settlement
	provision is not considered a conversion option for financial accounting purposes. Rather, these notes are recognized as share-settled
	debt at amortized cost.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Details
	of the 2014 Notes are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	May and September 2014, the Company issued a total of&thinsp;$455,000 of subordinated convertible promissory notes. These
	notes have a term of 12 months and bear interest at a rate of 8% per annum until paid in full. These notes are convertible
	upon a Qualified Equity Financing or upon a change of control at a price per share equal to seventy-five percent (75%) of
	the price per share paid by the investors (other than the 2014 Note holders) participating in the Qualified Equity Financing.
	The Company evaluated the change of control put embedded in these notes, which provides for cash settlement of these notes
	at two (2) times the principal amount upon a change of control, in accordance with ASC 815-15-25. The embedded change of control
	put is not clearly and closely related to the debt host instrument and therefore has been separately measured at fair value.
	The proceeds received upon issuing these notes was first allocated to the fair value of the embedded put with the remainder
	to the debt host instrument, resulting in a discount of approximately $21,000 to the face amount of the notes. The discount
	is amortized to interest expense over the term of the debt. The Company amortized approximately $10,000 to interest expense
	in the year ended December 31, 2014. Additionally, the Company recognized a gain of approximately $21,000 in the year ended
	December 31, 2014 due to the reduction in fair value of the put resulting from the decreased probability of a change in control
	occurring as the notes approached maturity and ultimate conversion.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	October 2014, the Company issued an $80,000 subordinated convertible promissory note. This note has a term of 12 months and
	bear interest at a rate of 8% per annum until paid in full. The terms of this note provided an automatic conversion upon a
	Qualified Equity Financing at a price per share equal to seventy-five percent (75%) of the price per share paid by the investors
	(other than the 2014 Note holders) participating in the Qualified Equity Financing.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition, the Company issued a $70,000 principal amount unsecured promissory note on October 9, 2014. This note bears interest
	at a rate of 5% per annum until paid in full. All principal and accrued interest under this note must be paid upon demand
	of the holder at any time after one year of the date of the note.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	described in Note 7, all of the Company&rsquo;s outstanding debt was converted or exchanged for Series C preferred stock and warrants
	to purchase common stock in December 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	6 &mdash; COMMITMENTS AND CONTINGENCIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Master
	Services Agreement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 30, 2015, we entered into a Master Service Agreement with Covance, Inc. (&ldquo;Covance&rdquo;), with an effective date
	of December 29, 2015. Pursuant to the terms of the Master Service Agreement, Covance (or one or more of its affiliates) will provide
	Phase 1, 2, 3, and 4 clinical services for a clinical study or studies to us, and, at our request, assist us with the design of
	such studies, in accordance with the terms of separate individual project agreements to be entered into by the parties. The term
	of the agreement is for three years and will renew automatically for successive one year periods unless Covance is no longer providing
	services under the agreement or either party has terminated the agreement upon written notice. We may terminate the Master Service
	Agreement or any individual project agreement entered into under the Master Service Agreement prior to the applicable study&rsquo;s
	completion at any time for any reason upon 30 days written notice to Covance, except when the reason for termination is the safety
	of subjects, in which case it may be terminated immediately. Covance may not terminate any individual project agreement without
	cause, except when the reason for the termination is the safety of subjects, in which case it may be terminated immediately. In
	the event of a termination of the Master Service Agreement, Covance will be entitled to full payment for (i) work performed on
	the applicable project upon through the date work on such project is concluded and (ii) reimbursement for all non-cancellable
	and non-refundable expenses and financial obligations which Covance (or an affiliate) has incurred or undertaken on our behalf.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Clinical
	Supply and Cooperation Agreement with Ricerche Sperimentali Montale (&ldquo;Ricerche&rdquo;) and Inalco SpA (&ldquo;Inalco&rdquo;)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Effective
	July 24, 2015, we entered into an amended Clinical Supply and Cooperation Agreement (the &ldquo;Amended Supply Agreement&rdquo;)
	with Ricerche and Inalco (collectively, &ldquo;RSM&rdquo;). The Amended Supply Agreement amends certain terms of the Clinical
	Supply and Cooperation Agreement, dated December 16, 2009, amended on September 25, 2010 (the &ldquo;Existing Supply Agreement&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	the Existing Supply Agreement, RSM granted us an exclusive worldwide option in a specified field and territory to assignment of
	all right, title and interest to a purified Galacto-oligosaccharides product (&ldquo;Improved GOS&rdquo;), the composition of
	matter of the Improved GOS and any information relating to the Improved GOS, including certain specified technical information
	and other intellectual property rights (the &ldquo;Improved GOS IP&rdquo;). Pursuant to the amended terms, we could exercise the
	option by paying RSM $800,000 within ten days after the effective date of the Amended Supply Agreement. We exercised this option
	on July 30, 2015 and RSM transferred the Improved GOS IP to us. Under the terms of the Existing Supply Agreement, if a further
	option payment of $1 million due in the future is not made, we may be required to return the Improved GOS IP to RSM.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Amended Supply Agreement also provides that we must pay RSM $400,000 within 10 days following FDA approval of a new drug application
	for the first product owned or controlled by us using Improved GOS as its active pharmaceutical ingredient. In addition, we agreed
	to purchase 350 kilos of Improved GOS for the sum of $250 per kilo for clinical supply of Improved GOS instead of $2,000 per kilo
	as under the Existing Supply Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	consideration for RSM entering into the Amended Supply Agreement, we issued 100,000 shares of our common stock, par value $0.001
	per share (the &ldquo;RSM Shares&rdquo;), to RSM on November 30, 2015. Fair value of these shares totaling $416,000 was recognized
	in stockholders&rsquo; equity in the balance sheet as of December 31, 2015. The stock purchase agreement includes a lock-up agreement
	by RSM in our favor pursuant to which RSM will not be able to sell the RSM Shares for a period ending on the earlier of (i) the
	public release by us of the final results of our Phase 2b/3 clinical trial of RP-G28 and (ii) the filing of our Form 10-Q with
	the Securities and Exchange Commission for the fiscal quarter in which we receives the results of our Phase 2b/3 clinical trial
	of RP-G28.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Lease
	Agreement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	lease office space for our headquarters in California. Until September 30, 2015, we leased office and storage space pursuant to
	a two-year agreement which called for a minimum monthly rent of approximately $5,000 and an annual increase of 3%.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	July 9, 2015, we entered into a lease with Century Park, a California limited partnership, pursuant to which we are leasing approximately
	2,780 square feet of office space in Los Angeles, California for our headquarters. The lease provides for a term of sixty-one
	(61) months, commencing on October 1, 2015. We paid no rent for the first month of the term and will pay base rent of $9,174 per
	month for months 2 through 13 of the term, with increasing base rent for each twelve month period thereafter under the term of
	the lease to a maximum of $10,325 per month for months 50 through 61. The base rent payments do not include our proportionate
	share of any operating expenses, including real estate taxes. We have the option to extend the term of the lease for one five-year
	term, provided that the rent would be subject to market adjustment at the beginning of the renewal term. We will recognize rent
	expense on a straight-line basis over the lease term.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Rent
	expense, recognized on a straight-line basis, was approximately $74,000 and $60,000 for the years ended December 31, 2015 and
	2014, respectively, and is recorded in general and administrative expenses in the accompanying statements of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following table summarized our lease obligations at December 31, 2015:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	LEASE COMMITMENTS
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Years ended December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Operating Lease
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 26%; TEXT-ALIGN: RIGHT">
	110,638
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	113,958
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	117,376
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	120,898
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	2020
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	103,254
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total minimum lease payments
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	566,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Employment
	Agreements
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Michael
	D. Step
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 2, 2014, Michael D. Step accepted an offer letter from us setting forth the terms of his employment as Chief Executive
	Officer. The offer letter provides that Mr. Step is entitled to an annual base salary of $360,000 and a total of three grants
	of options to purchase our common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	first two options entitle Mr. Step to purchase 646,537 and 73,377 of our shares, respectively, for an exercise price of&thinsp;$5.86
	per share. Each of these options was immediately exercisable in full as of the date of the grant, with 44/48
<SUP>
	ths
</SUP>
	of
	the total number of shares covered by each option subject to a right of repurchase by us upon termination of Mr. Step&rsquo;s
	employment with us for any reason. This right of repurchase lapses over a period of 44 months, with 1/44
<SUP>
	th
</SUP>
	of the total
	number of shares subject to the right of repurchase lapsing on January 1, 2015 and on the first day of each month thereafter.
	In addition, the right of repurchase will lapse in its entirety upon a termination of the employment under certain circumstances.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	third option became exercisable upon the closing of our initial public offering on June 29, 2015. The option is for a total of
	163,799 shares of our common stock, which, together with the shares subject to the first option, represent 7.5% of the shares
	of common stock deemed to be outstanding at June 29, 2015 on a fully-diluted basis, after giving effect to the number of shares
	subject to the third option. Seventy-five percent of the shares subject to the third option are subject to a right of repurchase
	by us upon termination of Mr. Step&rsquo;s employment for any reason. This right of repurchase lapses with respect to 1/36
<SUP>
	th
</SUP>
	of the total number of shares subject to the right of repurchase on the first day of each month following the date on which
	the third option becomes exercisable. In addition, the right of repurchase will lapse in its entirety upon Mr. Step&rsquo;s termination
	of employment under certain circumstances.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additionally,
	under the terms of his Executive Severance and Change in Control Agreement, also effective on December 2, 2014, Mr. Step is entitled
	to receive certain payments in the event his employment is terminated under certain scenarios.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Andrew
	Ritter and Ira Ritter
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	September 25, 2013, our board of directors approved the Executive Compensation Plan (the &ldquo;Compensation Plan&rdquo;) setting
	forth certain compensation to be paid to Andrew Ritter, our current President and former Chief Executive Officer, and Ira Ritter,
	our current Chief Strategic Officer (&ldquo;CSO&rdquo;), for their respective contributions to our company. Effective June 29,
	2015, in connection with our initial public offering, Andrew Ritter and Ira Ritter accepted offer letters from us setting forth
	the terms of their employment as President and CSO, respectively, of the Company. The offer letters superseded the Compensation
	Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Their
	respective offer letters provide that that Andrew Ritter is entitled to an annual base salary of $310,000 and Ira Ritter is entitled
	to an annual base salary of $295,000. In accordance with his offer letter, Andrew Ritter also became entitled to receive up to
	$180,000 payable over a three year period for tuition reimbursement. As of December 31, 2015, we paid an aggregate of $105,000
	and have an accrual of $75,000 in tuition reimbursement for Andrew Ritter and recognized such amount in general and administrative
	expenses in the accompanying statements of operations for the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Additionally,
	under the terms of their Executive Severance and Change in Control Agreements, also effective on June 29, 2015, each of Andrew
	Ritter and Ira Ritter is entitled to receive certain payments in the event their employment is terminated under certain scenarios.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to their respective offer letters, Andrew Ritter and Ira Ritter each have the opportunity to earn an annual bonus based upon a
	percentage of their base salary and the achievement of specific performance as determined by the Company. The initial target bonus
	opportunities are 40% and 35% of the base salary for Andrew Ritter and Ira Ritter, respectively. The board of directors determined
	that the specific performance requirements were met for fiscal year 2015 and accordingly, Andrew Ritter received 40% of his base
	salary, or $124,000 and Ira Ritter received 35% of his base salary, or $103,250. These bonus payments are recognized in general
	and administrative expense in the accompanying statements of operations for the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the Compensation Plan, as in effect prior to entering into their offer letters, Andrew Ritter and Ira Ritter had bonus opportunities
	to, upon the satisfaction of the events described below, each potentially receive the following cash payments and each potentially
	receive the following options to purchase up to 48,951 shares of our common stock (the &ldquo;Executive Options&rdquo;) pursuant
	to the 2008 Stock Plan:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	FDA
	Meeting Bonus Opportunities
</I>
	. Each executive was entitled to receive, and in April 2013 each executive received, a one-time
	cash bonus of $10,000 for a milestone associated with meeting with the FDA regarding RP-G28&rsquo;s path to FDA approval.
	In addition, upon satisfaction of this milestone, the executives became entitled to 3,496 of the Executive Options. 2,360
	shares of the Executive Options vested and became exercisable as of the grant date of September 25, 2013, with the balance
	of the 1,136 shares vesting ratably in 36 equal monthly installment beginning on September 30, 2013.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Clinical
	Trial Funding Commitment Bonus Opportunities
</I>
	. Each executive was entitled to receive a one-time cash bonus of $75,000
	upon our receipt of a commitment by a third party to fund a Phase 2 or later clinical trial; provided, however, that no such
	bonus would be paid at any time we had less than $2,000,000 in available cash. In addition, upon the satisfaction of this
	milestone, 35% of 10,489 shares of the Executive Options would vest and become exercisable, with the balance of the 10,489
	shares vesting in 36 equal monthly installments beginning on the last day of the following month. The board of directors determined
	that this milestone was satisfied; accordingly, each executive received a bonus of $75,000 which has been recognized in general
	and administrative expenses in the accompanying statements of operations for the year ended December 31, 2015. In addition,
	3,671 shares of the Executive Options vested and became exercisable as of June 29, 2015, with the balance of 6,818 shares
	vesting ratably on a monthly basis beginning July 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Fundraising
	Bonus Opportunities
</I>
	. Each executive was entitled to receive (i) a one-time cash bonus of $50,000 upon the sale of additional
	equity capital for cash, in one or more closings after July 17, 2012, and/or the actual deployment of funds by a third party
	for a clinical trial in an aggregate amount in excess of $2,000,000 and (ii) a one-time cash bonus of $150,000 upon the sale
	of additional equity capital for cash, in one or more closings after July 17, 2012 and/or the actual deployment of funds by
	a third party for a clinical trial in an aggregate amount in excess of $10,000,000 (which such bonus would be reduced by any
	cash bonus paid under subsection (i)); provided, however, that no bonus under subsection (i) or (ii) would be paid at any
	time we had less than $2,000,000 in available cash. In addition, upon the satisfaction of the milestone described in subsection
	(i), 35% of 6,993 shares of the Executive Options would vest and become exercisable, with the balance of the 6,993 shares
	vesting in 36 equal monthly installments beginning on the last day of the following month, and, upon satisfaction of the milestone
	described in subsection (ii), 35% of 13,986 shares of the Executive Options would vest and become exercisable, with the balance
	of the 13,986 shares vesting in 36 monthly installments beginning on the last day of the following month. The board of directors
	determined that this milestone as described in subsection (ii) above was satisfied upon the closing of our initial public
	offering on June 29, 2015 raising approximately $17.4 million, net of offering costs; accordingly, each executive received
	a bonus of $150,000 which has been recognized in general and administrative expenses in the accompanying statements of operations
	for the year ended December 31, 2015. In addition, 4,895 shares of the Executive Options vested and became exercisable as
	of June 29, 2015, with the balance of 9,091 shares vesting ratably on a monthly basis beginning July 31, 2015.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	License
	Event Bonus Opportunities
</I>
	. Each executive was entitled to receive the following bonus payments in connection with the
	closing of an exclusive license of RP-G28 and/or any future product candidate developed by the Company from time to time during
	the term of the Compensation Plan by and/or any option to exclusively license such product candidate to a third party (referred
	to under the Compensation Plan as a &ldquo;License Event&rdquo;) with a minimum upfront payment to the Company of $2,000,000:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.75IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#111;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	graduated cash bonus equal to (i) 5% of the Initial Period License Payment (as defined in the Compensation Plan) up to $5,000,000;
	(ii) 4% of the Initial Period License Payment in excess of $5,000,000 up to $10,000,000; and (iii) 3% of the Initial Period
	License Payment in excess of $10,000,000. In addition, upon our receipt of an Initial Period License Payment of more than
	$2,000,000, 35% of 45,454 shares of their Executive Options will vest and become exercisable, with the balance of the 45,454
	shares vesting in 36 monthly installments beginning on the last day of the following month.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#111;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	cash bonus equal to 3% of any Annual Excess Milestone Payments (as defined in the Compensation Plan); provided, however that
	no such bonus may be paid at any time the Company has less than $1,000,000 in available cash. In addition, upon our receipt
	of an Annual Excess Milestone Payment, 35% of 6,993 shares of their Executive Options will vest and become exercisable, with
	the balance of the 6,993 shares vesting in 36 monthly installments beginning on the last day of the following month.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015, 27,972 of the maximum 48,951 Executive Options potentially issuable to each executive had been issued to
	each executive subject to the vesting conditions described above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Legal
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company is not currently involved in any legal matters arising in the normal course of business. From time to time, the Company
	could become involved in disputes and various litigation matters that arise in the normal course of business. These may include
	disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically,
	the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential
	loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for
	the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such
	uncertainties, accruals are based on the best information available at the time. As additional information becomes available,
	the Company reassesses the potential liability related to pending claims and litigation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	7 &mdash; STOCKHOLDERS&rsquo; EQUITY (DEFICIT) AND PREFERRED STOCK SUBJECT TO REDEMPTION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Common
	Stock
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2014, the Company was authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share.
	Effective June 17, 2015, the Company effected a 1-for-7.15 reverse stock split and all common share amounts and per share amounts
	reflected in these financial statements and notes to financial statements have been adjusted to reflect that reverse stock split.
	The Company amended and restated its Certificate of Incorporation on June 29, 2015 (&ldquo;the Amended Certificate&rdquo;) and
	reduced the authorized shares of the Company&rsquo;s common stock to 25,000,000 with a par value of $0.001 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Initial
	Public Offering
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	June 29, 2015, the Company closed its initial public offering, selling 4,000,000 shares of the Company&rsquo;s common stock at
	an initial public offering price of $5.00 per share, for aggregate gross proceeds to the Company of $20 million. The Company paid
	to the underwriters underwriting discounts and commissions of approximately $1.6 million in connection with the offering, and
	approximately $1 million of other expenses in connection with the offering. The underwriters paid an aggregate purchase price
	of $100 for warrants to purchase 160,000 shares of the Company&rsquo;s common stock, representing 4.0% of the initial public offering
	shares, at an exercise price of $6.25 per share, which equaled 125.0% of the initial public offering price. The warrants are exercisable
	on June 29, 2016 and expire on June 29, 2020. Effective prior to the closing of the initial public offering, the Company converted
	all of its outstanding shares of Series A-1, Series A-2, Series A-3, Series B, and Series C preferred into an aggregate of 3,322,652
	shares of the Company&rsquo;s common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Common
	Stock Purchase Agreement
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	December 18, 2015, the Company entered into a common stock purchase agreement (the &ldquo;Purchase Agreement&rdquo;), with Aspire
	Capital Fund, LLC, an Illinois limited liability company, (&ldquo;Aspire Capital&rdquo;), which provides that, upon the terms
	and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of
	$10.0 million of the Company&rsquo;s shares of common stock over the approximately 30-month term of the Purchase Agreement. In
	consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company
	issued to Aspire Capital 188,864 shares of the Company&rsquo;s common stock as a commitment fee (the &ldquo;Commitment Shares&rdquo;).
	The fair value of the Commitment Shares were capitalized and recorded as a reduction of additional paid-in capital. Upon execution
	of the Purchase Agreement, the Company agreed to sell to Aspire Capital 500,000 shares of common stock, or the Initial Purchase
	Shares, at $2.00 per share for proceeds of $1.0 million.
<B>
</B>
	Concurrently with entering into the Purchase Agreement, the Company
	also entered into a registration rights agreement with Aspire Capital, (&ldquo;Registration Agreement&rdquo;), in which the Company
	agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933,
	as amended, (the &ldquo;Securities Act&rdquo;), the sale of the shares of our common stock that have been and may be issued to
	Aspire Capital under the Purchase Agreement. On December 31, 2015, the Company filed a registration statement on Form S-1 (File
	No. 333-208818) pursuant to the terms of the Registration Agreement, which registration statement was declared effective on February
	11, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Preferred
	Stock
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s Board of Directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of
	the authorized shares of preferred stock in series and to establish the number of shares to be included in each such series, and
	to fix the designation, powers, preferences and rights of the shares of each such series and any qualifications, limitations or
	restrictions thereon.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the Amended Certificate, as of June 29, 2015, the Company was authorized to issue 5,000,000 shares of preferred stock, $0.001
	par value per share. Prior to the Amended Certificate and as of December 31, 2014, the Company was authorized to issue 7,200,000
	shares, 1,687,500 shares, 4,220,464 shares, 7,658,182 shares, and 4,500,000 shares of Series A-1, Series A-2, Series A-3, Series
	B, and Series C preferred stock, respectively, with a par value of $0.001 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Upon
	the closing of the Company&rsquo;s initial public offering, all outstanding shares of convertible preferred stock and preferred
	stock subject to redemption were converted into an aggregate of 3,322,652 shares of common stock. The following provides material
	terms and certain historical information regarding the Series A-1, Series A-2, Series A-3, Series B and Series C Preferred Stock
	prior to their conversion to common stock:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Redemption.
</I>
	At any time after five years following the date of the initial issuance of the Series A-3, Series B, or Series C preferred
	stock, as applicable, and at the option of the holders of a majority of the then outstanding shares of Series A-3, Series B, and
	Series C preferred stock, voting together as a single class, the Company was required to redeem any outstanding shares that have
	not been converted by paying cash in an amount per share equal to the liquidation preference of $0.62 and $1.30 for the Series
	A-3 and Series C preferred stock, respectively, and $1.19 per share, plus any accrued but unpaid dividends, for the Series B preferred
	stock. Given the holders&rsquo; redemption option, the Series A-3, Series B, and Series C preferred stock is classified as preferred
	stock subject to redemption in the accompanying balance sheets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Dividends.
</I>
	The holders of outstanding shares of preferred stock were entitled to receive dividends, when, as and if declared by the Company&rsquo;s
	Board of Directors. The annual dividend rate was $0.00556 per share for the Series A-1 preferred stock, $0.032 per share for the
	Series A-2 preferred stock, $0.04957 per share for the Series A-3 preferred stock, $0.09524 per share for the Series B preferred
	stock, and $0.104 for Series C preferred stock (subject to adjustment). The right to receive dividends on shares of Series B preferred
	stock was cumulative and the dividends accrue to holders of Series B preferred stock whether or not dividends are declared or
	paid in a calendar year. Undeclared dividends in arrears for the Series B preferred stock was approximately $2 million and $1.7
	million as of June 29, 2015 and December 31, 2014, respectively. The right to receive dividends on shares of Series A and Series
	C preferred stock was not cumulative and no right to such dividends accrued to holders of Series A or Series C preferred stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Liquidations
</I>
	.
	In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B and Series
	C preferred stockholders receive an amount per share equal to the sum of the original purchase price of $1.19 plus all cumulative
	but unpaid dividends for Series B, and $1.30 for Series C. If upon the liquidation, the available assets are insufficient to permit
	payments to Series B and Series C holders, the entire assets legally available will be distributed in a pro rata basis among the
	holders in proportion to the full amounts they would otherwise be entitled to receive. Upon the completion of the distribution
	to the holders of the Series B and Series C preferred stock, the holders of the Series A preferred stock shall be entitled to
	receive, prior and in preference to any distribution of any of the assets of the Company to the holders of all other capital stock
	by reason of their ownership of such stock, an amount per share equal to the sum of the original issue price per share of $0.07,
	$0.40, and $0.62 for Series A-1, Series A-2, and Series A-3 preferred stock, respectively, plus any accrued but unpaid dividends
	on the preferred stock. Any remaining assets are distributed pro rata among the preferred and common shareholders.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Series
	C Financing
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	December 2014, the Company issued an aggregate of 2,369,228 shares of Series C preferred stock and warrants to purchase an aggregate
	of 331,358 shares of the Company&rsquo;s common stock (the &ldquo;Warrants&rdquo;), for aggregate gross proceeds of $3,081,893
	(the &ldquo;Series C Financing&rdquo;). All of these shares of Series C preferred stock were converted into 331,358 shares of
	the Company&rsquo;s common stock prior to the closing of the initial public offering. Each Warrant has a term of seven years and
	provides for the holder to purchase one share of the Company&rsquo;s common stock at a purchase price of $9.30 per share of common
	stock. The Warrants are indexed to the Company&rsquo;s own stock and classified within stockholders&rsquo; equity pursuant to
	ASC 815-40. The gross proceeds were allocated to the Series C preferred stock and Warrants on a relative fair value basis, resulting
	in a per share value of $7.83 for the Series C preferred stock. The allocation of proceeds to the Warrants creates a discount
	of $1.47 in the initial carrying per share value of the Series C preferred stock, which was recognized as accretion, similar to
	preferred stock dividends, over the five-year period prior to optional redemption by the holders.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the Series C Financing, all of the 2014 Notes were converted into shares of Series C preferred stock and Warrants
	as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$535,000
	unpaid principal plus accrued interest of $18,342 on convertible notes converted into 567,529 shares of Series C preferred
	stock, which was later converted into 79,374 shares of the Company&rsquo;s common stock, and 79,374 Warrants.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$70,000
	unpaid principal plus accrued interest of $537 on a note payable extinguished and converted into 54,259 shares of Series C
	preferred stock, which was later converted into 7,589 shares of the Company&rsquo;s common stock and 7,589 Warrants.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Notes
	with an unpaid principal balance of $535,000 were converted into shares of Series C preferred stock and warrants to purchase shares
	of common stock at 75% of the price paid by other purchasers of the Series C Financing. The Company recognized additional interest
	expense of $184,445 upon conversion, calculated as the fair value of incremental shares and warrants received by the holders compared
	to converting the outstanding debt and accrued interest at 100% of the price paid by purchasers of the Series C Financing. The
	note with an unpaid principal balance of $70,000 was exchanged for shares of Series C preferred stock and warrants to purchase
	shares of common stock at a price per share equal to the price per share paid by purchasers of the Series C Financing. As such,
	there was no gain recognized or loss incurred upon extinguishment of the note in 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Prepaid
	Forward Sale of Preferred Stock
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Research
	and Development Agreement &amp; License
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	November 30, 2010, the Company concurrently entered into a Research and Development Agreement &amp; License (&ldquo;R&amp;D Agreement&rdquo;)
	and a Put and Call Option Agreement (&ldquo;Option Agreement&rdquo;) with two commonly controlled entities, Kolu Pohaku Technologies,
	LLC (&ldquo;KPT&rdquo;) and Kolu Pohaku Management, LLC (&ldquo;KPM&rdquo;). The R&amp;D Agreement was subsequently amended on
	July 6, 2011, September 30, 2011, February 6, 2012 and November 4, 2013 to increase the funding received by the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	R&amp;D Agreement between the Company and KPM and KPT, a Qualified High Technology Business within the meaning of Hawaii Revised
	Statutes, called for KPT to make a series of payments to the Company totaling $1,750,000 in exchange for the Company performing
	research and development activities in Hawaii for the benefit of KPT (referred to herein as the KP Research). The KP Research
	consisted of the initial phase of research, including the conduct of Phase II clinical trials in Hawaii for RP-G28. Pursuant to
	the terms of the R&amp;D Agreement, the Company maintained ownership of the results of the Company&rsquo;s ongoing research related
	to RP-G28, but KPT maintained ownership of the results of the KP Research. Inventions, developments and improvements arising out
	of the KP Research were owned by KPT. Under the terms of the R&amp;D Agreement, the Company would bear any costs involved in obtaining
	patents for any inventions, developments or improvements resulting from the Research Project. In exchange for the irrevocable,
	perpetual, exclusive, worldwide right and license to the results of the KP Research, as they are generated under this R&amp;D
	Agreement, the Company agreed to pay a quarterly royalty payment to KPT of $32,000 commencing March 31, 2015 and continuing through
	December 31, 2035 or until such time as the KPM put or call option (as described below) was exercised. On March 26, 2015, the
	Company exercised the KPM put option and issued 1,469,994 shares of Series B preferred stock to KPM, resulting in the full satisfaction
	of the Company&rsquo;s obligation to make royalty payments to KPT.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Option
	Agreement
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the terms of the KPM Option Agreement, the Company had the right to put 1,469,994 shares of the Company&rsquo;s Series B Preferred
	Stock (&ldquo;Series B&rdquo;) to KPM and KPM had the option to call the same amount of shares of Series B from the Company at
	any time after December 31, 2014. The number of shares was determined by dividing the $1,750,000 of payments made by KPT to the
	Company under the R&amp;D Agreement by the Series B preferred stock original issue price of $1.19. Exercise of the put or call
	option would result in full satisfaction of the Company&rsquo;s obligation to make royalty payments to KPT under the R&amp;D Agreement
	and KPT&rsquo;s right, title and interest in the research conducted pursuant to the R&amp;D Agreement would become the property
	of the Company. On March 26, 2015, the Company exercised its right to the KPM put option and issued 1,469,994 shares of Series
	B preferred stock to KPM. Pursuant to the terms of the KPM Option Agreement, this resulted in the full satisfaction of the Company&rsquo;s
	obligation to make royalty payments to KPT under the R&amp;D Agreement and also resulted in the termination of the R&amp;D Agreement
	and all of KPT&rsquo;s right, title and interest in and to the KP Research, which rights now belong to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	R&amp;D Agreement and the put or call option have been recognized on a combined basis, pursuant to ASC 815-10-15-9, as a fully
	prepaid forward sale contract on the Company&rsquo;s Series B preferred stock. The fully prepaid forward sale contract is a hybrid
	instrument comprising (1) a debt host instrument and (2) an embedded forward sale contract, requiring the Company to issue 1,469,994
	shares of the Company&rsquo;s Series B for no further consideration. Payments received by the Company, totaling $1,750,000, are
	recognized as preferred stock subject to redemption in the balance sheet as of December 31, 2014. The Company converted these
	shares into an aggregate of 205,593 shares of the Company&rsquo;s common stock upon the closing of the IPO.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	8 &mdash; WARRANTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	described in Note 7, in 2014, the Company issued seven-year warrants (the &ldquo;Warrants&rdquo;) to investors for the purchase
	of 418,321 shares of the Company&rsquo;s common stock at an exercise price of $9.30 per share. Also described in Note 7, upon
	closing of the IPO, the underwriter paid an aggregate purchase price of $100 for the option to purchase an aggregate 160,000 shares
	of the Company&rsquo;s common stock at an exercise price of $6.25 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company analyzed the Warrants in accordance with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative
	and, if so, whether the Warrants meet the scope exception that provides for equity classification of derivative instruments issued
	or held by the reporting entity that are both (1) indexed to its own stock and (2) classified in stockholders&rsquo; equity. The
	Company concluded these Warrants should be classified as equity since they contain no provisions, which would require recognition
	as a liability.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following represents a summary of the warrants outstanding at December 31, 2015 and changes during the period then ended:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	Weighted Average
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Exercise Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 60%">
	Outstanding at December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	418,323
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	9.30
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	160,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Exercised/Expired/Forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Outstanding at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	578,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	8.45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Exercisable at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	418,323
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	9.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	9 &mdash; STOCK-BASED COMPENSATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Terms
	of the Company&rsquo;s share-based compensation are governed by the Company&rsquo;s 2015 Equity Incentive Plan, 2009 Stock Plan
	and 2008 Stock Plan (collectively the &ldquo;Plans&rdquo;.) The Plans permit the Company to grant non-statutory stock options,
	incentive stock options and other equity awards to the Company&rsquo;s employees, outside directors and consultants; however,
	incentive stock options may only be granted to the Company&rsquo;s employees. Beginning June 29, 2015, no further awards may be
	granted under the 2009 Stock Plan or 2008 Stock Plan. As of December 31, 2015, the aggregate number of shares of common stock
	available for issuance under the 2015 Equity Incentive Plan is 172,448. However, to the extent awards under the 2008 Plan or 2009
	Plan are forfeited or lapse unexercised or are settled in cash, the common stock subject to such awards will be available for
	future issuance under the 2015 Equity Incentive Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	exercise price for an option issued under the Plans is determined by the Board of Directors, but will be (i) in the case of an
	incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than
	110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair
	market value per share on the date of grant; and (ii) in the case of a nonstatutory stock option, no less than 100% of the fair
	market value per share on the date of grant. The options awarded under the Plans shall vest as determined by the Board of Directors
	but shall not exceed a ten-year period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Issued to Directors and Employees as Compensation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the terms of the Plans, from inception to December 31, 2014, the Company issued options to purchase an aggregate of 1,996,712
	shares to its executive officers and employees of the Company and non-employee directors for their services on the Board and its
	committees. Of these, 82,107 options were expired or exercised and 1,914,605 options remain outstanding as of December 31, 2014.
	The exercise prices of these option grants, as determined by the Company&rsquo;s Board of Directors, range from $0.79 to $13.23
	per share, and a portion of these vest subject to certain performance conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	2015, the Company granted an aggregate of 30,000 non-qualified 10-year term options to purchase the Company&rsquo;s common stock
	to its Board of Directors and an aggregate of 41,957 options to purchase the Company&rsquo;s common stock were automatically terminated
	due to certain performance conditions not being met. As of December 31, 2015, the Company has a total of 1,902,648 options issued
	to its executive officers, employees and non-employee directors outstanding. The exercise prices of the outstanding options, as
	determined by the Company&rsquo;s Board of Directors, range from $0.79 to $13.23 per share, and a portion of these vest subject
	to certain performance conditions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company recognized stock-based compensation expense for these services within general and administrative expense in the accompanying
	statements of operations of approximately $2.9 million and $0.7 million for the years ended December 31, 2015 and 2014, respectively.
	As of December 31, 2015, there was approximately $2.1 million of total unrecognized compensation cost related to un-vested stock-based
	compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.5 years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Issued to Nonemployees for Services Received
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company has issued options to purchase an aggregate of 106,573 shares of the Company&rsquo;s common stock since inception to 2014
	to nonemployee consultants under the Plans. Of these, 68,662 options were expired or exercised and 37,911 options remain outstanding
	as of December 31, 2014. In 2015, the Company granted an aggregate of 4,000 non-qualified 10-year term options to purchase the
	Company&rsquo;s common stock to it nonemployee contractors. During 2015, 6,025 options were expired or exercised and 35,886 options
	remain outstanding as of December 31, 2015. The exercise prices of the outstanding options, as determined by the Company&rsquo;s
	Board of Directors, range from $0.72 to $2.25 per share. These outstanding options, with the exception of an option to purchase
	7,272 shares granted to a consultant, vest 25% upon the first anniversary of the vesting commencement date with the remaining
	options vesting monthly in equal amounts over 36 months. The Company recognized an expense for these services of approximately
	$1,300 and $13,000 for the years ended December 31, 2015 and 2014, respectively, within research and development expense in the
	accompanying statements of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Options
	Valuation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes
	option-pricing method. If the Company determines that other methods are more reasonable, or other methods for calculating these
	assumptions are prescribed by regulators, the fair value calculated for the Company&rsquo;s stock options could change significantly.
	Higher volatility and longer expected lives would result in an increase to stock-based compensation expense to non-employees determined
	at the date of grant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock-based
	compensation expense to non-employee consultants affects the Company&rsquo;s general and administrative expenses and research
	and development expenses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	The
	fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors
	incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as
	follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	Years ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: CENTER">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 46%">
	Expected dividend yield
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 25%">
	0.00%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 25%; TEXT-ALIGN: CENTER">
	0.00%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected stock-price volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	51.45% - 67.08%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	51.45% - 64.24%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	0.77% - 2.27%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	0.88% - 3.04%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Term of options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	10
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	5 - 10
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Stock price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	$1.70 - $5.86
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	$1.14 - $5.86
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	dividend yield.
</I>
	The expected dividend is assumed to be zero as the Company has never paid dividends and has no current
	plans to pay any dividends on the Company&rsquo;s common stock.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	stock-price volatility.
</I>
	As the Company&rsquo;s common stock only recently became publicly traded, the expected volatility
	is derived from the average historical volatilities of publicly traded companies within the Company&rsquo;s industry that
	the Company considers to be comparable to the Company&rsquo;s business over a period approximately equal to the expected term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Risk-free
	interest rate.
</I>
	The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero
	coupon U.S. Treasury notes with maturities approximately equal to the expected term.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Expected
	term.
</I>
	The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&rsquo;s
	historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because
	of a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by
	the SEC. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life
	of the options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate
	the stock-based compensation for the Company&rsquo;s equity awards. The Company will continue to use judgment in evaluating the
	expected volatility, expected terms and forfeiture rates utilized for the Company&rsquo;s stock-based compensation calculations
	on a prospective basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Significant
	factors, assumptions and methodologies used in determining the estimated fair value of the Company&rsquo;s common stock
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company is also required to estimate the fair value of the common stock underlying the Company&rsquo;s stock-based awards when
	performing the fair value calculations using the Black-Scholes option-pricing model. The Company&rsquo;s Board of Directors, with
	the assistance of management, determined the fair value of the Company&rsquo;s common stock on each grant date. Option grants
	are based on the estimated fair value of the Company&rsquo;s common stock on the date of grant, which is determined by taking
	into account several factors, including the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	prices at which the Company sold the Company&rsquo;s convertible preferred stock and the rights, preferences, and privileges
	of the convertible preferred stock relative to those of the Company&rsquo;s common stock, including the liquidation preferences
	of the convertible preferred stock;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	important
	developments in the Company&rsquo;s operations;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	Company&rsquo;s actual operating results and financial performance;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	conditions
	in the Company&rsquo;s industry and the economy in general;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	stock
	price performance of comparable public companies;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	estimated likelihood of achieving a liquidity event, such as an IPO or an acquisition of the Company, given prevailing market
	conditions; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	the
	illiquidity of the common stock underlying stock options.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -20.15PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	table below presents the prices received from sales to third parties of the Company&rsquo;s common stock and various classes of
	the Company&rsquo;s preferred stock from inception to date:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Share Class
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Price per Share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 25%">
	2005
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Common
	Stock
<SUP>
	(a)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 23%; TEXT-ALIGN: RIGHT">
	1.79
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2006
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series A-2 Preferred
	Stock
<SUP>
	(a)(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2008&thinsp;&ndash;&thinsp;2009
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series A-3 Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	2010&thinsp;&ndash;&thinsp;2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series B Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series C Preferred
	Stock
<SUP>
	(b)
</SUP>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	After
	giving effect to the Company&rsquo;s conversion from an LLC to a corporation
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Each
	share of preferred stock is convertible into shares of the Company&rsquo;s common stock on a 7.15-for-1 basis, after giving
	effect to the Company&rsquo;s reverse stock split, which was effected on June 17, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	options issued from inception to 2013, in determining the estimated fair value of the Company&rsquo;s common stock, the Company&rsquo;s
	Board of Directors, with the assistance of management, used the market approach to estimate the enterprise value of the Company
	in accordance with the American Institute of Certified Public Accountants (&ldquo;AICPA&rdquo;) Accounting and Valuation Guide,
	Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &ldquo;AICPA Guide&rdquo;) for the three valuation
	dates of November 7, 2013, July 31, 2012, and December 31, 2010. The Market Approach is one of the three approaches (along with
	the Income Approach and Asset Approach) used to estimate enterprise and equity value. The market approach employs analysis using
	comparable companies in determining the value of the entity. Both public and private companies, if publicly available information
	exists, are considered in the market approach. Two information points commonly available&thinsp;&mdash;&thinsp;company valuation
	and transaction value&thinsp;&mdash;&thinsp;are used for their respective methodologies. There are a number of different methods
	within the Market Approach that may be used: the three main methods utilized are: the Guideline Pubic Companies Method; the Guideline
	Transactions Method; and the Backsolve Method.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	the early stage of the Company, the Backsolve Method was used to estimate the fair value of the Company&rsquo;s securities. This
	method derives an implied market value of invested capital from a transaction involving a company&rsquo;s own securities. The
	price of a company&rsquo;s security that was involved in a recent arms-length transaction is used as a reference point in an allocation
	of value. The Company first raised additional capital through the sales of the Company&rsquo;s LLC units. These units later converted
	into common shares and preferred shares upon the Company&rsquo;s conversion to a corporation. Subsequent to the Company&rsquo;s
	corporation conversion, the Company raised additional capital through the sales of the Company&rsquo;s Series A-1, Series A-2,
	Series A-3, Series B, and Series C preferred shares at the price of&thinsp; $0.07, $0.40, $0.62, $1.19, and $1.30, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company valued LLC units and common stock (after converting to a corporation) from inception through 2009 by reference to the
	Company&rsquo;s sales of units and/or common stock &amp; preferred stock over the period. Beginning in 2010, the Company valued
	the Company&rsquo;s common stock using the Backsolve Method. The Backsolve Method requires considering the rights and preferences
	of each class of equity and solving for the total market value of invested capital that is consistent with a recent transaction
	in the Company&rsquo;s own securities, considering the rights and preferences of each class of equity. However, management has
	decided that the liquidation preferences between the Company&rsquo;s preferred shares and common shares are immaterial for a pre-revenue
	company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Per
	the AICPA Guide, the Backsolve Method is generally the most reliable indicator of value of early-stage enterprises with no product
	revenue or cash flow, if relevant and reliable transactions have occurred in the Company&rsquo;s equity securities. This methodology
	is also prescribed by the AICPA when a valuation is conducted in close proximity to the date of a financing transaction, and when
	other methodologies are deemed less reliable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	stage of development of the Company&rsquo;s compound was reflected in the Company&rsquo;s selection of the term and volatility
	estimates used in the analysis. The estimate of the term considers the Company&rsquo;s existing cash runway and the time to the
	next potential financing or liquidity event, while the volatility estimate reflects the relative riskiness of the Company&rsquo;s
	equity securities (or asset base) relative to the general stock market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&rsquo;s
	preferred shares for one common share through the option-pricing method. The premise of this method is that the transaction implied
	a market price for a share which in turn implied values for the other classes of equity based on relative claims on equity value,
	such as liquidation preferences and conversion rights. The application of the backsolve method considering the Company&rsquo;s
	capital structure yielded a total market value of invested capital of approximately $15.5 million, $14.4 million, and $8.9 million,
	of which approximately $819,000, $870,000, and $670,000 were allocated to the total value of common stock as of the Company&rsquo;s
	three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	the three valuation dates of November 7, 2013, July 31, 2012, and December 31, 2010, after estimating the market value of invested
	capital, the Company allocated it to the various equity classes comprising the subject company&rsquo;s capitalization table. This
	process ultimately results in creating a final estimate of value for the subject company&rsquo;s underlying equity interests.
	While there are many different value allocation methods, these various methods can be grouped into three general categories as
	defined by the AICPA Guide, one of which is the Option-Pricing Method (&ldquo;OPM&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company used the OPM to allocate market value of invested capital to the various equity classes and debt comprising the Company&rsquo;s
	capitalization structure. The Company chose the OPM over other acceptable methods due to the complex capital structure, the uncertainty
	related to market conditions, and the lack of visibility on an imminent exit event. Under the OPM, each equity class is modeled
	as a call option with a distinct claim on the equity of the Company. The option&rsquo;s exercise price is based on the Company&rsquo;s
	total equity value available for each participating equity holder. The characteristics of each equity class determine the equity
	class&rsquo; claim on the total equity value. By constructing a series of options in which the exercise price is set at incremental
	levels of value, which correspond to the equity value necessary for each level of equity to participate, the Company determined
	the incremental option value of each series. When multiplied by the percentage of ownership of each equity class participating
	under that series, the result is the incremental value allocated to each class under that series.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	OPM relies on the Black-Scholes option-pricing model to value the call options on the Company&rsquo;s invested capital. The following
	inputs were applied in the Black-Scholes calculations of the OPM:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Valuation Dates
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	November 7, 2013
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	July 31, 2012
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31, 2010
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: LEFT">
	Risk-free rate
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	0.55
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	0.57
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	2.01
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Maturity (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	58.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Discounts
	ranging from 35.8% to 40% were applied for lack of control and lack of marketability for the common stock. The calculation resulted
	in a fair value for the common stock of&thinsp;$1.17, $1.19, and $1.03 per share as of the Company&rsquo;s three valuation dates
	of November 7, 2013, July 31, 2012, and December 31, 2010, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	options issued in 2014, given the Company&rsquo;s distinct possible exit scenarios of an initial public offering, the Company
	used the probability weighted expected return method (PWERM) to estimate the fair value of the Company&rsquo;s common equity.
	Under this method, an analysis of future values of a company is performed for several likely liquidity scenarios. The value of
	the common stock is determined for each scenario at the time of each future liquidity event and discounted back to the present
	using a risk-adjusted discount rate. The present values of the common stock under each scenario are then weighted based on the
	probability of each scenario occurring to determine the value for the common stock. The Company&rsquo;s management determined
	the probability weighting of potential liquidity events to be 45% for an initial public offering and 55% for other scenarios,
	which represents all other likely outcomes for the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	estimated the implied market value of invested capital of the Company by backsolving for the purchase price of the Company&rsquo;s
	preferred shares for one common share through the use of OPM. The application of the backsolve method considering the Company&rsquo;s
	capital structure yielded a total market value of invested capital of approximately $25.2 million, of which approximately $1.4
	million was allocated to the total value of common stock as of the Company&rsquo;s valuation date of October 31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Given
	the lack of marketability for the common stock, the Company applied a discount of 21.4% for using the average strike put option
	approach. This resulted in a probability weighted common share value, after adjustment, of&thinsp;$5.86 per share as of valuation
	date of October 31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Stock-based
	Compensation Summary Tables
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Information
	regarding the Company&rsquo;s stock option grants to the Company&rsquo;s employees and non-employees, along with the estimated
	fair value per share of the underlying common stock, for stock options granted since 2005 is summarized as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Grant Date
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Number of Common
<BR>
	Shares Underlying
<BR>
	Options Granted
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Exercise Price per
<BR>
	Common Share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Estimated Fair Value
<BR>
	per Share of Common
<BR>
	Stock
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Intrinsic
	Value
</B>
</FONT>
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Per
	Option
</B>
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: LEFT">
	2005
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	58,321
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	0.07
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 19%; TEXT-ALIGN: RIGHT">
	1.79
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	1.72
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2009
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,559
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.72
	- $0.79
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.71
	- $3.64
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2011
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,846
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.03
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2012
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	60,019
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2013
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.14
	- $1.30
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,626,740
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.86
	- $13.23
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.86
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following represents a summary of the options granted to employees and non-employees outstanding at December 31, 2015 and changes
	during the period then ended:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Weighted Average Exercise
	Price
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 60%">
	Outstanding at December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	1,952,516
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 16%; TEXT-ALIGN: RIGHT">
	7.022
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 10PT; PADDING-BOTTOM: 1.5PT">
	Exercised/Expired/Forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(47,982
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(1.246
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Outstanding at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	1,938,534
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	7.081
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	Exercisable at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	697,832
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5.285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Expected to be vested
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,240,702
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	8.091
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	10 &mdash; RELATED PARTY TRANSACTIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	director of the Company is a managing director of Javelin Venture Partners GP, LLC, the general partner of Javelin Venture Partners
	GP, L.P., which held a significant investment in the Company&rsquo;s Series A-1, Series A-2, Series A-3, Series B, and Series
	C preferred stock that was converted into common stock prior to the Company&rsquo;s initial public offering. Two directors of
	the Company have acted as a managing director of Stonehenge Partners, LLC, which held significant investment in the Company&rsquo;s
	Series A-1 preferred stock and also held investments in the Company&rsquo;s Series A-2 and Series B preferred stock that was converted
	to common stock prior to the Company&rsquo;s initial public offering.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Prior
	to and during his employment with the Company, Mr. Ira Ritter served as CEO of Andela Group Inc, (&ldquo;Andela&rdquo;) a company
	he founded in 1987, which is involved in corporate management, strategic and financial consulting. During the year ended December
	31, 2014, the Company incurred approximately $176,000 of expenses for services received from Andela, all of which were classified
	in general and administrative expenses in the statements of operations as Mr. Ritter was an employee of the Company at the time
	of the services. There were no services received from Andela during the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other
	than disclosed, the Company has not entered into or been a participant in any transaction in which a related party had or will
	have a direct or indirect material interest.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	11&thinsp;&mdash;&thinsp;INCOME TAXES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015, the Company has net operating loss carryforwards of approximately $15.3 million available to reduce future
	taxable income, if any, for Federal and state income tax purposes. The U.S. federal and state net operating loss carryforwards
	will begin to expire in 2028.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of December 31, 2015, the Company has research and development credit carryforwards of approximately $488,000 available to reduce
	future taxable income, if any, for Federal and state income tax purposes. The Federal credit carryforwards begin to expire in
	2028. California credits have no expiration date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Under
	the Internal Revenue Code (&ldquo;IRC&rdquo;) Sections 382 and 383, annual use of the Company&rsquo;s net operating loss and research
	tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not
	completed an analysis to determine whether any such limitations have been triggered as of December 31, 2015. The Company has no
	income tax affect due to the recognition of a full valuation allowance on the expected tax benefits of future loss carry forwards
	based on uncertainty surrounding realization of such assets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	reconciliation of the statutory income tax rates and the Company&rsquo;s effective tax rate is as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: LEFT">
	Statutory U.S. federal rate
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	State income tax, net of federal benefit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Meals &amp; entertainment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Others
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Forward sale of preferred stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Non-cash interest on conversion
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.8
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(39.7
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)%
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(32.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Provision for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	0.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	As of December 31,
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Deferred tax assets:
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net operating loss carry forwards
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	6,192,058
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	3,675,012
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Patent costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	410,913
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	318,652
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Capitalized interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	85,568
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	85,568
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued vacation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,852
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,237
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development credit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	345,721
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	200,482
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,480,266
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	383,381
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	5,195
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	4,460
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Gross deferred tax assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,547,573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,677,792
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(8,547,573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	(4,677,792
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 20PT">
	Net deferred tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company did not record any accruals for income tax accounting uncertainties for the years ended December 31, 2015 and 2014
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	.
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Authoritative
	guidance requires companies to accrue interest and related penalties, if applicable, on all tax positions for which reserves have
	been established consistent with jurisdictional tax laws. The Company&rsquo;s policy is to recognize interest and penalties that
	would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company
	did not accrue either interest or penalties from inception through December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company does not have any unrecognized tax benefits that will significantly decrease or increase within 12 months of December
	31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s major tax jurisdictions are the United States and California. All of the Company&rsquo;s tax years will remain
	open three and four years for examination by the Federal and state tax authorities, respectively, from the date of utilization
	of the net operating loss. The Company does not have any tax audits pending.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<A NAME="FORM10-K_HTM_A_020">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	There
	has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices or
	financial disclosure required to be reported under this Item.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<A NAME="FORM10-K_HTM_A_021">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	9A. Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Evaluation
	of Disclosure Controls and Procedures
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our
	management, with the participation of our chief executive officer (our principal executive officer) and vice president finance
	(our principal financial officer), evaluated the effectiveness of our disclosures controls and procedures, as defined in Rules
	13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), as of December 31, 2015.
	The term &ldquo;disclosure controls and procedures,&rdquo; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act,
	means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company
	in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
	periods specified in the SEC&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation, controls
	and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits
	under the Exchange Act is accumulated and communicated to the company&rsquo;s management, including its principal executive and
	principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
	achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
	controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2015, our principal
	executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were
	effective at a reasonable assurance level.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Internal
	Control Over Financial Reporting
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Annual Report on Form 10-K does not include a report of management&rsquo;s assessment regarding internal control over financial
	reporting or an attestation report of our independent registered public accounting firm due to a transition period established
	by the rules of the SEC for newly public companies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Inherent
	Limitations of Internal Controls
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Because
	of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
	of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
	in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	Changes
	in Internal Control over Financial Reporting
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve
	controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include
	such activities as implementing new, more efficient systems, consolidating activities, and migrating processes. During the quarter
	ended December 31, 2015, we implemented an enterprise resource planning system as well as hired additional experienced staff in
	an effort to strengthen our overall control environment. Other than these changes mentioned, there were no changes in our internal
	control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control
	over financial reporting.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_022">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	9B. Other Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	None.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; OPTIONS: NEWSECTION; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_023">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	III
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_024">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	10. Directors, Executive Officers, and Corporate Governance
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item with respect to our directors and executive officers will be contained in our 2016 Proxy Statement
	under the caption &ldquo;Board of Directors and Corporate Governance&mdash;The Board of Directors in General&rdquo; and &ldquo;&mdash;Executive
	Officers&rdquo; and is incorporated by reference into Item 10 of this Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item with respect to Section 16(a) beneficial ownership reporting compliance will be contained in
	our 2016 Proxy Statement under the caption &ldquo;Ownership of the Company&mdash;Section 16(a) Beneficial Ownership Reporting
	Compliance&rdquo; and is incorporated by reference into Item 10 of this Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item with respect to Audit Committee matters will be contained in our 2016 Proxy Statement under
	the caption &ldquo;Board of Directors and Corporate Governance&mdash;Committees of the Board of Directors&mdash;Audit Committee&rdquo;
	and is incorporated by reference into Item 10 of this Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item with respect to our Code of Business Conduct and Ethics will be contained in our 2016 Proxy
	Statement under the caption &ldquo;Board of Directors and Corporate Governance &ndash; Code of Business Conduct and Ethics&rdquo;
	and is incorporated by reference into item 10 of this Annual Report.&nbsp;
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_025">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	11. Executive Compensation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item will be contained in our 2016 Proxy Statement under the caption &ldquo;Executive and Director
	Compensation&rdquo; and is incorporated by reference into Item 11 of this Annual Report.
</FONT>
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_026">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item will be contained in our 2016 Proxy Statement under the caption &ldquo;Ownership of the Company&mdash;Security
	Ownership of Certain Beneficial Owners and Management&rdquo; and &ldquo;Equity Compensation Plan Information&rdquo; and is incorporated
	by reference into Item 12 of this Annual Report.
</FONT>
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_027">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	13. Certain Relationships and Related Transactions and Director Independence
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item will be contained in our 2016 Proxy Statement under the caption &ldquo;Board of Directors and
	Corporate Governance&mdash;Certain Relationships and Related Party Transactions&rdquo; and &ldquo;&mdash;Director Independence&rdquo;
	and is incorporated by reference into Item 13 of this Annual Report.
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_028">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	14. Principal Accountant Fees and Services
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information required by this item will be contained in our 2016 under the caption &ldquo;Relationship With Independent Registered
	Public Accounting Firm&rdquo; and is incorporated by reference into Item 14 of this Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_029">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	IV
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<A NAME="FORM10-K_HTM_A_030">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
	15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.4IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	Statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.4IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	response to this portion of Item 15 is set forth under Part II, Item 8 above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 27.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.4IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	Statement Schedules.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.4IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	schedules have been omitted because they are not required or because the required information is given in the Financial Statements
	or Notes thereto set forth under Item 8 above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0.4IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.4IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	See
	the Exhibit Index immediately following the signature page of this Annual Report. The exhibits listed in the Exhibit Index below
	are filed or incorporated by reference as part of this Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<A NAME="FORM10-K_HTM_A_031">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
	to be signed on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	RITTER
	PHARMACEUTICALS, INC.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 5%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Michael D. Step
</I>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Michael
	D. Step
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Executive Officer
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Date:
	March 21, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant
	to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
	of the registrant on March 21, 2016 in the capacities indicated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 35%; PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Signature
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 16%; PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Michael D. Step
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Executive Officer and Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Michael
	D. Step
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal
	Executive Officer)
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Ellen Mochizuki
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Vice
	President Finance
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ellen
	Mochizuki
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal
	Financial Officer and Principal Accounting Officer)
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Ira E. Ritter
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Chairman, Chief Strategic Officer
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ira
	E. Ritter
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	and
	Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Andrew J. Ritter
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	President
	and Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Andrew
	J. Ritter
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Noah Doyle
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Noah
	Doyle
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Matthew W. Foehr
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Matthew
	W. Foehr
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Paul V. Maier
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Paul
	V. Maier
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	Gerald T. Proehl
</I>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Gerald
	T. Proehl
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.8PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-RIGHT: 0.8PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	EXHIBIT
	INDEX
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="7" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Incorporated
	by Reference
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.7IN; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
	No.
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Form
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	File
	No.
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Filing
	Date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amended
	and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8-K
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7/1/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amended
	and Restated Bylaws of Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8-K
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7/1/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Common Stock Certificate of Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1/A
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/22/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amended
	and Restated Investors&rsquo; Rights Agreement, dated as of November 17, 2010, by and among Ritter Pharmaceuticals, Inc. and
	the persons and entities named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/23/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 1 to the Amended and Restated Investors&rsquo; Rights Agreement, dated as of January 13, 2011, by and among Ritter Pharmaceuticals,
	Inc. and the persons and entities named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/23/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 2 to the Amended and Restated Investors&rsquo; Rights Agreement, dated as of February 6, 2012, by and among Ritter Pharmaceuticals,
	Inc. and the persons and entities named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/23/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 3 to the Amended and Restated Investors&rsquo; Rights Agreement, dated as of December 4, 2014, by and among Ritter Pharmaceuticals,
	Inc. and the persons and entities named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.5
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/23/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 4 to the Amended and Restated Investors&rsquo; Rights Agreement, by and among Ritter Pharmaceuticals, Inc. and the persons
	and entities named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-208818
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.6
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/31/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Common Stock Purchase Warrant
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-208818
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/31/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.8
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Representative&rsquo;s Warrant Agreement
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1/A
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.7
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.9
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Registration
	Rights Agreement, dated December 18, 2015, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8-K
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;4.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/21/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Office
	Lease, dated June 25, 2013, by and between Douglas Emmett 1997, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.2+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Offer
	Letter, dated December 2, 2014, by and between Michael D. Step and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.3+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Compensation Plan
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.4+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Severance &amp; Change in Control Agreement, dated October 1, 2014, by and between Ritter Pharmaceuticals, Inc. and Michael
	D. Step
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.5+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2008
	Stock Plan
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-8
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-207709
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	99.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10/30/15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.6+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2009
	Stock Plan
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.6
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/23/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.7+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
	Equity Incentive Plan
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-8
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-207709
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	99.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10/30/15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.8+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Notice of Grant of Stock Option under the 2015 Equity Incentive Plan
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-8
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-207709
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	99.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10/30/15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.9+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Michael D. Step
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.8
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.10+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Michael D. Step
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.9
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.11+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Michael D. Step
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.10
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.12+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated September 25, 2013, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.11
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.13+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.12
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.14+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.13
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.7IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.15+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated September 25, 2013, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.16+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.15
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.17+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Option Agreement, dated December 2, 2014, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.16
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research
	and Development Agreement &amp; License, dated November 30, 2010, by and among Kolu Pohaku Technologies, LLC, Kolu Pohaku
	Management, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.17
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 1 to Research and Development Agreement &amp; License, dated July 6, 2011, by and among Kolu Pohaku Technologies, LLC,
	Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.18
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 2 to Research and Development Agreement &amp; License, dated September 30, 2011, by and among Kolu Pohaku Technologies,
	LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 3 to Research and Development Agreement &amp; License, dated February 6, 2012, by and among Kolu Pohaku Technologies,
	LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 4 to Research and Development Agreement &amp; License, dated November 4, 2013, by and among Kolu Pohaku Technologies,
	LLC, Kolu Pohaku Management, LLC and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.23
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Put
	and Call Option Agreement, dated November 30, 2010, by and between Kolu Pohaku Technologies, LLC and Ritter Pharmaceuticals,
	Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.24
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subordinated
	Convertible Promissory Note to SJ Investment Company, LLC, dated May 23, 2014, in the principal amount of&thinsp; $25,000.00
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.23
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.25
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subordinated
	Convertible Promissory Note to Javelin Venture Partners, L.P., dated May 23, 2014, in the principal amount of&thinsp; $350,000.00
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.24
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.26
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subordinated
	Convertible Promissory Note to Javelin Venture Partners, L.P., dated September 8, 2014, in the principal amount of&thinsp;
	$80,000.00
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.25
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.27
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unsecured
	Promissory Note to Javelin Venture Partners, L.P., dated October 9, 2014, in the principal amount of&thinsp; $70,000.00
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.26
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.28
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subordinated
	Convertible Promissory Note, dated October 20, 2014, in the principal amount of&thinsp; $80,000.00
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.27
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.29
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Series
	C Preferred Stock and Warrant Purchase Agreement, dated December 4, 2014, by and among Ritter Pharmaceuticals, Inc. and the
	Investors named therein
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.28
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5/8/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.30+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Form
	of Indemnification Agreement between Ritter Pharmaceuticals, Inc. and each of its directors and executive officers
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1/A
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.29
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4/24/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.31
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Clinical
	Supply and Operation Agreement, dated December 16, 2009, by and among Ritter Pharmaceuticals, Inc. and Ricerche Sperimentali
	Montale SpA and Inalco SpA
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1/A
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.30
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4/24/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.32
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	1 to the Clinical Supply and Cooperation Agreement, dated September 25, 2010, by and among Ritter Pharmaceuticals, Inc. and
	Ricerche Sperimentali Montale SpA and Inalco SpA
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1/A
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-202924
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.31
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4/24/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.33+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Offer
	Letter, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/12/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.34+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Offer
	Letter, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/12/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.35+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Severance &amp; Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/12/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.36+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Severance &amp; Change in Control Agreement, by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8/12/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.37
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lease
	Agreement, dated July 9, 2015, between the Company and Century Park
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/10/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.38
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment
	No. 2 to Clinical Supply and Cooperation Agreement, effective July 24, 2015, between Ritter Pharmaceuticals, Inc., Ricerche
	Sperimentali Montale SpA, and Inalco SpA
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.2
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/10/2015
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.7IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.39+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Offer
	Letter, dated August 14, 2015, by and between Ritter Pharmaceuticals, Inc. and Ellen Mochizuki
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.6IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.3
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 0.1IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 0.8IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/10/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.40+
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Letter
	of Agreement, dated October 20, 2015 between Ritter Pharmaceuticals, Inc. and Chord Advisors, LLC
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10-Q
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.4
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11/10/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.41
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Common
	Stock Purchase Agreement, dated December 18, 2015, by and between Ritter Pharmaceuticals, Inc. and Aspire Capital Fund, LLC
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8-K
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	001-37428
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;10.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/21/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.42
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Master
	Services Agreement, effective December 29, 2015, by and between Covance Inc. and Ritter Pharmaceuticals, Inc.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	S-1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	333-208818
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.42
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12/30/2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	23.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Consent
	of Mayer Hoffman McCann P.C., independent registered public accounting firm
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	24.1*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Power
	of Attorney (included on signature page)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	31.1*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certificate
	of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
	Act of 2002.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	31.2*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certificate
	of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
	Act of 2002.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	32.1*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	Certificate
	of principal executive officer and principal financial officer pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to Section
	906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.INS#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Instance Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.SCH#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Taxonomy Extension Schema Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.CAL#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Taxonomy Extension Calculation Linkbase Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.DEF#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Taxonomy Extension Definition Linkbase Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.LAB#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Taxonomy Extension Label Linkbase Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	101.PRE#
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	XBRL
	Taxonomy Extension Presentation Linkbase Document.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	*
	Filed herewith.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	+
	Indicates management contract or compensatory plan or arrangement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	#
	XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration
	statement or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section
	18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 61 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_INDEX>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage90"></A>
<A NAME="EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Exhibit
	23.1
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	CONSENT
	OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	independent registered public accountants, we hereby consent to the incorporation by reference in Registration Statement Nos.
	333-202924 and 333-208818 of Ritter Pharmaceuticals, Inc. on Form S-l and Registration Statement No. 333-207709 on Form S-8 pertaining
	to the 2008 Stock Plan, 2009 Stock Plan, and 2015 Equity Incentive Plan of Ritter Pharmaceuticals, Inc. of our report dated March
	21, 2016, with respect to the financial statements of Ritter Pharmaceuticals, Inc. (which report includes an explanatory paragraph
	relating to the uncertainty of the Company&rsquo;s ability to continue as a going concern) for each of the years in the two year
	period ended December 31,2015, included in this annual report on Form 10-K of Ritter Pharmaceuticals, Inc. for the year ended
	December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 17PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 17PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Orange
	County, California
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 17PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	March
	21, 2016
</FONT>
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 17PT 0 1PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage92"></A>
<A NAME="EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Exhibit
	31.1
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	I,
	Michael D. Step, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.
	I have reviewed this Annual Report on Form 10-K of Ritter Pharmaceuticals, Inc.;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.
	Based on my knowledge, this Annaul Report does not contain any untrue statement of a material fact or omit to state a material
	fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
	with respect to the period covered by this Annual Report;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this Annual Report;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
	procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant is made known to us by others within those entities, particularly
	during the period in which this Annual Report is being prepared;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report our
	conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual
	Report based on such evaluation; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c)
	Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
	the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
	that has materially affected, or is reasoeably likely to materially affect, the registrant&rsquo;s internal control over financial
	reporting; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date:
	March 21, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	MICHAEL D. STEP
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Michael
	D. Step
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chief
	Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Principal
	Executive Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage94"></A>
<A NAME="EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Exhibit
	31.2
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	I,
	Ellen Mochizuki, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.
	I have reviewed this Annual Report on Form 10-K of Ritter Pharmaceuticals, Inc.;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.
	Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material
	fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
	with respect to the period covered by this Annual Report;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this Annual Report;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
	procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant is made known to us by others within those entities, particularly
	during the period in which this Annual Report is being prepared;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report our
	conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual
	Report based on such evaluation; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c)
	Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
	the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
	that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
	reporting; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a)
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b)
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date:
	March 21, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	/s/
	ELLEN MOCHIZUKI
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ellen
	Mochizuki
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Vice
	President Finance
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Principal
	Financial Officer)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage96"></A>
<A NAME="EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Exhibit
	32.1
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATIONS
	PURSUANT TO 18 U.S.C. 1350
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section
	1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect; 1350), as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002 Michael D. Step, the Chief Executive Officer (principal executive officer) of Ritter Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;),
	and Ellen Mochizuki, the Vice President of Finance (principal financial officer) of the Company, each hereby certifies that, to
	his/her knowledge on the date hereof:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(a)
	The Annual Report on Form 10-K of the Company for the period ended December 31, 2015 filed on the date hereof with the Securities
	and Exchange Commission (the &ldquo;Annual Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the
	Securities Exchange Act of 1934, as amended; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(b)
	The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results
	of operations of the Company for the period covered by the Annual Report.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	These
	certifications accompanying the Annual Report to which they relate, are not deemed filed with the Securities and Exchange Commission
	and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
	Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report), irrespective of any
	general incorporation language contained in such filing. A signed original of this written statement required by Section 906 has
	been provided to the Company and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 50%; LINE-HEIGHT: 107%; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; LINE-HEIGHT: 107%; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1.5PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	/s/
	MICHAEL D. STEP
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Michael
	D. Step &nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 1.8PT 0 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chief
	Executive Officer
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 1.8PT 0 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Principal
	Executive Officer)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March
	21, 2016
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 11PT CALIBRI, HELVETICA, SANS-SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 50%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	/s/
	ELLEN MOCHIZUKI
</I>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ellen
	Mochizuki
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Vice
	President Finance
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Principal
	Financial Officer)
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March
	21, 2016
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
